Surgical & Breast Mesh Injuries: The Complete Patient Guide

Name: Surgical & Breast Mesh Injuries: The Complete Patient Guide
Creator: Ralph P. Manginello

A plain-English, primary-source reference on transvaginal/pelvic mesh, hernia mesh, and breast scaffolds & acellular dermal matrix (GalaFLEX, Phasix, AlloDerm, Strattice, SERI) — the devices, the documented injuries, the manufacturers’ record, and the regulatory history.

About This Guide — and the Team Behind It

If you or someone you love has surgical mesh or a breast-reconstruction scaffold inside their body — and you are trying to understand what it is, how it can fail, and what the public record actually says about it — this guide was written for you. It is a comprehensive, plain-English reference on surgical and breast mesh injuries, built so that patients and families can understand these devices and their documented risks without needing a medical degree or a law degree.

Our goal here is education first. We explain what these implants are, how they are intended to work in the body, the ways they are documented to fail, and what regulators, courts, and the medical literature have established about them. Where there is a hard fact, we cite it to a primary source — a court record, an FDA database or safety communication, a company’s own filing with the U.S. Securities and Exchange Commission, or a peer-reviewed medical study — so you can follow the link and read it yourself. Where something is alleged but not yet proven, we say so plainly and attribute it to the party making the allegation.

This guide is for general information and education; it is not medical advice and is not a substitute for professional medical care. Always consult your own physician about your specific condition, your implant, and any decision affecting your treatment.

Who wrote this

This guide is written and maintained by the attorneys of The Manginello Law Firm, PLLC, the Houston firm known as Attorney 911. We have decades of experience representing seriously injured Texans, and we built this resource the way we build a case file: by going to the underlying records rather than relying on summaries. Throughout these pages we draw on FDA clearance, recall, and adverse-event data; filings and rulings in federal and state courts; disclosures companies have made to the SEC; and the published, peer-reviewed medical literature.

Two attorneys stand behind this work:

Ralph P. Manginello — Managing Partner. Licensed to practice in Texas since 1998 and admitted before the U.S. District Court for the Southern District of Texas. His standing is a matter of public record and can be confirmed through the State Bar of Texas member directory (texasbar.com).
Lupe Peña — Associate Attorney. Licensed to practice in Texas since 2012 and admitted before the U.S. District Court for the Southern District of Texas. A former insurance-defense attorney who now represents injured people, Lupe offers full Spanish-language consultations. His standing is likewise a matter of public record through the State Bar of Texas member directory (texasbar.com).

Our firm is licensed in Texas and before the federal courts. This guide is legal and medical information, not legal or medical advice, and reading it does not create an attorney-client relationship — please see the Important Disclaimers for the full picture.

How to use this guide

The material is organized so you can start wherever your question begins:

Start with the devices. If you are not sure what was actually implanted in you, begin with What Surgical Mesh and Breast Scaffolds Actually Are. It explains the difference between pelvic mesh, hernia mesh, acellular dermal matrix, and bioabsorbable breast scaffolds in everyday terms.
Understand the central mechanism. Almost every injury in this guide traces back to one biological reality — the body treats an implant as something foreign. We explain that in The Foreign-Body Response (Why the Body Reacts to Mesh), which underlies the Foreign-Body Granuloma and many other complications.
Look up a specific injury, A to Z. The injury sections are grouped by type — structural failures, pain and nerve injuries, infection and life-threatening complications, functional and organ-system injuries, material-degradation and immune reactions, and breast-reconstruction and scaffold injuries — so you can find the complication that matches your experience.
Read the manufacturer record. For what the documented public record shows about specific companies and devices, see the company sections, beginning with Becton Dickinson / C.R. Bard / Davol and Johnson & Johnson / Ethicon.
Trace the regulatory history. To understand how these devices were cleared and what the FDA did over time, see FDA Action on Surgical Mesh: 2008 → 2011 → 2016 → the 2019 Ban and How These Devices Reached the Market.

To learn more about the firm itself, see About Attorney 911 — The Manginello Law Firm, PLLC.

A word on trust: we cite primary sources throughout precisely so you do not have to take our word for anything. Every case is different, and nothing in this guide is a prediction or guarantee about any particular outcome. If you or a loved one has been affected by a surgical mesh or breast scaffold complication, our team offers a free, confidential consultation — but the information on this page is yours to use whether or not you ever call us.

↑ Top · What Surgical Mesh and Breast Scaffolds Actually Are ▶

What Surgical Mesh and Breast Scaffolds Actually Are

Surgical mesh is a sheet of material — woven, knitted, or formed into a thin film — that a surgeon implants to support, reinforce, or rebuild soft tissue that has been weakened, stretched, or removed. The basic idea is simple: the mesh acts as a scaffold, and the body’s own tissue is meant to grow into and around it so that the repair holds. Today that same idea is being applied far beyond its origins, including inside the breast, where bioabsorbable scaffolds and tissue matrices are marketed to surgeons as an “internal bra.” Understanding what these implants are actually made of — and, just as importantly, what the U.S. Food and Drug Administration (FDA) has and has not signed off on — is the foundation for everything else on this page.

This section explains the materials in plain English and describes their regulatory status in neutral, accurate terms. The ways these devices can fail in the body, and the documented litigation history, are covered in later sections — we cross-link to them throughout. For how the body itself reacts to an implanted foreign material, see The Foreign-Body Response and How Mesh Is Supposed to Work — and How It Fails in the Body.

Breast scaffolds and the “internal bra”

The newest and most legally contested use of surgical mesh is in the breast — during mastopexy (a lift), breast augmentation, and reconstruction after mastectomy. Surgeons place a scaffold or matrix in the lower pole of the breast to support the tissue or to cover and position an implant. Marketing language commonly calls this an “internal bra.” A threshold fact runs through the entire category and is repeated by both the FDA and the peer-reviewed literature: no surgical mesh of any kind is FDA-cleared or FDA-approved for use in breast surgery. As one 2024 systematic review put it, “No mesh device has gained FDA-approved indication for breast reconstruction.” Source The FDA stated the same thing directly in a November 9, 2023 Letter to Health Care Providers concerning bioabsorbable/absorbable mesh and scaffolds: “There are no surgical mesh products cleared or approved by the FDA for use in breast surgery, including in augmentation or reconstruction.” Source Use of these products in the breast is therefore off-label — a physician’s choice that the law permits but that the FDA has not vetted for safety or effectiveness in that setting.

Three families of material dominate breast use:

1. Bioabsorbable P4HB scaffolds — GalaFLEX, GalaFLEX 3D, and Phasix. GalaFLEX and Phasix are FDA-cleared resorbable surgical meshes knitted from poly-4-hydroxybutyrate (P4HB), a biosynthetic polymer. The GalaFLEX 510(k) summary describes it as “a sterile, knitted, resorbable mesh, constructed of non-dyed monofilament fibers made from poly-4-hydroxybutyrate (P4HB).” Source Both products are now owned by Becton, Dickinson and Company (BD) through subsidiaries including Tepha, Inc., Galatea Surgical, Inc., C.R. Bard, Inc., and Davol, Inc. Source

A point that matters legally and clinically: these are surgical mesh, not sutures. The FDA’s own clearance letters classify them as Class II surgical mesh under 21 CFR 878.3300, product code OOD. Source The FDA’s product-classification database defines that mesh category as material “to be implanted to reinforce soft tissue or bone where weakness exists.” Source Their cleared indications cover general soft-tissue reinforcement in plastic and reconstructive surgery — and never mention the breast. Source

A defining feature of P4HB scaffolds is that they are designed to dissolve. Peer-reviewed work reports that “complete resorption occurs within 18–24 months through hydrolysis,” and that lower-pole support at one year and beyond “was primarily dependent on neovascularized connective tissue ingrowth rather than the P4HB scaffold itself.” Source In other words, the long-term support comes from the patient’s own ingrown tissue, not from a permanent device. What can go wrong when that scaffold breaks down or fails to do its job is discussed in Bioabsorbable Scaffold Failure: P4HB (GalaFLEX) “Internal Bra” Collapse, and the manufacturer’s documented record is in Breast Scaffolds & Acellular Dermal Matrix and Becton Dickinson / C.R. Bard / Davol.

2. Silk-derived scaffold — SERI. SERI Surgical Scaffold was a bioresorbable surgical mesh made from purified silk fibroin protein of the Bombyx mori silkworm. Source It reached the U.S. market through the 510(k) pathway as a general soft-tissue scaffold (510(k) K123128, cleared April 25, 2013) — never approved through a premarket-approval (PMA) process and never cleared specifically for breast surgery. Source SERI was later discontinued and, as of December 31, 2021, is no longer commercially available. Source

3. Acellular dermal matrix (ADM) — AlloDerm, Strattice, and related products. An acellular dermal matrix is a sheet of donated human skin (or, in some products, animal skin) that has been processed to strip out the cells, leaving a collagen-elastin scaffold. In breast reconstruction the ADM is used as a “sling” or hammock to support and cover a tissue expander or implant after mastectomy. AlloDerm is human-derived; Strattice is porcine (pig) skin; other ADMs in breast use include FlexHD, AlloMax, SurgiMend (bovine), DermACELL, and Cortiva. Source

ADMs occupy a distinct and important regulatory niche. Human ADMs such as AlloDerm are regulated by the FDA as banked human tissue — a Human Cells, Tissues, and Cellular and Tissue-Based Product (HCT/P) under Section 361 of the Public Health Service Act (21 CFR Parts 1270 and 1271) — rather than as an approved or cleared medical device. Source Products in that framework receive no PMA and no 510(k) safety-and-effectiveness clearance. The FDA’s March 31, 2021 Safety Communication stated plainly that “FDA has not cleared or approved any ADM product for use in breast reconstruction,” noting that some ADMs are cleared only for other uses such as hernia repair. Source That same communication reported that certain ADMs (it named FlexHD and AlloMax) showed higher major-complication rates two years after surgery than others in a multicenter dataset. Source The complications associated with breast scaffolds and ADM — including seroma, Red Breast Syndrome, capsular contracture, and reconstruction failure requiring explantation — are detailed in the Breast Reconstruction & Scaffold Injuries cluster.

Broadening the lens: pelvic mesh and hernia mesh

The breast scaffolds above are the newest chapter, but synthetic surgical mesh has a much longer history in two other areas.

Transvaginal and pelvic mesh is made primarily of polypropylene, a permanent (non-absorbable) plastic. It was implanted through the vagina or abdomen to treat pelvic organ prolapse (POP) — where the bladder, uterus, or bowel descends as supporting tissue weakens — and stress urinary incontinence (SUI), often using a mid-urethral “sling.” Because the polypropylene is permanent, the body’s reaction to it is ongoing rather than time-limited. The specific failure modes seen with pelvic mesh — including erosion through the vaginal wall, perforation of nearby organs, mesh contraction and shrinkage, chronic pelvic pain, and in-vivo degradation of the polypropylene fibers — are covered in detail in the structural-failure and material-degradation clusters. The FDA’s regulatory actions on transvaginal mesh, culminating in a 2019 order halting sales of certain products, are traced in FDA Action on Surgical Mesh.

Hernia mesh is used to reinforce the abdominal wall or groin where a hernia has pushed through weakened tissue. It includes permanent polypropylene products (such as BD/Bard’s Ventralight ST, PerFix Plug, and 3DMax lines) as well as the bioabsorbable P4HB material sold under the Phasix brand — the same polymer used in GalaFLEX. Source Hernia mesh can be placed inside the abdominal cavity, which raises distinct risks such as adhesions to the bowel and other organs, bowel obstruction, and recurrence of the hernia. The documented litigation history of BD/C.R. Bard/Davol hernia mesh — a separate product line from the breast scaffolds, though involving the same corporate defendants — is set out in Becton Dickinson / C.R. Bard / Davol — The Documented Record.

How these devices reached the market: the 510(k) pathway, in neutral terms

Most surgical mesh products — including the P4HB scaffolds, SERI, and the polypropylene pelvic and hernia meshes — reached the U.S. market through the FDA’s 510(k) premarket-notification pathway. Under that pathway, a manufacturer demonstrates that its new device is “substantially equivalent” to a legally marketed predicate device, and the FDA clears it as Class II. This is the standard route for many moderate-risk medical devices; it is a real FDA regulatory process, distinct from the more rigorous premarket-approval (PMA) process used for the highest-risk devices.

A few accurate points help a patient understand what 510(k) clearance does and does not mean:

Clearance is tied to the cleared indication. GalaFLEX, Phasix, and SERI were each cleared for general soft-tissue reinforcement, with predicate devices that were themselves surgical mesh — for example, GalaFLEX’s cleared predicates included earlier TephaFLEX mesh and the SERI Surgical Scaffold. Source None of those clearances named the breast.
510(k) clearance is not the same as FDA “approval.” Manufacturers and marketing materials sometimes blur this line. For breast use specifically, there is neither clearance nor approval — the FDA has said so directly. Source
Independent bodies have studied the pathway itself. The U.S. Government Accountability Office (GAO) and the Institute of Medicine (now the National Academies) have each published reviews of the 510(k) process; those critiques are attributed to those bodies in How These Devices Reached the Market.

How the 510(k) pathway works in practice, how adverse events are reported through the FDA’s MAUDE database, and what independent expert bodies have said about it are all covered in detail in How These Devices Reached the Market: 510(k), MAUDE Reporting & Expert Review.

Why this foundation matters

For a patient, the key takeaways from this overview are straightforward. Surgical mesh and breast scaffolds are implanted supports made of permanent plastic (polypropylene), absorbable polymer (P4HB), or processed human/animal tissue (ADM). Some are designed to stay in the body permanently; others, like the P4HB scaffolds and SERI, are designed to dissolve over months to years. Most reached the market through the 510(k) substantial-equivalence pathway. And for breast surgery specifically, the FDA has stated that no surgical mesh is cleared or approved — making that use off-label. The remaining sections of this page explain, with citations, how these devices can fail, what injuries have been reported and documented, and what the courts and regulators have done.

This page is educational and is not medical or legal advice. It is not a substitute for the care of your own physician, and nothing here should be read as a recommendation to remove or to keep any implanted device — those are decisions for you and your treating doctor. Always consult your own physician about your specific situation.

◀ About This Guide — and the Team Behind It · ↑ Top · How Mesh Is Supposed to Work — and How It Fails in the Body ▶

How Mesh Is Supposed to Work — and How It Fails in the Body

Before you can understand any of the injuries described elsewhere in this guide, it helps to understand what these implants actually are, what they are made of, and what they are supposed to do. This section is foundational. It explains the basic biology and engineering in plain English. The specific failure mechanisms and the litigation are covered in later sections, which we cross-link as we go.

The short version: a surgical mesh or scaffold is a sheet of material — synthetic plastic, a slowly dissolving polymer, or processed human or animal tissue — that a surgeon implants to reinforce weak or stretched tissue. It is meant to act like rebar in concrete: the body grows into and around it, and the combined “tissue-plus-mesh” is stronger than the tissue alone. When it works, the patient never thinks about it again. When it fails, the same material that was supposed to quietly support the repair becomes the source of the problem — because the body does not treat an implant as a neutral object. It mounts a lifelong reaction to it, described in detail in The Foreign-Body Response (Why the Body Reacts to Mesh).

The breast: scaffolds and the “internal bra”

In breast reconstruction (most often after a mastectomy for cancer) and in cosmetic or revision breast surgery, surgeons increasingly use a sheet of supportive material to hold breast tissue or an implant in position. Two broad families are used.

Bioabsorbable poly-4-hydroxybutyrate (P4HB) scaffolds — GalaFLEX, GalaFLEX 3D, and Phasix. These are knitted monofilament scaffolds made of P4HB, a polymer designed to be slowly broken down and absorbed by the body over roughly 12 to 24 months rather than to remain permanently. The concept marketed around them is an “internal bra”: the scaffold is meant to provide temporary mechanical support and to stimulate the patient’s own tissue to lay down new collagen, so that by the time the scaffold itself has dissolved, the reinforced tissue holds the shape on its own. In the laboratory and in animal models, P4HB generates a foreign-body and macrophage response while it is present, but because it resorbs, that reaction is self-limiting rather than permanent; one two-year evaluation reported higher collagen content and lower contractile-myofibroblast differentiation than permanent polypropylene, with no mesh exposures at 24 months (P4HB two-year evaluation, PMC11024044).

The regulatory status here must be stated precisely. GalaFLEX and Phasix are FDA-cleared bioabsorbable P4HB surgical scaffolds. Their cleared predicates under the FDA’s 510(k) substantial-equivalence pathway are surgical mesh (FDA product codes OOD/OXF), not sutures. Crucially, clearance for soft-tissue support and reinforcement is not the same as clearance for use in the breast. Use of these scaffolds to support breast reconstruction is generally off-label — that is, a use a physician may choose in their clinical judgment, but one for which the device is not specifically FDA-cleared. Peer-reviewed studies of P4HB scaffolds in breast tissue do exist (P4HB scaffold in the ptotic breast, Aesthet Surg J 2018), so it is not accurate to say the material has “never been studied” in the breast — but the data base for that specific application is far younger and thinner than for the device’s cleared indications. When a P4HB “internal bra” loses strength before the patient’s own tissue can carry the load, the result is the loss of support and contour change described in Bioabsorbable Scaffold Failure: P4HB (GalaFLEX) “Internal Bra” Collapse.

Acellular dermal matrix (ADM) — AlloDerm, Strattice, DermACELL, SimpliDerm — and the silk-derived scaffold SERI. ADM is a biologic material: human (cadaveric) or animal (porcine/bovine) dermis that has been processed to remove the donor cells, leaving behind the collagen scaffold. The goal is for the patient’s own cells to migrate in and remodel the matrix into the patient’s own tissue — integration rather than permanent encapsulation. ADM is widely used in implant-based breast reconstruction to create a supportive “sling” or pocket for a tissue expander or implant. As a biologic scaffold it is associated with lower capsular-contracture rates than some alternatives, but it is not biologically inert: explant histology still scores genuine inflammation, foreign-body giant-cell reaction, capsule fibrosis, and contractile myofibroblasts (ADM capsule histology, PubMed 27070347; DermACELL host-response study, PMC4161921). The characteristic breast-scaffold complications — fluid collections, sterile redness, and capsule formation — are covered in Seroma Formation with Breast ADM & Scaffolds, Red Breast Syndrome (Sterile Inflammatory Erythema of ADM), and Capsular Contracture (Periprosthetic Fibrous Capsule).

Breast material	What it is	Intended role	FDA status (in neutral terms)
GalaFLEX / GalaFLEX 3D / Phasix (P4HB)	Bioabsorbable synthetic monofilament scaffold; resorbs over ~12–24 months	Temporary “internal bra” support while the body lays down its own collagen	FDA-cleared as surgical mesh/scaffold for soft-tissue reinforcement; breast use is generally off-label
AlloDerm / Strattice / DermACELL / SimpliDerm (ADM)	Acellular human or animal dermis (decellularized collagen)	Supportive sling/pocket meant to be remodeled into the patient’s own tissue	Regulated as a tissue product/device; breast use widely practiced
SERI	Silk-derived bioresorbable scaffold	Temporary soft-tissue support and reinforcement	Cleared as a surgical scaffold for soft-tissue support

Broadening out: pelvic mesh and hernia mesh

The same basic idea — implant a sheet to reinforce weak tissue — is used in two other major areas, and these are where the longest safety and litigation history lies.

Transvaginal and pelvic mesh. This is most often knitted monofilament polypropylene (PP), a permanent (non-absorbable) plastic. It has been used to support a prolapsed pelvic organ (pelvic organ prolapse, or POP) and, in the form of a mid-urethral “sling,” to support the urethra and treat stress urinary incontinence. The mesh is meant to act as a permanent scaffold that the body’s tissue grows into.

Hernia mesh. Also most often polypropylene (and in some products polyester or ePTFE, sometimes with a coating or absorbable barrier layer), hernia mesh reinforces a weak spot in the abdominal wall so the hernia is less likely to recur. Some hernia products are placed inside the abdomen, against or near the bowel.

A central point about polypropylene is that, although it was historically described as “permanent” and “inert,” peer-reviewed analyses of mesh explanted from human patients and from animal models report that it is not inert in the body: it can undergo surface oxidation, cracking, embrittlement, and loss of molecular weight over time (Imel et al., Biomaterials 2015, DOI 10.1016/j.biomaterials.2015.09.015; Talley et al., J Biomater Sci Polym Ed 2017, PubMed 28081670; Smith et al., J Biomater Appl 2016, PubMed 26454268). Notably, an accelerated-aging study co-authored by FDA scientists likewise reported that oxidation and surface cracking increased with aging time and that no standardized bench test for oxidative susceptibility yet exists (Jain et al., J Biomed Mater Res B 2023, PubMed 37596906). We note for accuracy that the degree and clinical significance of in-vivo polypropylene degradation remain scientifically debated in the literature, with published exchanges on both sides (Int Urogynecol J 2016, “the myth”; rebuttal, “hardly a myth”). The detail of this process is covered in In-Vivo Oxidative Degradation & Cracking of Polypropylene Mesh, and the shed-particle question in Particle & Debris Shedding from Degrading Mesh.

What “supposed to work” means — and why it fails

Across all of these materials, the implant is meant to do one job: provide structural reinforcement while the body’s own healing builds durable support. The failure modes flow from how the body actually responds.

It is recognized as foreign. When a synthetic mesh is implanted, the immune system coats it with proteins, floods it with inflammatory cells, and dispatches scavenger cells (macrophages) that try and fail to digest fibers far larger than themselves — a stuck state pathologists call frustrated phagocytosis. The macrophages fuse into multinucleated foreign-body giant cells and recruit scar-making cells that wrap the mesh in a dense, contracting fibrous capsule. With a permanent mesh, the stimulus never goes away, so the reaction does not resolve — it becomes chronic (Nolfi et al., Am J Obstet Gynecol 2016, PMC5201165). This is the engine behind The Foreign-Body Response (Why the Body Reacts to Mesh) and the granulomatous reaction in Foreign-Body Granuloma & Chronic Granulomatous Reaction.
The scar contracts. The same scar capsule that the body builds around the mesh physically shrinks. Symptomatic pelvic mesh can contract substantially as the capsule tightens, tethering nerves and soft tissue (Nolfi et al., 2016, PMC5201165). This is the basis for Mesh Contraction / Shrinkage (“Roping” or Banding) and contributes to the pain injuries in Pain, Nerve & Quality-of-Life Injuries.
The material itself can change. For permanent polypropylene, oxidative attack by the body’s own immune chemistry can degrade the fiber surface over time, an irreversible chemical change discussed in Material Degradation & Systemic / Immune Reactions and In-Vivo Oxidative Degradation & Cracking of Polypropylene Mesh.
A resorbable scaffold can give out too early. For a bioabsorbable P4HB “internal bra,” the failure mode is not oxidative cracking but resorption and loss of strength — if the scaffold loses its mechanical support before the patient’s own tissue can carry the load, the repair sags or collapses, as described in Bioabsorbable Scaffold Failure: P4HB (GalaFLEX) “Internal Bra” Collapse.

For a fuller catalog of the materials themselves, see What Surgical Mesh and Breast Scaffolds Actually Are.

The regulatory backdrop, in neutral terms

Many of these devices reached the U.S. market through the FDA’s 510(k) substantial-equivalence premarket pathway, under which a manufacturer demonstrates that a new device is substantially equivalent to a legally marketed “predicate” device. We describe this pathway accurately in How These Devices Reached the Market: 510(k), MAUDE Reporting & Expert Review. The pathway itself has been the subject of published critiques by the U.S. Government Accountability Office (GAO) and the Institute of Medicine / National Academies — critiques we report attributed to those bodies, in their words, rather than in our own.

For transvaginal POP mesh specifically, the FDA’s position evolved over more than a decade. After safety communications in 2008 and 2011 and a 2016 reclassification of transvaginal POP mesh to the highest-risk Class III, on April 16, 2019 the FDA ordered the remaining manufacturers (Boston Scientific and Coloplast) to stop selling and distributing their transvaginal mesh products for pelvic organ prolapse, stating that the data submitted “did not provide a reasonable assurance of safety and effectiveness” for those devices (FDA: Urogynecologic Surgical Mesh Activities). It is important to keep this precise: that 2019 order applied to transvaginal mesh for pelvic organ prolapse. It did not ban hernia mesh, and it did not ban all mid-urethral slings for stress urinary incontinence. The full timeline is laid out in FDA Action on Surgical Mesh: 2008 → 2011 → 2016 → the 2019 Ban.

Separately — and this is the FDA action most relevant to breast scaffolds — on November 9, 2023 the FDA issued a “Letter to Health Care Providers” concerning the use of absorbable and bioabsorbable mesh and scaffolds (including P4HB) in implant-based breast reconstruction and breast revision surgery, addressing this class of bioabsorbable products generally rather than singling out any one named product as requiring an immediate labeling change (FDA, Letter to Health Care Providers, Nov. 9, 2023).

If you or a loved one has been affected by a surgical mesh or breast-scaffold complication, our team offers a free, confidential consultation. This page is educational legal and medical information, not medical advice; it does not tell you whether to keep or remove any device, and it is not a substitute for the guidance of your own physician. Decisions about your implant should always be made with your treating doctor.

◀ What Surgical Mesh and Breast Scaffolds Actually Are · ↑ Top · Structural-Failure Injuries (Pelvic & Hernia Mesh) ▶

Structural-Failure Injuries (Pelvic & Hernia Mesh)

Surgical mesh is meant to be a flat, soft reinforcement that the body quietly walls off and ignores. The injuries in this cluster are what happens when that does not occur — when a permanent implant instead wears through the wall it was buried in, drifts out of position, or is squeezed into a stiff band by the body’s own scar tissue. Each of these is a structural failure: the device is no longer where, or what, it was supposed to be. They share a single biological root — the foreign-body response and the way mesh fails inside the body — and they overlap heavily with the pain, infection, and functional injuries described elsewhere on this page.

Mesh Erosion, Exposure & Extrusion

What it is. Surgical mesh — usually knitted polypropylene — is implanted to hold up a dropped bladder, uterus, or vaginal wall (pelvic organ prolapse), or to support the urethra and stop urine leakage (a “sling”). It is supposed to stay buried in tissue while scar grows through its pores and locks it in place. In erosion, exposure, and extrusion, the mesh instead works its way out of the tissue. Clinicians use three overlapping terms, and the distinction matters:

Exposure / extrusion — the mesh wears through the lining of the vagina and becomes visible or palpable in the vaginal canal. Medical literature defines extrusion as “the presence of exposed graft material in the vagina.” Source
Erosion — the mesh works into the lumen of a neighboring hollow organ, e.g., “the presence of graft material in the lumen of the urinary tract,” meaning the mesh is now inside the bladder or urethra. The same process can carry mesh into the rectum after abdominal (sacrocolpopexy) repairs. Source

The biological mechanism. Erosion is the visible end-stage of the foreign-body response. On contact, host proteins coat the fibers; macrophages arrive but cannot digest a polypropylene filament many times their size and so fuse into multinucleated foreign-body giant cells that remain on the fiber “for the lifetime of the device,” discharging reactive oxygen species, acid, and matrix-degrading enzymes. Source On explanted human vaginal mesh, the normal handoff from pro-inflammatory (M1) to healing (M2) macrophages never completes: researchers measured an M2:M1 ratio of 0.260 on mesh explants versus 1.772 in mesh-free controls (P = .001), with TNF-α elevated 2.13-fold — a chronic, persistent inflammatory state. Source Two forces then push the mesh through the wall: active tissue degradation (in exposure specimens, pro-MMP-9 ran 88% higher than in painful encapsulated mesh, P = .035) and pressure necrosis, where a folded or over-tensioned band restricts the tissue’s blood supply until it dies and the fiber advances. Source As one review put it, “rolling of the tape during placement or vaginal suturing may produce a narrow band that can result in pressure necrosis and erosion.” Source

What patients notice. Vaginal exposure can feel like a sharp or rough edge in the vagina and causes chronic discharge, recurrent infection, abnormal bleeding, and pain or injury to a partner during intercourse. Erosion into the bladder or urethra produces relentless urgency and frequency, recurrent urinary infections that never fully clear, blood in the urine, pain on urination, and stones that crystallize onto the exposed fibers. Source Bowel erosion presents with rectal bleeding, discharge, pain, or fistula. These problems can appear years after a technically “successful” implant. Source

Why it matters / reversibility. Severity scales with location. Small vaginal exposures sometimes re-epithelialize with vaginal estrogen and abstinence. Source But authorities are explicit that “erosion into the urinary tract mandates complete removal of mesh regardless of mesh type,” because the eroded segment will not heal in place and seeds chronic infection and stones. Source Because polypropylene does not dissolve, the inciting foreign body persists for life unless surgically excised — and excision means cutting mesh out of living, scarred tissue, often in multiple operations and frequently incompletely. Source The U.S. FDA reclassified transvaginal mesh for prolapse as a Class III (high-risk) device in 2016 and, on April 16, 2019, ordered all manufacturers to stop selling and distributing transvaginal mesh kits for pelvic organ prolapse, having concluded the makers could not show a reasonable assurance of safety and effectiveness — with erosion, pain, bleeding, and dyspareunia among the driving complications. Source This injury is associated above all with permanent polypropylene devices from manufacturers including C.R. Bard / Davol (now Becton Dickinson), Johnson & Johnson / Ethicon, Boston Scientific, American Medical Systems, and Coloplast. See also how mesh fails and the device overview.

Perforation of Bladder, Bowel or Ureter

What it is. Mesh is placed millimeters away from hollow organs — the bladder, loops of bowel, and the ureters (the thin tubes carrying urine from the kidneys to the bladder). “Perforation” means the mesh has worked its way through the wall of one of those organs, either at the time of surgery or, far more often, by slowly cutting and eroding its way in over months to years. The result is a hole, a chronic open wound, or an obstruction that does not heal on its own because the foreign object is still there.

The biological mechanism. This is the same foreign-body response that drives erosion. Frustrated macrophages that cannot engulf the fiber switch into a pro-inflammatory M1 phenotype and pour out IL-1β, IL-6, and TNF-α; many fuse into foreign-body giant cells that stay glued to the mesh “for the entire life of the implant,” continuously secreting degradative enzymes. Source Two forces then combine to make a hole: the chronic inflammatory enzyme bath continuously erodes the soft tissue at the mesh–organ interface, while fibrotic contraction folds the flat sheet into stiff, sharp ridges that abrade the thin, constantly moving organ wall — and because urine and stool are not sterile, low-grade chronic infection accelerates the breakdown. Source

What patients notice.

Organ	Typical symptoms
Bladder	Recurrent UTIs that keep returning despite antibiotics, blood in the urine, burning, urgency, incomplete emptying, pain, and stones forming on the mesh. In one series, two-thirds of patients with sling erosion presented with recurrent UTI symptoms. Source
Bowel	Chronic abdominal pain, abscess or fistula, bouts of infection, and sometimes blockage — a recognized, if uncommon, late complication. Source
Ureter	Often silent at first; the ureter is kinked, scarred, or compressed, urine backs up, and the kidney swells (hydronephrosis), sometimes found only on imaging after silent kidney damage. Source

A defining and difficult feature is delay: these injuries frequently announce themselves more than two years after the original operation. Source

Why it matters / reversibility. Bladder perforation produces recurrent infection, bleeding, stones, and pain; bowel perforation can produce abscess, fistula, and life-threatening infection; ureteral involvement can cause hydronephrosis and, if unrecognized, silent loss of kidney function. Source Eroded mesh does not heal over or extrude on its own, so the only definitive fix is surgical removal of the involved mesh plus repair of the organ — sometimes with formal reconstruction such as ureteral reimplantation. Source But “removable” is not “reversible”: minimally invasive excision often cannot reach the portion buried in the bladder wall, and incomplete removal is associated with recurrence of erosion. Source Even with dedicated removal, one holmium-laser series reported symptomatic improvement in about 80% of patients but anatomic clearance after a single procedure in only about 63% of cystoscopies, so repeat operations are common. Source The fibrosis, contraction, and tissue loss the mesh created do not reverse when the device is removed. This injury is overwhelmingly a permanent-synthetic-mesh phenomenon — chiefly knitted polypropylene; the FDA’s published material-safety summaries note that patients receiving synthetic polypropylene mesh are at greater risk for mesh erosion than those receiving biologic graft or native-tissue repair. Source The devices involved are the polypropylene hernia meshes and slings of Becton Dickinson / C.R. Bard / Davol, Atrium and Covidien, and the pelvic-mesh makers listed above.

Fistula Formation (Vesicovaginal, Rectovaginal, Enterocutaneous)

What it is. A fistula is an abnormal tunnel between two body spaces that are never supposed to be connected. When mesh slowly cuts through an organ wall by erosion and perforation, it can carve one of these tunnels:

Vesicovaginal fistula — bladder to vagina; the person leaks urine continuously out of the vagina, day and night.
Rectovaginal fistula — rectum to vagina; stool, gas, and foul discharge pass out through the vagina, with recurrent infection and a constant odor. Source
Enterocutaneous fistula — bowel to skin; intestinal contents drain out through an opening on the abdominal wall, often years after a hernia repair. Source

The hallmark is the loss of a basic control — continence of urine or stool — replaced by leakage no pad or hygiene routine can contain. Between January 2011 and December 2013 the FDA logged 19,043 adverse-event reports for surgical mesh used in pelvic organ prolapse repair, with pain, erosion, and injury the most common. Source

The biological mechanism. A mesh-erosion fistula is the end stage of the same chronic foreign-body reaction. Macrophages coat the protein-flagged fibers, fail to engulf them, and fuse into foreign-body giant cells (defined as cells with three or more nuclei) that blanket the fiber for the life of the implant. Source The giant cells and macrophages pump out TGF-β, which converts fibroblasts into contractile myofibroblasts that lay down dense type I collagen and physically contract, shrinking the implant. Source The tunnel then forms when two forces converge on the organ wall: mechanical abrasion by the stiff, contracting scar plate, and chemical erosion by ongoing matrix-metalloproteinase activity that digests the tissue meant to hold the organ together. Source Once both walls are breached, a permanent epithelialized tunnel is established — in the abdomen, a process described as gradual erosion that may take several years. Source

What patients notice. Continuous, uncontrollable leakage of urine (vesicovaginal), passage of stool and gas from the vagina (rectovaginal), or intestinal drainage from the abdominal wall (enterocutaneous), with recurrent infection, skin breakdown, painful or impossible intercourse, and — for enterocutaneous fistulas — fluid and electrolyte loss, malnutrition, and the danger of sepsis. The damage is typically not sudden but a slow process that often appears months or years after surgery. Source

Why it matters / reversibility. A mesh-erosion fistula is among the most disabling complications of implant surgery; the FDA emphasized in its 2011 Safety Communication that serious complications are “NOT rare.” Source Reversal is partial and rarely clean. The fistula will not close while the mesh remains, so the eroded mesh must be surgically removed and the fistula then repaired. Source Removal is difficult and often incomplete — in one vesicovaginal case, removing the eroded mesh produced a fresh 2 cm × 2 cm rent into the bladder, and repair required staged reconstruction with an interposed Martius flap. Source Even when a fistula is successfully closed, the scarring, tissue loss, and contraction caused by the foreign-body reaction are often irreversible. Source Reported transvaginal-mesh fistula rates run roughly 0.15%–1% for rectovaginal fistula, with exposure occurring in roughly 3.2%–4.3% of cases. Source This injury is overwhelmingly a permanent-polypropylene phenomenon associated with the pelvic-mesh and hernia-mesh devices of the manufacturers documented on this page; reflecting this risk profile, the FDA ordered transvaginal prolapse mesh off the market in April 2019. Source

Mesh Migration & Displacement

What it is. The surgeon intends mesh to stay exactly where it is anchored, get incorporated into the body by scar tissue, and never move. Migration is what doctors call it when the mesh does not stay put — shifting from a few millimeters to far enough to end up wadded inside the bladder, bowel, or vagina, or floating loose in the abdomen. Migration and erosion are tightly linked: erosion is one of the main ways mesh travels, and a migrating mesh erodes as it goes. Source

The biological mechanism. Surgeons divide migration into two routes. Primary (mechanical) migration is a poorly fixed mesh sliding along the path of least resistance. Secondary migration is slow trans-anatomical creep “owing to the erosion and destruction of tissue structure caused by foreign body reaction between the mesh and tissue.” Source The driver of secondary migration is the chronic foreign-body response: macrophages that cannot resolve the implant remain at the interface “for the lifetime of the implanted device,” polarize to M1, and fuse into giant cells that secrete reactive oxygen species, acids, and matrix metalloproteinases onto the implant and adjacent tissue — with infrared spectroscopy of explanted polypropylene showing significant oxidative degradation of the material over time. Source Meanwhile TGF-β drives myofibroblast differentiation; these α-SMA-positive cells pull the collagen scar tight through the mesh pores, balling a flat sheet into a crumpled plaque — and myofibroblast contraction itself activates more latent TGF-β1, a feed-forward loop that “tends toward irreversible fibrosis.” Source That contracting traction plus giant-cell erosion is what moves the mesh through tissue planes.

What patients notice. New, persistent pain in the groin, pelvis, or abdomen, and a hard, lumpy, or “pulling” sensation. Vaginal erosion presents as exposed mesh felt by the patient or partner, discharge or bleeding, and pain during sex — the complication most reported to the FDA for these devices. Source Migration into the bladder produces blood in the urine, repeated infections, and stones; migration into the bowel can cause chronic abdominal pain, bleeding with anemia, blockage, abscess, fistula, and life-threatening infection. Source

Why it matters / reversibility. Severity ranges from an incidentally found asymptomatic mesh to a surgical emergency such as bowel obstruction with intra-abdominal sepsis. Source The underlying fibrosis is essentially irreversible — contracted, cross-linked collagen does not relax back. Source Removal is possible but often partial: because permanent mesh becomes densely integrated into scar and may be wrapped around or eroded into bladder, bowel, nerves, or vessels, complete excision is technically difficult and frequently requires multiple operations. The FDA warns that mesh complications — particularly pain and the effects of mesh contraction — may persist after the device is removed and “may not be completely correctable with surgery.” Source The material principally involved is non-absorbable polypropylene, which shows the highest rate of penetrating the bladder muscularis among mesh types. Source Cone-shaped mesh “plugs” are particularly associated with primary mechanical migration into the bladder and bowel. Source The associated devices are the polypropylene hernia and pelvic products of Becton Dickinson / Bard, Atrium / Covidien, and the pelvic-mesh manufacturers whose transvaginal kits the FDA ordered off the market.

Mesh Contraction / Shrinkage (“Roping” or Banding)

What it is. Mesh goes in as a flat, flexible, tension-free sheet. It does not shrink like wool in hot water — instead the body walls it off in living scar tissue that actively pulls, dragging the mesh into a smaller, thicker, wrinkled, rope-like wad. This is why surgeons describe explanted mesh as “bunched, rolled, tight-band, wadded, gathered, or taut” rather than flat; in one 14-year surgical removal series, roughly 70% of the meshes were found not lying flat or tension-free at the time of removal. Source Measured shrinkage of a polypropylene implant can reach 30–50% of its original surface area within about four weeks in experimental models, and in humans after inguinal hernia repair the mesh area continued shrinking to about 84% of its original area by one year. Source

The biological mechanism. Contraction is the visible end-result of the foreign-body response, which around a permanent material stalls in a chronic contractile state. Around polypropylene the M1 macrophage state persists; in a direct study of polypropylene hernia mesh, the inflammatory response was chronic and macrophage-driven, with TNF, IL-1β, and IL-6 strongly upregulated and persisting without attenuation for up to 90 days in animals and confirmed in human explants more than a year after implantation, even in asymptomatic patients. Source The persistent macrophages and giant cells release TGF-β1, which — combined with mechanical tension — drives fibroblasts (and macrophages themselves, via macrophage-to-myofibroblast transition) to become myofibroblasts. In a primate prolapse-mesh model, active and latent TGF-β1 rose with increasing mesh burden, and the highest TGF-β1 coincided with the highest fraction of macrophage-derived myofibroblasts. Source The myofibroblast is defined by α-smooth-muscle actin assembled into contractile stress fibers; these cells grip the surrounding collagen and physically shorten, dragging the embedded mesh into folds. Source The loop is self-amplifying — mechanical pulling frees active TGF-β1 from its latent stores with no enzyme required, so more contraction yields more TGF-β1 yields more myofibroblasts, and the rigid mesh supplies the stiff surface the loop needs. Source

What patients notice. Wherever the mesh sits, soft, mobile tissue can become a tight, tethered band:

Pelvic / transvaginal mesh: vaginal shortening and tightening, a palpable hard band or ridge, pelvic and vaginal pain, and pain with intercourse. The FDA formally recognized “vaginal shortening, tightening, and/or pain due to mesh contraction” as a distinct, previously under-appreciated risk of transvaginal prolapse mesh. Source
Hernia mesh: a hard, sometimes tender plate in the abdominal or groin wall, restricted movement, chronic pain, and a contracted mesh that pulls away from its anchors — a recognized contributor to recurrence. Source
Breast scaffold / acellular dermal matrix with implants: capsular contracture — the scar shell tightens, hardens, distorts, and can become painful. Source

Why it matters / reversibility. This is a measurable, microscopic, mechanical process — living scar cells loaded with muscle-type contractile protein squeezing a permanent implant into a hard band. Once a mature fibrotic capsule with persistent α-SMA myofibroblasts forms around a non-degrading mesh, the contractile state is self-sustaining; the stiff implant keeps activating TGF-β1 and blocks the programmed death of the myofibroblasts that would normally die off after healing. Source Removal is only surgical and imperfect: the contracted mesh is incorporated into dense scar and entrapped in tissue, often cannot be removed in one clean piece, and demands advanced surgical expertise. Source In a long-term transvaginal mesh-removal series, pain resolved in about 50% of patients and dyspareunia in about 52%, but roughly 12% had persistent dyspareunia and about 2% developed new dyspareunia after removal — outcomes are not uniform, and the scar and nerve injury already laid down may persist even after the mesh is gone. Source Contraction is associated above all with permanent polypropylene mesh used in hernia repair, prolapse, and slings, as well as polyester and ePTFE; the FDA’s safety communications on transvaginal-mesh contraction preceded its order removing those products from the U.S. market. Source For the breast counterpart of this scar-shell injury, see capsular contracture and the breast scaffold cluster.

This is general medical information, not medical advice. Outcomes vary from person to person and no result is guaranteed; discuss any symptoms or treatment decisions with your own physician.

◀ How Mesh Is Supposed to Work — and How It Fails in the Body · ↑ Top · Pain, Nerve & Quality-of-Life Injuries ▶

Pain, Nerve & Quality-of-Life Injuries

Some of the most common and most disabling consequences of surgical and breast mesh are not dramatic events like a perforation — they are slow, progressive injuries to the body’s pain and nerve systems: chronic pelvic pain, trapped nerves, painful or numb sex, hardened painful breast tissue, and the depression and trauma that can follow living with constant pain. This section explains, in plain English, what each of these injuries is, the cellular biology that drives it, what patients may experience, and how serious and how reversible it tends to be. To understand why the body reacts to an implant at all, it helps to first read how mesh is supposed to work — and how it fails in the body and the foreign-body response.

Chronic Pelvic Pain (Fibrotic Foreign-Body Injury)

Surgical mesh is a permanent plastic implant — most often a knitted polypropylene net — placed in the pelvis to support organs that have dropped (pelvic organ prolapse) or to support the urethra against urine leakage (stress incontinence). The body does not incorporate this plastic as part of itself; the published literature describes it surrounding the mesh, mounting an inflammatory response, and walling it off in scar tissue, much as it would a foreign object it cannot dissolve. Because the mesh does not degrade, that walling-off process can continue, producing a low-grade inflammatory reaction that may persist for years.

As the scar tissue matures, it shrinks and tightens around the mesh. Published measurements show transvaginal prolapse meshes can contract substantially after implantation, putting tension on adjacent tissue and nerves (Int Urogynecol J, PMC6909865). Patients may experience this as constant pelvic or groin pain, a “pulling” sensation, painful bowel movements, painful intercourse, and a tightening of the whole pelvic floor (Management of Mesh Complications, PMC4418012). The FDA recognized vaginal shortening, tightening, and pain caused by mesh contraction as a risk of these devices and, in April 2019, ordered manufacturers to stop selling transvaginal prolapse mesh in the U.S. because they had not demonstrated a reasonable assurance of safety and effectiveness (FDA — Urogynecologic Surgical Mesh: FDA Activities). See the FDA’s 2008→2019 timeline and mesh contraction / shrinkage.

The mechanism, step by step. The injury follows the well-described foreign-body reaction. With a non-degradable implant like polypropylene, the published literature reports that the reaction does not reach resolution; it settles into a chronic, self-renewing inflammatory and fibrotic state (Macrophages, Foreign Body Giant Cells and Their Response to Implantable Biomaterials, PMC5512621).

Protein adsorption (seconds). Host proteins coat the mesh surface; this film is what the immune system “reads” (PMC5512621).
Acute inflammation (hours to days). Neutrophils and mast cells arrive; mast cells release IL-4 and IL-13, influencing how aggressive the later reaction will be (PMC5512621).
Macrophage recruitment and “frustrated phagocytosis.” Macrophages attempt to engulf the fibers but cannot — polypropylene is too large and chemically stable — so they remain activated, releasing IL-1β, IL-6, and TNF-α. In animal implants IL-1 was reported to rise rather than fall over time (30 days greater than 4 days) (Pro-inflammatory cytokines and MMP activation in PP mesh, PMC6092648). Hernia-repair studies describe polypropylene driving a myeloid-cell–driven persistent inflammation that does not switch off (Polypropylene mesh causes myeloid cell–driven persistent inflammation, JCI Insight, PMC6413778).
Foreign-body giant cells. Unable to engulf the fiber, macrophages fuse into multinucleated foreign-body giant cells (driven by IL-4/IL-13) that adhere to the fibers for the life of the implant (PMC5512621).
Myofibroblasts and contraction — a source of the pain. Under TGF-β1, fibroblasts convert into myofibroblasts that express α-smooth-muscle actin and gain a contractile apparatus (TGF-β1 and myofibroblast differentiation, PMC3663506). They lay down dense, disorganized collagen and contract it, drawing the mesh and tethered tissue inward (PMC6909865).
Nerve involvement. Matrix metalloproteinases (MMP-2/3/9) continuously remodel tissue, and the advancing scar can encase and entrap pelvic nerves, converting a mechanical problem into chronic neuropathic pain (PMC6092648; PMC4418012).

What the pathologist sees. A study of mesh explanted from women with mesh complications and pain documented a dense chronic inflammatory infiltrate hugging every fiber (682 ± 143 cells per field vs. 442 ± 126 in controls, P < .001); foreign-body giant cells on the polypropylene filaments; a macrophage population skewed to the inflammatory M1 phenotype (M2:M1 ratio 0.26 ± 0.16 in mesh vs. 1.77 ± 1.92 in controls, P = .001); TNF-α elevated 2.13-fold (P < .001); and MMP-9 activity elevated roughly 2.9-fold (P < .0001) (Host response to synthetic mesh in women with mesh complications, PMC5201165). The reported picture is a persistently inflamed scar surrounding a non-degradable object rather than fully healed tissue.

Which devices. The principal material is non-degradable knitted monofilament polypropylene, used in the transvaginal prolapse and sling devices the FDA acted against and in hernia mesh (PMC5512621; PMC6413778). The 2019 order applied to the remaining transvaginal POP-mesh manufacturers (FDA Activities). By contrast, the bioabsorbable poly-4-hydroxybutyrate (P4HB) scaffolds GalaFLEX and Phasix are gradually resorbed and, in published studies, provoke a milder, largely self-limiting response, with significantly lower myofibroblast differentiation than polypropylene at 180 days and 24 months (Short-term host response of P4HB scaffold, PMC9303173; Two-year evaluation of P4HB scaffold for POP, PMC11024044). See what these devices are, the manufacturers’ documented records, and Coloplast and Cook.

How serious, and is it reversible? The FDA states adverse events from transvaginally placed mesh “can be life-altering for some women,” with pain among the persistent sequelae (FDA Activities). The injury is frequently not reversible: because polypropylene becomes incorporated into dense scar, removal is “very difficult,” often requires multiple operations, and carries its own risk of bleeding, fistula, neuropathy, and prolapse recurrence; both the FDA and the surgical literature warn that pain can persist even after the mesh is removed; and in reviewed series only about 28% of patients reported relief of chronic pain after salvage surgery (PMC4418012; FDA Activities). See hard-to-remove mesh and failure requiring explantation.

Neuropathic Pain & Nerve Entrapment

Nerves are the body’s electrical wiring. When a permanent plastic mesh is implanted — for a hernia, a prolapse, or as a sling — the body walls it off in a dense band of scar. If a sensory nerve runs through that zone, or is pinned by a tack, suture, or the mesh edge, the scar can compress, tether, and constrict the nerve. The result is neuropathic pain — pain generated by a damaged nerve itself, not by ongoing injury to skin or muscle.

Patients describe burning, electric-shock, or stabbing pain; numbness or pins-and-needles; a sensation of sitting on a golf ball; and pain that flares with movement, sitting, intercourse, or a full bladder. The location depends on which nerve is affected:

Nerve	Typical device/route	What the patient feels
Pudendal	Pelvic/prolapse mesh, slings	Pain in the vulva, perineum, scrotum, penis, or anus; worse sitting, eased standing; painful intercourse; burning with urination/bowel movements (pudendal neuralgia) (Pudendal Nerve Entrapment Syndrome, StatPearls/NCBI)
Obturator	Transobturator slings (TOT/TVT-O)	Inner-thigh and groin pain/numbness, sometimes leg weakness severe enough to impair walking (Int Urogynecol J 2020, Springer)
Ilioinguinal / iliohypogastric	Inguinal hernia mesh	Burning groin pain to the inner thigh, base of penis/scrotum or labia, worse on walking/twisting (inguinodynia) (Role of neurectomy in inguinodynia, PMC8742623)

The mechanism. Two processes combine. First, the same chronic foreign-body response — protein adsorption, macrophage recruitment, foreign-body giant cell fusion, and TGF-β–driven myofibroblast conversion — builds a dense, contracting collagen capsule within weeks (Foreign body reaction to polypropylene meshes in the human abdomen, PMC8881270; Macrophage polarization to ECM-coated mesh, PMC4347831). Second, when a sensory nerve runs through that contracting scar or is fixed by a tack or suture, it can sustain a compression injury: pressure causes venous stasis, edema, and thickening of the nerve sheaths, then focal demyelination (loss of the insulating layer), then axonal degeneration. A demyelinated, scar-tethered nerve can fire spontaneously, and this ectopic firing is described as the physical source of the burning, electric pain (US for nerve injury and entrapment neuropathy, RadioGraphics 2021; Role of neurectomy in inguinodynia, PMC8742623).

What the pathologist sees. An explanted polypropylene specimen shows a dense inner cellular infiltrate (predominantly mononuclear cells) — a mixture of macrophages and lymphocytes with foreign-body giant cells — surrounded by an outer fibrotic capsule; immunostaining shows CD68+ macrophages alongside CD4+ and FoxP3+ T cells (PMC8881270). A resected entrapped nerve shows epineurial fibrosis, perineurial thickening, demyelination/remyelination, loss of large myelinated axons, and sometimes a traumatic neuroma — changes described as irreversible once established (RadioGraphics 2021).

Which devices. The most-implicated material is non-degradable polypropylene: transvaginal prolapse mesh (e.g., Boston Scientific Uphold LITE and Xenform; Coloplast Restorelle DirectFix Anterior — all ordered off the U.S. market on April 16, 2019), midurethral slings placed through the obturator route, and polypropylene inguinal hernia mesh (FDA Activities; FDA — POP Surgical Mesh Considerations). The resorbable P4HB scaffold GalaFLEX still provokes a foreign-body reaction with giant cells but resorbs over roughly 18–24 months and, in the literature, tends to shift macrophages toward a remodeling phenotype, generally producing less permanent fibrosis (The History of GalaFLEX P4HB Scaffold, Aesthet Surg J, PMC5070449).

How serious, and is it reversible? Chronic groin pain after inguinal hernia mesh is reported at roughly 1%–19%, with about 6% suffering severe chronic pain (PMC8742623); groin/thigh pain after transobturator slings is reported in up to about 9.7% (Persistent groin pain after TOT, Int Urogynecol J 2008). Caught early, removal can reverse the nerve damage — “the sooner the tape is removed, the better the chance” of reversibility (Int Urogynecol J 2020). But once the process matures into epineurial fibrosis, demyelination, and axonal loss, the changes are typically permanent, and the FDA expressly warns that mesh is a permanent implant whose removal may require multiple operations, may be incomplete, and can create additional complications (FDA — POP Surgical Mesh Considerations). No single treatment — medication, physiotherapy, nerve blocks, neurolysis, neurectomy, or neuromodulation — is reliably curative (Pudendal Nerve Entrapment Syndrome, StatPearls).

Dyspareunia, Loss of Sensation & Sexual Dysfunction

When mesh is placed in or near the vagina, a recognized and not-rare result is painful sex (dyspareunia), a deadening or loss of normal sensation, and a broader collapse of sexual function. The FDA found that serious complications of transvaginal prolapse mesh are not rare and specifically identified vaginal shortening, tightening, and pain from mesh contraction as a risk (FDA — POP Surgical Mesh Considerations).

What patients describe falls into a few patterns:

A short, tight, scarred vagina. The mesh can harden the tissue into a stiff, sometimes banded plate so that penetration meets an unyielding, tender wall. In a clinical series cited by the FDA, every sexually active woman with contracted mesh reported dyspareunia, with pinpoint tenderness over the contracted mesh (FDA — POP Considerations).
Sharp, catching, or burning pain on contact — often from mesh that has eroded through the vaginal skin, leaving a hard exposed edge. Erosion through the vagina is the most common mesh-specific complication of prolapse surgery (FDA — Urogynecologic Surgical Mesh Implants). See mesh erosion, exposure & extrusion.
Loss of sensation and loss of orgasm, as scar replaces the normal soft, well-innervated vaginal wall.
Partner pain (“hispareunia”). Where mesh has eroded through the vaginal wall, the exposed edge can scratch or contact the partner during intercourse; the FDA lists partner pain as a recognized symptom of mesh exposure (FDA — Urogynecologic Surgical Mesh Implants).

The mechanism. Because the body does not dissolve permanent polypropylene, it mounts the foreign-body response that the literature reports does not fully switch off (host response review, PMC9035125). Macrophages swarm the fibers — about a quarter of the cells in the foreign-body granuloma are CD68+ macrophages concentrated at the mesh interface (PMC8881270) — and, unlike a normal wound, the inflammation has been observed to continue without substantial attenuation over a 90-day course in hernia-mesh models (JCI Insight, PMC6413778). Macrophages fuse into foreign-body giant cells, release IL-1β, IL-6, and TNF-α, and secrete TGF-β, which converts fibroblasts into contractile myofibroblasts (Dysregulated Wound Healing, PMC10698181). The myofibroblasts contract the scar — the same mechanism behind capsular contracture around breast implants — shortening, tightening, and puckering the vaginal wall and pulling on nerves. A direct, dose-dependent relationship has been reported: increasing histologic fibrosis around vaginal mesh explants is linearly associated with higher pelvic-pain scores, and women with persistent pain after removal had roughly double the TGF-β of women who improved (PMC10698181). Nerve entrapment is one documented pathway, though in 173 excised specimens abnormal nerve proliferation was found in only about 2.9%, pointing back to the cytokine-and-fibrosis mechanism as the dominant cause (ICS 2024 Abstract #832).

What the pathologist sees. Around the empty vacuoles left where each filament sat, the reports describe granulomatous chronic inflammation, multinucleated foreign-body giant cells rimming the fibers, a mixed macrophage-and-T-cell infiltrate, dense fibrosis with prominent α-SMA-positive myofibroblasts, and, in older implants, frayed/cracked filaments and enlarged vacuoles signaling fiber degradation (PMC8881270; sacrocolpopexy explant series, PMC10945158). See in-vivo degradation and cracking.

Which devices. Permanent polypropylene is the principal material involved. On April 16, 2019, the FDA ordered the last manufacturers of transvaginal polypropylene prolapse mesh to stop selling in the U.S.: Boston Scientific’s Uphold LITE Vaginal Support System and Xenform Soft Tissue Repair System, and Coloplast’s Restorelle DirectFix Anterior (FDA press announcement, April 16, 2019). The resorbable P4HB scaffolds GalaFLEX and Phasix degrade over roughly 12–24 months and, in published studies, drive an earlier shift toward a pro-remodeling macrophage phenotype with milder, more self-limited fibrosis (P4HB scoping review, PMC10130450). Acellular dermal matrix (e.g., Strattice) is a biologic scaffold meant to be repopulated by host cells and is reported to elicit fewer myofibroblasts and a thinner capsule (ADM reduces myofibroblasts, PubMed 31333946). See breast scaffolds & ADM.

How serious, and is it reversible? This is a quality-of-life injury, not a minor one. The FDA’s central finding was that serious complications of transvaginal POP mesh are not rare and that the benefits did not outweigh the risks — the basis for removing these devices (FDA — Urogynecologic Surgical Mesh Implants). Permanence is central: polypropylene does not absorb, removal is often incomplete because tissue grows through the pores, and removal does not guarantee relief because the contractile myofibroblasts and collagen left behind can continue to generate pain — women with persistent post-removal pain carried roughly double the TGF-β of those who recovered (PMC10698181). Partner pain (“hispareunia”) is usually relieved by trimming the exposed edge but can recur if exposure recurs (FDA — Urogynecologic Surgical Mesh Implants).

Fat Necrosis & Chronic Breast Pain (Mastalgia)

When a surgeon uses a sheet of mesh or a graft of processed tissue — a “scaffold” — to support the breast during a lift, reduction, augmentation, or reconstruction after cancer, the body treats the sheet as a foreign object and mounts a slow defensive reaction. Two problems commonly result, and they often travel together.

The first is fat necrosis — a patch of the breast’s own fat dies. Fat is among the most fragile breast tissue, kept alive by a delicate blood supply. Surgery, tension, pressure from the scaffold, and the inflammation it provokes can compromise that supply. The dead fat does not simply disappear: the body breaks it down into fatty acids that combine with calcium to form a soapy, chalky residue (a saponification reaction), and the area scars down. The patient may feel a firm, sometimes hard, tender lump, sometimes with skin dimpling or retraction. Because a hard, irregular, calcified lump can resemble breast cancer on examination and on a mammogram, fat necrosis routinely triggers callbacks, repeat imaging, and biopsies (StatPearls / NCBI Bookshelf, NBK542191; Lipids in Health and Disease 2019, PMC6560815).

The second is chronic breast pain (mastalgia) that outlasts normal healing — burning, aching, shooting, or electric pain driven by the same foreign-body inflammation, by nerves trapped or sprouting into painful knots (neuromas) within the scar, and, when an implant is present, by a thick contracting capsule (Post-Mastectomy Pain Syndrome, PMC7734930; Diagnosis and Management of Neuropathic Breast Pain, PMC11666212).

The mechanism. The foreign-body response is the dominant event at the scaffold–tissue interface, and around a permanent material the literature reports the inflammatory cells stay “for the lifetime of the device” (Macrophages, Foreign Body Giant Cells, PMC5512621; Mechanisms of Foreign Body Giant Cell Formation, PMC10007405). Macrophages polarize to the pro-inflammatory M1 phenotype, fail to engulf the material, and fuse into foreign-body giant cells (driven by IL-4/IL-13 through STAT6); with permanent synthetic mesh, IL-1β, IL-6, and TNF-α stay elevated and the macrophages do not switch to a healing phenotype even after 90 days (Polypropylene mesh persistent inflammation, JCI Insight, PMC6413778). The giant cells secrete TGF-β, converting fibroblasts into α-SMA-positive myofibroblasts that lay down dense collagen and pull the tissue tight; contracted, painful breast-implant capsules show significantly greater collagen alignment and α-SMA immunoreactivity than uncontracted ones, directly linking myofibroblast contraction to clinical stiffness and pain (Histological Characterization of Human Breast Implant Capsules, PMC4434852).

The fat-necrosis arm runs in parallel: ischemia kills adipocytes, lipase liberates free fatty acids that complex with calcium into saponified deposits, lipid-laden “foamy” macrophages and giant cells move in to clear the debris, and the area resolves into fibrosis, oil cysts, or chalky calcification (NBK542191; PMC6560815). The pain arm is largely neuropathic — neuromas, nerve entrapment in contracting scar, and injury to sensory nerves, with the same IL-1β/IL-6/TNF-α sensitizing nociceptors and the central nervous system “winding up” over time (PMC7734930; Traumatic neuroma as a cause of breast pain, PMC6119675).

What the pathologist sees. Fat necrosis: anucleate “ghost” adipocytes, sheets of foamy lipid-laden histiocytes, multinucleated foreign-body giant cells, hemosiderin-laden macrophages, saponified debris, oil cysts, dystrophic calcification, and a rim of fibrosis (NBK542191; Fat necrosis: a consultant’s conundrum, PMC9978799). Synthetic mesh explants show dense infiltration of mononuclear cells, giant cells, and collagen deposition around the fibers, with neuromas at the mesh–tissue interface (PMC6413778). A central diagnostic pitfall: fat necrosis and post-scaffold change can be difficult to distinguish from cancer recurrence (Abnormal Ultrasonographic Findings of ADM, PMC8877379).

Which devices. Polypropylene mesh drives a robust, persistent foreign-body reaction that, in published models, does not resolve over 90 days; the FDA reclassified transvaginal polypropylene mesh to Class III (high-risk) in 2016 and in April 2019 ordered transvaginal POP mesh off the U.S. market (Reclassification of Surgical Mesh, Federal Register 2016; FDA — Urogynecologic Surgical Mesh Implants). GalaFLEX is an FDA-cleared bioabsorbable P4HB surgical scaffold; its use as soft-tissue support in the breast is off-label (not FDA-cleared for that indication). It resorbs gradually with a remodeling response, but, as a synthetic implant, it provokes the same initial foreign-body cascade while present, and the long-term human histomorphologic record remains limited (Use of P4HB Scaffold in the Ptotic Breast, Aesthetic Surgery Journal 2018; Histomorphologic Outcomes of GalaFLEX, PMC12461751). Acellular dermal matrix (AlloDerm, DermACELL) provokes a documented inflammatory and foreign-body response and is the material implicated in red breast syndrome, reported as linked to residual endotoxin and significantly more frequent with AlloDerm RTU (26%) than DermACELL (0%) (Red Breast Syndrome and ADM, PMC10259633). Silicone/saline implants add the capsular contracture dimension (PMC4434852). See breast reconstruction & scaffold injuries and the breast-scaffold manufacturers’ record.

How serious, and is it reversible? Fat necrosis is not rare — it complicates roughly 1–9% of breast reduction procedures and is common after reconstruction and free-flap surgery (NBK542191). It ranges from a small firm nodule to large disfiguring masses, with the added harm of closely mimicking cancer on imaging (PMC6560815). Fibrosis and calcification are essentially permanent — the body does not restore living, soft fat. The foreign-body reaction to a permanent device does not resolve. Removal is possible but imperfect: it is itself major surgery that can cause new ischemia and new fat necrosis and may not relieve neuropathic pain once neuromas and central sensitization are established (FDA — Urogynecologic Surgical Mesh Implants; PMC6119675).

Psychological & Quality-of-Life Sequelae

A surgical mesh is a permanent piece of plastic netting sewn into living tissue, and in a substantial fraction of patients the body does not stop reacting to it — the literature describes it surrounding every fiber with inflamed scar that thickens, hardens, and shrinks over months and years. When that scar tightens around or grows into nerves, the result can be a chronic pain syndrome that does not behave like the pain of an ordinary healing wound: it can outlast the surgery by months or years, often does not show on a normal scan, and can worsen over time (Baseline measures, London Complex Mesh Centre, Br J Pain 2024, PMC10851885).

Because that pain is constant, often invisible to others, sometimes disbelieved by clinicians, and located in private parts of the body, it does not necessarily stay a purely physical problem. The medical literature documents a downstream cascade of depression (including suicidal thinking), anxiety and post-traumatic stress, the collapse of sexual function through dyspareunia, and damage to marriages and intimate partnerships — what the law calls loss of consortium. In one qualitative study, women described their lives as “irreversibly altered for the worse,” reported being suicidal at their lowest points, and described intimacy as “completely gone” (Dunn et al., “When things go wrong,” Int Urogynecol J 2023, PMC10287809). The medical literature describes these as documented consequences associated with an implant that, in non-degradable form, can trigger a persistent inflammatory reaction.

The mechanism. The driver is the foreign-body response, which, with non-degradable plastics, is reported not to fully shut off. Monocyte-derived macrophages dominate the reaction in early and late stages; one study of human mesh explants found inflammation with “rapid and strong myeloid cell accumulation, without substantial attenuation for up to 90 days,” and emphasized “the lack of a switch to an anti-inflammatory response” (Polypropylene mesh causes myeloid cell–driven persistent inflammation, JCI Insight 2019, PMC6413778). Macrophages fuse into foreign-body giant cells; the cytokines IL-1, IL-6, and TNF-α perpetuate inflammation and sensitize local nerves; and TGF-β converts fibroblasts into contractile myofibroblasts that deposit and shrink scar (macrophage response to mesh, Acta Biomater, PMC4347831). The mechanical traction of contracting scar can then injure and entrap nerves, producing neuropathic pain and, over time, central sensitization: sensitized spinal neurons become more responsive to pain signals, and this can “manifest long after the effects of the surgical injury have resolved” (Mechanisms of chronic postsurgical pain, PMC6037807). Once central sensitization is established, the nervous system itself, not just the mesh, can generate the pain.

What the pathologist sees. A foreign-body granulomatous reaction around each fiber, with multinucleated giant cells and a lymphoplasmacytic infiltrate; the presence of giant cells and plasma cells indicates an active, not burnt-out, reaction at the time of removal (characterization of FBR to PP mesh, PMC8881270; explant materials characterization, J Biomed Mater Res B, PMC4031756). Scanning electron microscopy of explanted polypropylene showed surface crazing/cracking indicative of oxidation, and infrared spectroscopy detected carbonyl groups absent in pristine mesh — chemical evidence reported as consistent with the plastic oxidizing in the body (PMC4031756). See material degradation.

Which devices. Knitted permanent polypropylene — used in hernia repair, transvaginal prolapse repair, and midurethral slings — is the dominant, most-studied material involved (PMC6413778). The FDA received 11,274 transvaginal POP-mesh adverse-event reports, with pain the single most common complaint (3,717 reports), followed by erosion/exposure (3,509) and infection (1,794), and ordered all transvaginal POP-mesh products off the U.S. market (FDA — FDA takes action to protect women’s health, 2019). ePTFE and polyester hernia meshes also provoke chronic granulomatous reactions (PMC4031756). The resorbable P4HB scaffold (GalaFLEX/Phasix) triggers a foreign-body response and collagen deposition while present but, in published studies, evokes a more M2-skewed healing profile and is resorbed by roughly 18–24 months (Two-year evaluation of P4HB scaffold for POP, PMC11024044). Acellular dermal matrix (AlloDerm) provokes its own host reaction and is associated with red breast syndrome but is reported to induce fewer myofibroblasts than the implant capsule alone (ADM reduces capsule formation, PMC7949984). See the manufacturers’ documented records: Becton Dickinson / C.R. Bard / Davol, Johnson & Johnson / Ethicon, and Boston Scientific.

How serious, and is it reversible? The FDA treated the volume of serious transvaginal-mesh reports as a safety concern requiring market withdrawal, noting many reports cited the need for additional medical or surgical treatment and hospitalization, and listed “emotional problems” among reported outcomes (FDA — Urogynecologic Surgical Mesh Update, July 2011). The psychological injuries are documented in the literature: women reported active suicidal ideation, and the literature notes suicide risk roughly doubles in chronic-pain patients; experiences were described as “psychologically traumatic,” compounded by medical dismissal; and patients described the loss of intimacy in concrete terms (“the intimacy’s gone, completely gone”) — the kind of medical record that can underlie a loss-of-consortium claim (PMC10287809). On permanence: a permanent polypropylene mesh provokes a reaction that does not resolve while the mesh is in place, and removal is not a reliable cure — in a series of 233 revision/removal patients, 73% reported pain improvement, 8% got worse, and 19% were unchanged (Symptom resolution after operative management of transvaginal mesh complications, PMC4055867), and review data converge on roughly 19–30% with persistent pain after excision, noting that “even after mesh is completely explanted, pain due to inflammation from foreign body reaction may persist” (Symptomatic improvement after mesh removal, PMC8497415). One proposed reason removal so often fails to undo the injury is central sensitization: taking out the mesh removes the original driver but not the established pain circuit (PMC6037807).

To understand who is publishing this guide, see About Attorney 911 — The Manginello Law Firm, PLLC.

This is general medical information for adults, not medical advice, and reading it does not create an attorney-client relationship. Discuss any symptoms or decisions about your device with your own physician; do not start or stop any treatment based on this page. Outcomes vary, and no particular result is promised.

◀ Structural-Failure Injuries (Pelvic & Hernia Mesh) · ↑ Top · Infection & Life-Threatening Complications ▶

Infection & Life-Threatening Complications

Some of the most serious problems associated with surgical mesh are not mechanical failures a patient can feel, but infections and inflammatory reactions that build slowly inside the body — sometimes for years — and that can, in a minority of patients, become life-threatening. This cluster explains three related but distinct injuries: chronic mesh infection driven by bacterial biofilm, the foreign-body granuloma the body forms around permanent mesh, and the rare but serious fatal complications (sepsis, necrotizing soft-tissue infection, and hemorrhage) that can follow. To understand why these happen at all, it helps to first read How Mesh Is Supposed to Work — and How It Fails in the Body and The Foreign-Body Response (Why the Body Reacts to Mesh).

Mesh Infection, Bacterial Biofilm & Chronic Inflammation

When a surgeon implants a permanent synthetic mesh — for a hernia, for pelvic-organ prolapse or incontinence, or to support a breast implant — the body recognizes the material as a foreign object it cannot break down. Two things can then go wrong, often at the same time: a persistent inflammatory reaction to the material itself, and a hidden bacterial infection living on its surface.

Chronic inflammation (the foreign-body reaction). The immune system mounts a low-grade, persistent response to the mesh. Because polypropylene does not degrade, the reaction does not end — studies of mesh removed from women with complications show it is still active years after implantation (Kalaba et al., Bioactive Materials review of polypropylene mesh, 2016; Nolfi et al., Am J Obstet Gynecol, 2016). This is the same process described in detail in Foreign-Body Granuloma & Chronic Granulomatous Reaction.

Bacterial biofilm infection. Skin bacteria — usually Staphylococcus — can adhere to the mesh during or after surgery and build a slimy, glued-down community called a biofilm. This is not the red, hot, pus-filled infection most people picture. It can be silent and smoldering, sitting on the mesh for years. Ordinary blood tests and even routine surgical cultures often come back “negative” because the bacteria are buried in matrix and barely dividing (Kathju et al., Surgical Infections, 2015).

What the patient notices. Chronic, deep, aching or burning pain at the implant site; a sensation of pulling, tightness, or a hard ridge where the mesh has contracted; pain with movement, sex, or sitting; sometimes a draining sinus or a wound that keeps reopening; in breast cases, a breast that becomes hard and distorted. The pain frequently arrives or worsens months to years after the original surgery — a clue pointing to chronic foreign-body reaction or biofilm rather than a simple early wound infection. Repeated antibiotic courses may help briefly and then symptoms return, because antibiotics cannot reliably reach bacteria living inside a biofilm (Kathju et al., 2015; Ciofu et al., biofilm and antibiotic tolerance review, 2022).

How biofilm forms and why it resists treatment. Bacteria — most often Staphylococcus aureus and Staphylococcus epidermidis — adhere to the mesh and secrete an extracellular polymeric substance: a self-made matrix of polysaccharide, protein, and extracellular DNA that glues a multi-layered bacterial community to the fibers (Kathju et al., 2015; Ciofu et al., 2022). According to that biofilm review, the matrix:

Physically blocks antibiotics, antibodies, and white blood cells from reaching the bacteria — the biofilm “acts as a physical barrier that reduces the rate of penetration of antibiotics, antibodies, and granulocytic cell populations” (Ciofu et al., 2022).
Harbors “persister cells” — dormant, slow-dividing bacteria that tolerate antibiotics through a changed phenotype (drug tolerance, not classic genetic resistance) and regrow after treatment stops (Ciofu et al., 2022).
Keeps the immune system permanently switched on, because the body senses the bacteria but cannot clear them through the slime (Ciofu et al., 2022).

What the pathologist sees. Ordinary H&E staining and ordinary culture frequently miss the bacteria because they are sparse, slow-growing, and embedded in matrix. Biofilm is reliably demonstrated only with specialized techniques — confocal laser scanning microscopy, fluorescence in-situ hybridization (FISH), and molecular/PCR methods. In one explant series, these techniques showed adherent biofilms on the mesh of all five patients, detecting more organisms than standard culture (Kathju et al., 2015). In a larger hernia-mesh series, confocal microscopy found biofilm on roughly 75% of explants and PCR on roughly 85%, dominated by S. aureus and coagulase-negative staphylococci (Kathju et al., hernia-mesh staphylococcal biofilm study, 2022). S. aureus and S. epidermidis account for roughly 90% of mesh infections in the reviewed literature (Ciofu et al., 2022).

Which devices are associated with it.

Polypropylene (PP) mesh — the classic permanent synthetic mesh used in hernia, transvaginal prolapse, and mid-urethral sling repairs. Because PP is non-degradable, it provokes a lifelong foreign-body reaction with persistent inflammation, fibrosis, and contraction, and is the device on which biofilms are most consistently demonstrated (Wolf et al., Acta Biomaterialia, 2014; Nolfi et al., 2016; Kathju et al., 2015). Devices in this category are made by Becton Dickinson / C.R. Bard / Davol, Johnson & Johnson / Ethicon, Boston Scientific, and others, and they are central to the scale of mesh litigation.
Poly-4-hydroxybutyrate (P4HB) scaffold — marketed as GalaFLEX — an FDA-cleared, bioabsorbable monofilament surgical scaffold used in plastic and soft-tissue surgery; its use in the breast is off-label (not an FDA-cleared indication). It triggers the same foreign-body cascade initially, but in head-to-head studies it shows a more favorable host response than PP — higher collagen content, lower myofibroblast differentiation, and a higher M2/M1 macrophage ratio — and it hydrolyzes away over roughly 18–24 months, after which the inflammatory stimulus is removed (Deeken & Matthews, history of the P4HB scaffold, Aesthetic Surgery Journal, 2017). It is still a synthetic implant and can seed a biofilm while present. See Breast Scaffolds & Acellular Dermal Matrix and Bioabsorbable Scaffold Failure.
Acellular dermal matrix (ADM) — human- or porcine-derived processed dermis used in implant-based breast reconstruction. ADM is biologic and tends to provoke less chronic inflammation than synthetic capsule, and is often used specifically to reduce capsular contracture. Like any implanted material, however, it can be colonized by biofilm, and bacterial contamination is a recognized contributor to the capsular-contracture cascade around breast implants (capsular contracture pathophysiology review, 2021).

How serious is it, and can it be reversed? The combined process can drive chronic pain, mesh shrinkage and contraction, erosion and exposure, draining sinuses, recurrence of the original defect, and — around breast implants — hard, painful capsular contracture. For permanent polypropylene, the foreign-body reaction is not self-limiting and does not resolve on its own; it is demonstrable in human explants years after surgery (Nolfi et al., 2016). Because biofilm bacteria are shielded by matrix and include dormant persister cells, systemic antibiotics alone generally cannot eradicate an established biofilm; the implanted material usually has to be removed to clear it (“source control”) (Ciofu et al., 2022). Removal can resolve symptoms — in the confocal-confirmed series above, mesh removal resolved the complaints in all cases, with healing maintained over four to seven years of follow-up (Kathju et al., 2015). But removal is not a clean reversal: permanent mesh becomes densely incorporated into scar, the fibrosis and any nerve injury already produced may persist, and explantation is technically difficult and carries its own risks (see Mesh Ingrowth & Fibrotic Encapsulation).

Foreign-Body Granuloma & Chronic Granulomatous Reaction

When a permanent synthetic mesh (most often polypropylene) is implanted, the body recognizes it as a foreign object it cannot dissolve, digest, or expel. Unable to get rid of the mesh, the immune system does the next best thing: it walls it off, surrounding every individual fiber with a permanent collar of inflammatory cells and then wrapping that in dense scar tissue. Each tiny inflammatory collar is a foreign-body granuloma; collectively, the lifelong low-grade inflammation around the whole implant is the chronic granulomatous foreign-body reaction. This is not an allergy, an infection, or a “bad batch” — it is the normal, expected response of human tissue to a permanent synthetic implant, and for polypropylene mesh it never fully shuts off (Klinge et al., summarized in Hernia, 2020; Sridharan et al., Acta Biomaterialia review, 2017).

What the patient experiences flows from this biology. The scar tissue laid down around the mesh contracts and stiffens over months to years, so the mesh shrinks and hardens, tugging on nerves and pulling tissues out of position. The result can be chronic pain, a palpable hard ridge, painful intercourse (dyspareunia), restricted movement, and a sensation of pulling or burning. The FDA lists mesh shrinkage (contraction), scarring, and chronic pain among the recognized complications of mesh, and notes that a non-absorbable mesh “will remain in the body indefinitely” (FDA, Surgical Mesh Used for Hernia Repair; FDA, Urogynecologic Surgical Mesh Implants).

The foreign-body response cascade, step by step. Biomaterials scientists divide it into roughly five overlapping phases (Sridharan et al., 2017):

Protein adsorption (seconds to minutes). The instant mesh contacts tissue, blood proteins — fibrinogen, albumin, immunoglobulins, complement — coat its surface, forming a “provisional matrix.” This protein layer is what the immune system actually reads; the cells never touch bare material.
Acute inflammation (hours to days). Neutrophils arrive first, drawn by the tissue damage and adsorbed proteins. In a biocompatible setting this acute phase resolves within about a week.
Macrophage recruitment and adhesion. Monocytes flood in and mature into macrophages, the master cell of the reaction. Frustrated by a particle far too large to engulf (“frustrated phagocytosis”), they release a cocktail of signals — interleukin-1 (IL-1), interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-α), the chemokine MCP-1, and transforming growth factor-beta (TGF-β) (Sridharan et al., 2017; molecular signaling in biomaterial-induced foreign body response, Am J Physiol Cell Physiol, 2025).
Foreign-body giant cell formation. When a single macrophage cannot clear the fiber, neighboring macrophages fuse into one huge multinucleated cell — the foreign-body giant cell (FBGC), the histologic hallmark of the reaction. Fusion is driven by the T-cell cytokines IL-4 and IL-13. These giant cells adhere directly to the fiber and remain for the life of the implant, continuously secreting pro-fibrogenic mediators (Sridharan et al., 2017).
Fibrosis, encapsulation, and contraction. TGF-β converts fibroblasts into myofibroblasts — contractile, collagen-spinning cells that carry the same actin machinery as muscle (molecular signaling review, 2025). They lay down dense collagen and physically contract the scar, fusing the entire mesh and surrounding tissue into one rigid plate — the cellular engine behind clinical mesh shrinkage and stiffening (Klinge et al., 2020).

With a permanent material like polypropylene, this cascade does not resolve — the stimulus (the fiber) never goes away, so macrophages, giant cells, and lymphocytes persist at the fiber–tissue interface for the lifetime of the device (Sridharan et al., 2017; characterization of immune cells in human mesh foreign-body reaction, 2022).

What the pathologist sees on the explant. On an H&E-stained section of explanted polypropylene mesh, the lesion is stereotyped and highly localized, organized in concentric zones around each empty round/oval space where a fiber sat (the fiber usually dissolves out during processing) (Klinge et al., 2020):

At the fiber surface: multinucleated foreign-body giant cells hugging the fiber — present in all explant samples in the human studies reviewed — with a dense inner cuff of macrophages and lymphocytes. Cell density is highest right at the fiber (roughly 4,100 cells/mm²) and falls off with distance (about 1,600 cells/mm² at 250–350 µm away) (Klinge et al., 2020).
Macrophage phenotype: the chronic interface is dominated by M2 (“wound-healing”/pro-fibrotic) macrophages, which outnumber M1 macrophages by roughly 29–40 to 1 — a signature of sustained remodeling. About 55% of macrophages express MMP-2, indicating ongoing collagen turnover (Klinge et al., 2020).
Adaptive immune component: in meshes explanted after a median of about one year, infiltrates included CD68+ macrophages, CD4+ T-helper cells, FoxP3+ regulatory T cells, CD8+ cytotoxic T cells, B cells, and NK cells — all concentrated within ~50–100 µm of the fibers, evidence of persistent, unresolved immune stimulation (immune-cell characterization, 2022).
Outer zone: a dense fibrotic (collagenous) capsule, with collagen-I concentrated nearest the fiber and collagen-III increasing with distance, bridging adjacent fibers to entomb the mesh in scar (Klinge et al., 2020).

A path report typically dictates this as “foreign-body-type granulomatous reaction with multinucleated foreign-body giant cells, chronic inflammatory infiltrate, and dense fibrosis surrounding refractile/polarizable foreign material consistent with mesh” — the synthetic fibers being birefringent (polarizable) under polarized light.

Which devices cause it.

Polypropylene (PP) mesh — the classic and most heavily studied culprit. Knitted non-absorbable PP (hernia repair, transvaginal prolapse repair, mid-urethral slings) reliably produces a lifelong foreign-body giant-cell reaction with M2-driven fibrosis in every human explant studied (Klinge et al., 2020; immune-cell characterization, 2022). The FDA states that PP mesh “remains in the body indefinitely” and, in April 2019, ordered manufacturers to stop selling transvaginal pelvic-organ-prolapse mesh in the United States after concluding the manufacturers had not demonstrated a reasonable assurance of safety and effectiveness (FDA’s Activities: Urogynecologic Surgical Mesh). See the FDA history and What the Rest of the World Did.
Poly-4-hydroxybutyrate (P4HB) — GalaFLEX scaffold — an FDA-cleared, bioabsorbable monofilament surgical scaffold used in breast and soft-tissue surgery (its breast use is off-label). Because it is gradually degraded and replaced (about 70% strength retained at 12 weeks; essentially fully resorbed by 18–24 months), published histomorphologic follow-up reports a constructive remodeling pattern with mononuclear infiltrate that decreases over time, rather than the dense, contractile capsule seen with permanent PP (histomorphologic outcomes of P4HB scaffold in breast surgery, Aesthetic Surgery Journal, 2025).
Acellular dermal matrix (ADM) — a biologic (decellularized human or porcine dermis) used in implant-based breast reconstruction and hernia repair. It elicits an attenuated response: histology typically shows fibroblast and capillary ingrowth with only patchy chronic inflammation and few giant cells. The attenuation appears partly mediated by the matrix protein osteopontin (long-term ADM histology, 2024; osteopontin attenuates foreign-body response to silicone, Nature Biomedical Engineering, 2025).

The key dividing line is permanent versus resorbable/biologic: permanent polypropylene drives a sustained granulomatous giant-cell reaction and contractile fibrosis; resorbable P4HB and biologic ADM are designed to be remodeled and provoke a milder, more transient response.

Can it be reversed? For permanent polypropylene, the chronic granulomatous reaction is lifelong by design — the fiber is never cleared, so the giant-cell-and-fibrosis interface persists for as long as the mesh is in the body (Sridharan et al., 2017). Reversibility is limited and removal is genuinely difficult: because tissue grows into and through the mesh pores, the construct cannot simply be “pulled out.” The FDA states that managing mesh complications may require multiple additional surgeries, that complications “may remain unresolved despite treatment,” and that prior mesh placement makes future repairs more challenging (FDA, Urogynecologic Surgical Mesh Implants). Even when mesh is removed, the surrounding fibrosis and nerve injury may not be undone, and removal itself can injure the organs the mesh fused to — covered further in Mesh Ingrowth & Fibrotic Encapsulation.

Fatal Complications (Sepsis, Necrotizing Infection, Hemorrhage)

In most people the body walls mesh off with scar tissue and tolerates it. But in a minority, the mesh becomes the starting point of a chain of events that can be fatal. This entry covers four such pathways — included not to alarm, but because these are documented outcomes that patients and families deserve to understand.

Sepsis — an infection seeded on the mesh spreads into the bloodstream, and the body’s own immune reaction begins shutting down organs.
Necrotizing soft-tissue infection — a fast, tissue-destroying infection of the muscle and fat planes around the mesh.
Hemorrhage — the mesh, or the operation to remove it, tears a major blood vessel.
Bowel perforation — the mesh slowly erodes or migrates through the wall of the intestine, spilling stool into the abdomen and producing overwhelming infection.

What the person experiences depends on the pathway. A smoldering mesh infection can feel like a wound that drains for weeks or months, low-grade fevers, a lump that won’t heal, and pain out of proportion to a routine recovery. When it crosses into sepsis, the person may become confused, breathe fast, develop a racing heart and falling blood pressure, and — without treatment — progress to organ failure. Necrotizing infection can announce itself with pain far worse than the visible skin suggests, skin that turns dusky or blisters or crackles with gas under it, and rapid deterioration. Bowel erosion can remain hidden for years and then present as obstruction, a fistula draining stool to the skin or vagina (see Fistula Formation), or sudden peritonitis. Hemorrhage from mesh is usually sudden and tends to occur during placement or removal. A notable feature is time lag: erosion into bowel has been reported from weeks to more than 20 years after the original operation (Aryan et al., Cureus, 2025; single-centre series of mesh eroding into bowel, 2025).

The shared root: the foreign-body reaction. All four pathways grow out of the same immune cascade described above — protein adsorption, acute inflammation, chronic inflammation, foreign-body giant-cell formation, and fibrous encapsulation (Anderson et al., Foreign body reaction to biomaterials, Seminars in Immunology, 2008; Klopfleisch & Jung, pathology of the foreign-body reaction, 2017). In human polypropylene-mesh explants taken from women with complications, the macrophages surrounding each fiber are skewed toward the destructive M1 subtype, with the M2:M1 ratio falling roughly seven-fold compared with control vaginal tissue (0.260 vs. 1.772) (Nolfi et al., Am J Obstet Gynecol, 2016). Macrophage-derived TGF-β converts fibroblasts into contractile myofibroblasts (marked by alpha-smooth-muscle actin), and because polypropylene is non-degradable, this stimulus never ends — producing permanent fibrosis, loss of compliance, nerve entrapment, and mesh contraction (Desmoulière et al., J Cell Biol, 1993; Wipff et al., myofibroblast contraction activates latent TGF-β1, J Cell Biol, 2007).

How the chronic reaction can become lethal. The same biology that scars the mesh in place can open the four fatal doors:

Erosion and perforation. Two mechanisms can act together. Mechanically, the stiff, contracted mesh and its rigid edges or fixation tacks chronically abrade adjacent organ walls, and the mesh can then erode through (mesh migration and bowel perforation report, 2022). Biologically, the elevated proteases of the chronic reaction — pro-MMP-9 was 2.85-fold higher and active MMP-2 2.08-fold higher in mesh explants than controls — degrade the surrounding tissue holding organs apart (Nolfi et al., 2016). See Perforation of Bladder, Bowel or Ureter and Mesh Migration & Displacement.
Infection and biofilm. The braided, high-surface-area mesh is an ideal scaffold for bacterial biofilm that the host immune response and antibiotics struggle to penetrate. In one series, every explanted ventral-hernia mesh showed biofilm (Kathju et al., direct demonstration of biofilm on mesh, 2015). S. aureus and S. epidermidis account for about 90% of mesh infections in the reviewed literature (Pérez-Köhler et al., functionalized-mesh review, 2024). When the infection breaches into soft-tissue planes or the bloodstream, it can produce necrotizing infection or sepsis — the connection to Mesh Infection & Biofilm above.
Hemorrhage. In the presacral space used for sacrocolpopexy, the left common iliac vein, the middle sacral vessels, and the sacral venous plexus lie directly beneath the implant site. Mesh placement near — or, especially, the dissection required to remove infected, fibrosed mesh — can tear these thin-walled veins, producing venous hemorrhage that is difficult to control (presacral anatomy and hemorrhage, 2018; life-threatening bleeding during infected-mesh removal, 2023).

What the pathologist sees. On an explant, the chronic reaction shows mesh fibers as optically empty clefts surrounded by a cellular cuff; a localized, fiber-centered infiltrate of CD68-positive macrophages densest at the mesh knots; foreign-body giant cells hugging the fiber surface; and a two-layer architecture of an inner mononuclear cuff inside an outer dense fibrous capsule (Nolfi et al., 2016; innate and adaptive immune cells in human mesh foreign-body reaction, 2022). In complicated explants the macrophages are M1-predominant with elevated tissue TNF-α (about 2.1-fold) and MMP-9 — markers of an unresolved, destructive state. In infected explants the report additionally notes microabscesses, granulation tissue, and bacterial colonies/biofilm (Kathju et al., 2015).

Which devices are involved.

Knitted polypropylene mesh (dominant across hernia, prolapse, and sling devices) is the prototypical permanent, non-degradable implant. Because it never resorbs, its foreign-body reaction is permanent and “typically associated with fibrosis, decreased tissue compliance, and low-grade localized chronic inflammation” (Wolf et al., macrophage polarization on polypropylene mesh, 2014). On April 16, 2019, the FDA ordered the remaining manufacturers (Boston Scientific’s Uphold LITE and Xenform; Coloplast’s Restorelle DirectFix Anterior) to stop selling transvaginal prolapse mesh, having concluded the manufacturers had not demonstrated a reasonable assurance of safety and effectiveness; the devices had earlier been reclassified to high-risk Class III in 2016 (FDA, FDA takes action to protect women’s health, 2019). See Boston Scientific and Coloplast and Cook Medical.
Poly-4-hydroxybutyrate (P4HB) — GalaFLEX / Phasix. FDA-cleared, bioabsorbable monofilament surgical scaffolds that retain about 70% of strength at 12 weeks and are essentially fully resorbed by 18–24 months, degrading by hydrolysis to 4-hydroxybutyrate, a natural metabolite (Deeken & Matthews, 2017). They still elicit a foreign-body reaction while present but, because they resorb, are reported to promote “constructive remodeling” with reduced chronic inflammation relative to permanent polypropylene; the trade-off is that their strength is temporary. (Use of these P4HB scaffolds in the breast is off-label.) See Breast Scaffolds & Acellular Dermal Matrix.
Acellular dermal matrix (ADM) — e.g., AlloDerm, DermACELL (processed human or animal dermis, used mainly in implant-based breast reconstruction). ADM is meant to be recellularized by host cells rather than permanently walled off; its characteristic complications are seroma and surgical-site infection — both of which can be the entry point to deep infection and sepsis (ADM practice survey, 2015). See Seroma Formation and Red Breast Syndrome.

Severity, permanence, and reversibility. These are among the worst-outcome complications of mesh, and they can be irreversible even when treated. Once a fatal pathway is in motion, the only definitive treatment is major surgery, and the surgery itself carries mortality:

In an eight-patient single-centre series of mesh eroding into bowel, all required laparotomy, seven needed bowel resection, six needed mesh explantation, five needed a stoma — and one patient died of sepsis (single-centre series, 2025).
Necrotizing soft-tissue infection carries a reported 25–35% mortality even with optimal treatment (aggressive surgical debridement plus antibiotics) (necrotizing soft-tissue infection and biofilm review, 2016).
Hemorrhage from the presacral veins during mesh placement or removal can be immediately life-threatening and may require vascular-surgery rescue (life-threatening bleeding during mesh removal, 2023; presacral anatomy and hemorrhage, 2018).

Removing the mesh does not equal cure. The fibrotic capsule, contracted scar, and any nerve damage are laid down in the patient’s own permanent tissue and persist after the synthetic material is gone. Explantation of fibrosed, infected, or eroded mesh is itself a high-risk operation — the mesh is densely scarred into vessels, bowel, and bladder, which is precisely why removal can trigger the hemorrhage and bowel-perforation outcomes described above. Mesh that has eroded into the bowel cannot simply be pulled out; it requires resecting the involved segment of intestine (single-centre series, 2025). And biofilm-laden mesh cannot be sterilized in place — the infection is resolved only by complete removal of the foreign material (Kathju et al., 2015; Pérez-Köhler et al., 2024).

This is general medical and legal information, not medical or legal advice. Outcomes vary from patient to patient, and reading this page does not guarantee any particular result. Discuss any symptoms or treatment decisions with your own physician.

◀ Pain, Nerve & Quality-of-Life Injuries · ↑ Top · Functional & Organ-System Injuries ▶

Functional & Organ-System Injuries

Surgical mesh is meant to be a quiet, supportive patch, but the body treats permanent synthetic mesh as a foreign object it cannot dissolve — and the scar it builds around the mesh can shrink, stiffen, and pull on the bladder, the bowel, and the repair itself. This cluster describes the injuries that can follow when mesh stops behaving as a passive implant and begins to change how an organ system works: new urinary and bowel problems the patient never had before, failure of the repair the mesh was supposed to secure, internal organs bound together by scar, and mesh that grows so deeply into living tissue that it can no longer be safely removed. Each of these is downstream of the same biology explained in How Mesh Is Supposed to Work — and How It Fails in the Body and the foreign-body response, and each is documented in peer-reviewed pathology and FDA records.

This section is general medical and legal information, not medical or legal advice; outcomes vary from patient to patient and no result is guaranteed. Always discuss your own symptoms and treatment with your physician.

Urinary Dysfunction (Urgency, Retention, Obstruction, Recurrent UTI)

What it is. When a strip of synthetic mesh — most often a “midurethral sling” — is placed under the urethra to treat stress urinary incontinence, or a larger mesh is placed to repair pelvic organ prolapse, the device sits in intimate contact with the bladder, the urethra, and the detrusor muscle that empties the bladder. In some patients it becomes the source of an entirely new set of urinary problems. Clinicians group these into four overlapping syndromes:

De novo urgency / urge incontinence — a sudden, hard-to-defer need to urinate, sometimes with leakage, that the patient never had before the implant.
Urinary retention — the bladder cannot empty; the stream is weak or stop-and-start, urine is left behind, and in the worst form a catheter is needed.
Obstruction / obstructed voiding — the sling is too tight or has scarred into a stiff band, kinking or compressing the urethra so urine must fight its way out.
Recurrent urinary tract infections (UTIs) — repeated bladder infections, often because retained urine stagnates or because mesh has worn through into the urethra or bladder, where it acts as a persistently colonized foreign body and a scaffold for stones.

These syndromes share one engine: the body’s reaction to a permanent foreign object placed against the most movement-dependent, sensation-rich part of the urinary tract. Source

Mechanism. Polypropylene is non-degradable, so the body cannot heal and move on — it walls the material off in a foreign-body response that never fully resolves. Source Macrophages coat each fiber, attempt to engulf it, and — because the fiber is enormous relative to the cell — become stuck in “frustrated phagocytosis,” releasing TNF-α, IL-1β, and IL-6 and fusing into multinucleated foreign-body giant cells. Source These cells secrete transforming growth factor-beta (TGF-β), which converts fibroblasts into contractile myofibroblasts that lay down dense collagen and physically pull on it, hardening a soft “hammock” into a rigid, foreshortened band. Source In symptomatic urogynecologic explants, TGF-β1 is reported roughly doubled and PDGF-BB increased more than five-fold versus controls — a tissue biased toward relentless fibrosis. Source

That cascade becomes each syndrome: a rigid, contracted scar plate tethers or compresses the urethra, producing bladder-outlet obstruction and, ultimately, retention when the bladder decompensates. Source De novo urgency is attributed to partial outlet obstruction remodeling the detrusor, direct irritation of the bladder neck by firm mesh, and abnormal urethral sensory signaling. Where mesh slowly erodes through the urethral or bladder wall (see Mesh Erosion, Exposure & Extrusion and Perforation of Bladder, Bowel or Ureter), the exposed polypropylene becomes a surface that bacteria colonize, driving recurrent UTIs and calculi (stones) that themselves obstruct and re-infect. Source

What the pathologist sees. A layered foreign-body granuloma: a dense inner cuff of macrophages and lymphocytes hugging each filament, multinucleated giant cells applied directly to the fiber surface, and an outer fibrous collagen capsule — persisting a year or more after implantation. Source Both innate and adaptive immunity drive it: CD68+ macrophages make up roughly a quarter of cells, with T lymphocytes nearly as abundant. Source

Which devices. The principal cause is permanent, non-absorbable knitted polypropylene mesh — the material of essentially all synthetic midurethral slings and transvaginal prolapse meshes, associated most strongly with Becton Dickinson / C.R. Bard / Davol, Johnson & Johnson / Ethicon, Boston Scientific, and Coloplast and Cook Medical. The FDA reclassified transvaginal POP mesh to Class III, and on April 16, 2019 ordered manufacturers to stop selling it in the U.S. Source Bioabsorbable poly-4-hydroxybutyrate (P4HB) scaffolds (GalaFLEX, Phasix) hydrolyze to a natural human metabolite over roughly 12–18 months and are reported to provoke less chronic inflammation than polypropylene, though as a newer material their long-term urinary-tract profile is less extensively characterized. Source

How serious; is it reversible? Voiding dysfunction after sling surgery is reported in roughly 2–25% of patients; most cases are reported as mild and transient. Source Erosion into the bladder or urethra is reported in up to about 0.8% of cases and can appear anywhere from months to seven years after implant. Source Early retention usually resolves with time or temporary catheterization; persistent obstruction is often correctable by sling loosening, incision, or urethrolysis. Source But delay matters: prolonged obstruction is associated with irreversible bladder dysfunction, de novo urgency may persist after revision, and because the mesh is encased in dense scar, removal is often partial — pain is reported to persist after removal in roughly half of urogynecologic mesh patients. Source Whether any of this applies to you is a question for your own physician.

Bowel Dysfunction (Constipation, Obstructed Defecation, Obstruction)

What it is. When mesh is implanted to repair a hernia or a pelvic-floor defect, the body wraps it in scar tissue that does not stay soft — it shrinks, stiffens, and pulls. When that scarring happens near the intestine, the bowel can become bound to the mesh, kinked, narrowed, or strangled, producing a spectrum that runs from chronic constipation to a surgical emergency:

Constipation and incomplete emptying — stool moves slowly or won’t fully pass; the person strains, splints, or needs enemas.
Obstructed defecation — the rectum no longer relaxes and empties normally (most relevant to pelvic/rectal mesh such as ventral mesh rectopexy).
Bowel obstruction — the intestine is physically blocked by adhesion bands, a kink, or eroded/migrated mesh, bringing cramping pain, bloating, vomiting, and a complete stop of stool and gas (most relevant to abdominal hernia mesh).

The FDA lists among hernia-mesh adverse events adhesion, “blockage of the large or small intestine (obstruction),” fistula, perforation, and the mesh-specific risk of “migration or shrinkage (contraction).” Source A complete obstruction is dangerous: if the blocked segment loses its blood supply, the bowel wall can die, perforate, and spill stool, producing peritonitis, sepsis, and potentially death.

Mechanism. A permanent synthetic mesh sets off the stereotyped foreign-body reaction — protein adsorption, acute then chronic inflammation, giant-cell formation, and fibrosis. Source Polypropylene implantation produces myeloid-cell-driven persistent inflammation in which IL-1β, IL-6, and TNF are highly upregulated, lasting beyond one year in patients even without complications. Source TGF-β converts fibroblasts into α-SMA-positive myofibroblasts that contract the scar and shrink the mesh. Source The decisive step for the bowel is adhesion: when bare polypropylene contacts the serosal surface of the intestine, the same fibrotic response binds the bowel to the mesh — in animal models, bowel adhered to intraperitoneal polypropylene in about half of cases, with up to roughly three-quarters of the mesh surface covered by adhesions. Source Those adhesions kink, tether, or band the intestine into a mechanical obstruction, occurring chiefly when the mesh sits in direct contact with bowel serosa. Source Chronic pressure can also let stiffened mesh erode through the bowel wall or migrate into the lumen — see Mesh Migration & Displacement and Fistula Formation.

What the pathologist sees. A layered, concentric architecture centered on each fiber: empty fiber spaces (the polymer dissolves during processing), multinucleated giant cells “at the surface of some mesh fibers in all samples,” an inner cuff of mononuclear cells skewed to an M2 tissue-remodeling phenotype (~60% M2 vs ~6% M1), and an outer fibrotic capsule of dense collagen with elevated TGF-β1. Source On electron microscopy and FTIR, long-dwelling polypropylene is reported to show surface oxidation and environmental stress cracking — the supposedly inert fiber chemically breaking down (see In-Vivo Oxidative Degradation & Cracking of Polypropylene Mesh). Source

Which devices. The principal culprit is permanent polypropylene, the workhorse of synthetic hernia and pelvic meshes; polyester and ePTFE provoke a comparable reaction. Source Resorbable P4HB (GalaFLEX, Phasix) degrades over ~12–18 months and is reported to produce “a constructive remodeling response devoid of chronic inflammation or foreign body response” once integrated. Source Biologic acellular dermal matrix is meant to be repopulated by host cells, though crosslinked or irradiated products can elicit a more pronounced inflammatory response. Source

How serious; is it reversible? Severity ranges from chronic constipation to complete obstruction with ischemia, perforation, peritonitis, and death. In FDA-reviewed data, the reported incidence of bowel obstruction after hernia mesh repair “does not exceed 3.8%.” Source The underlying tissue change is largely permanent: macrophages persist at the fiber interface for years, and mature scar does not spontaneously dissolve. Source A frank obstruction is treated by adhesiolysis (itself a major operation that can re-form adhesions), and mesh removal is technically difficult because the mesh is fused into scar and often bound to bowel; even after removal, the established collagen capsule remains. Source For pelvic mesh, functional bowel symptoms may not fully resolve after reoperation. Source

Failure of the Repair & Recurrence of Prolapse or Hernia

What it is. A hernia repair or pelvic-organ-prolapse repair is meant to fix the patient — the bulge gone, the pelvic floor lifted back into place. Failure of the repair (recurrence) means the fix did not hold: the bulge returns, the organs sag again, or the mesh shrinks, hardens, pulls away from its anchors, or lets go. Recurrence can be harder to treat than the first operation, because the first repair leaves scar and a mesh implant can itself contribute to the failure — the scar meant to hold it contracts like a drying sponge, wrinkles the mesh, and can tear it loose. Recurrence is common: even with modern fully absorbable mesh, ventral hernia recurrence is reported around 9% beyond 18 months of follow-up Source, and biologic acellular dermal matrix used to bridge large defects has reported recurrence rates of 20–30%. Source

Mechanism. A repair fails mechanically (overpowered by the forces it must resist) and biologically (the body’s reaction degrades the repair). The biological engine is the foreign-body response: plasma proteins adsorb to the fiber, CCR2-dependent myeloid cells are recruited Source, macrophages enter “frustrated phagocytosis” and stay persistently elevated past a year, and they fuse into foreign-body giant cells under IL-4 and IL-13. Source Explant gene arrays show upregulation of IL-1β, IL-6, and TNF-α and a failure to switch on the IL-10/STAT3/STAT6 resolution program. Source TGF-β then drives fibroblasts to become α-SMA-positive myofibroblasts that lay down cross-linked collagen and contract — an activation that is self-amplifying, because contraction against stiff scar releases more active TGF-β. Source

This can produce recurrence directly: myofibroblast contraction shrinks the mesh, so the construct becomes simultaneously too stiff (a rigid plate that generates pain) and too small (no longer bridging the defect), and the hernia or prolapse can re-herniate at the now-uncovered margin. Source In pelvic mesh, the same fibrosis appears with pore collapse — pores crush shut as fibers crowd, converting a soft net into a hard band. Source In absorbable scaffolds, the failure mode is the opposite: if host collagen is laid down weaker or slower than the scaffold degrades, the repair can lose strength before the body rebuilds it, and it tears. Source

What the pathologist sees. Empty fiber clefts ringed by a layered foreign-body reaction — inner giant cells, a zone of CD68-positive macrophages, and an outer shell of myofibroblasts and dense collagen — with chronic non-resolving inflammation, M2-dominated macrophages, pore collapse, and polymer surface cracking and oxidation that increases with implant duration. Source

Which devices. Polypropylene is the dominant permanent synthetic — used in hernia products from manufacturers including C.R. Bard/Davol and Ethicon and historically in transvaginal POP repair — and it never resorbs, so its foreign-body reaction is lifelong. Source The FDA’s transvaginal-mesh actions concerned polypropylene POP devices including Boston Scientific’s Uphold LITE and Xenform and Coloplast’s Restorelle DirectFix Anterior. Source Absorbable P4HB (Phasix, GalaFLEX) resorbs in 12–18 months but is still reported at ~9% recurrence beyond 18 months because the repair depends on the host laying down adequate collagen first. Source Acellular dermal matrix (AlloDerm, Strattice) has 20–30% recurrence when used to bridge defects. Source

How serious; is it reversible? Severity ranges from a returning bulge to a disabling, multi-organ injury with chronic pain, dyspareunia, and erosion. The FDA states plainly that mesh complications “may require additional intervention, including medical or surgical treatment,” that some “may not be completely correctable,” and that complete removal “may not be possible”; on April 16, 2019 it ordered manufacturers to stop selling transvaginal mesh for POP repair, finding the data did not demonstrate “a reasonable assurance of safety and effectiveness.” Source Removal is itself a serious injury risk and is often incomplete, though when symptomatic mesh is removed, one explant series reported pain scores falling from 9.0 to 1.2. Source

Visceral Adhesions from Intraperitoneal Hernia Mesh

What it is. To fix a hernia, surgeons often patch the hole with mesh. When mesh is placed on the inside of the abdominal wall, directly facing the bowel and omentum — “intraperitoneal onlay mesh” (IPOM) — it sits in the normally frictionless peritoneal cavity where the intestines slide freely. A visceral adhesion is what happens when that slipperiness fails: the body lays down bands of internal scar that bind bowel, omentum, and other organs onto the mesh and onto each other. Patients may feel nothing, or chronic dragging abdominal pain, tightness, bloating, and cramping. The dangerous endpoint is bowel obstruction — scar bands kink or strangle a loop of intestine — a surgical emergency; over years, mesh can also erode through the bowel wall, creating a fistula or perforation. Source

Mechanism. Adhesions arise from two overlapping injuries that feed each other. First, peritoneal healing failure: the mesothelial lining that keeps the surface frictionless and dissolves stray clots is injured, a fibrin bridge forms within hours, and whether it becomes temporary or permanent is decided by the balance between tissue-plasminogen activator (tPA) and its inhibitor PAI-1. When inflammation drives PAI-1 up and tPA down, the fibrin is not dissolved, fibroblasts invade it, and a soft reversible adhesion converts into a permanent fibrous (collagen) one — accelerated when mesothelial cells undergo TGF-β-driven transition into myofibroblasts. Source Second, the foreign-body response to the plastic keeps that machinery running: protein adsorption, neutrophils, then macrophages that polarize and secrete IL-1β, IL-6, and TNF-α, fuse into foreign-body giant cells under IL-4/IL-13, and recruit myofibroblasts that build a contracting fibrous capsule. Source Because the plastic is never resorbed, these steps never resolve — human explant data describe “an ongoing chronic process that never completely stops.” Source

What the pathologist sees. A two-zone, fiber-centered granuloma — a dense inner mononuclear infiltrate with multinucleated giant cells on the fiber surface, surrounded by an outer collagen capsule — with a steep spatial gradient (cell density highest at the fiber, ~4,400 cells/mm², falling toward background by 250–350 µm out), disorganized collagen, and on the fiber itself surface oxidation and cracking detectable a median of one year and out to six years after implantation. Source

Which devices. Polypropylene is the strongest adhesion-former: in a controlled comparison, 0 of 8 bare PP implants were adhesion-free at 4 weeks, versus 7 of 8 for a porcine-collagen comparator. Source Polyester and ePTFE provoke the same response. Source Composite/barrier-coated meshes add a temporary anti-adhesive layer on the visceral side; once it resorbs, the bare polymer is exposed. Source Resorbable P4HB (GalaFLEX/Phasix) is reported to show a minimal, self-limited reaction that resolves as the scaffold resorbs Source, and biologic ADM is reported markedly less adhesiogenic than PP. Source

How serious; is it reversible? The FDA’s analysis of over 55,000 hernia-mesh adverse-event reports lists adhesion, bowel obstruction, fistula, and perforation among the most common events, and identifies recalled mesh products as a main cause of bowel perforation and obstruction in that data. Source With non-absorbable mesh the stimulus is permanent, and a fibrous adhesion does not spontaneously dissolve once the fibrinolytic window (roughly the first 5–7 days) is lost. Source Reversal requires another operation — adhesiolysis with or without explantation — that is itself hazardous: intraperitoneal mesh significantly raises the rate of inadvertent enterotomy and unplanned bowel resection at future abdominal surgery, and roughly one-third of reoperated patients in case series had dense adhesions to the mesh. Source Re-operating re-injures the mesothelium and can re-trigger the same cascade, so adhesions may reform.

Mesh Ingrowth & Fibrotic Encapsulation (Hard-to-Remove Mesh)

What it is. When mesh is placed in the body, the body does not simply accept it. Within hours immune cells coat every fiber; within weeks scar tissue grows into and through the open pores and binds the mesh to muscle, vagina, bladder wall, bowel, nerves, and vessels. This tissue integration (ingrowth) matures into a dense “scar plate” that then shrinks and contracts, pulling surrounding tissue tight like a drawstring. Source Patients can experience chronic pain, a pulling sensation, pain with intercourse, and nerve pain radiating into the groin, buttock, or leg when contracting scar traps a nerve. A central difficulty: the very property that makes mesh integrate — tissue growing into it — is what can make it very difficult to remove. By the time symptoms appear, the mesh may be fused inside the tissue, and a surgeon must cut healthy, nerve-rich, blood-rich anatomy away from it, often in fragments, sometimes leaving pieces behind. Source

Mechanism. Ingrowth is the foreign-body response running to completion: protein adsorption forms a provisional matrix; acute inflammation transitions, around a permanent foreign body, into chronic inflammation; macrophages enter frustrated phagocytosis and fuse into foreign-body giant cells under IL-4 and IL-13, remaining plastered to the fiber for the life of the device. Source With polypropylene this myeloid-driven inflammation is persistent rather than self-limiting. Source TGF-β then transforms fibroblasts into α-SMA-positive myofibroblasts that lay down dense collagen and contract — building a fibrous capsule that bridges between adjacent fibers and knots, knitting the whole mesh into a single rigid scar plate and producing the observed shrinkage and stiffness. Source The mesh is not merely surrounded by scar; it is infiltrated and bonded by scar throughout its pore structure.

What the pathologist sees. Empty fiber clefts arranged in the weave pattern, a rim of CD68-positive macrophages and multinucleated giant cells lining the clefts, dense disorganized fibrocollagenous tissue filling the inter-fiber spaces with α-SMA-positive myofibroblasts, a mixed chronic infiltrate, neovascularization, and fibers deformed, contracted, and twisted with entwined tissue. Source A typical report reads “fragments of synthetic mesh material surrounded by foreign-body giant-cell reaction, chronic inflammation, and dense fibrosis.”

Which devices. Polypropylene is the classic offender (transvaginal POP/SUI mesh, slings, hernia mesh) — permanent, non-degradable, provoking lifelong giant-cell infiltration, progressive fibrosis, contraction, and material degradation; the FDA identified vaginal shortening, tightening, and pain from mesh contraction as a distinct risk and on April 16, 2019 ordered transvaginal POP mesh off the market. Source ePTFE and polyester likewise contract and entwine on explant. Bioabsorbable P4HB / GalaFLEX integrates by ingrowth but is engineered to be resorbed, with biopsy series reporting remodeling without the dense capsular contraction of permanent PP (see GalaFLEX, Phasix & breast scaffolds). Source Biologic ADM is meant to be recellularized and revascularized, but is incorporated as living tissue and so also cannot be cleanly peeled out once integrated. Source

How serious; is it reversible? Integration of permanent polypropylene is, for practical purposes, often irreversible, making explant/revision a high-morbidity undertaking. Authoritative urogynecology guidance states that “complete excision of mesh might not be possible,” and partial removals can make future removals harder because the retained fragment retracts into scar. Source Removal can be bloody and escalates with extent: removing mesh from multiple vaginal compartments was reported to carry roughly 3× the estimated blood loss and 9.7× higher odds of requiring a transfusion (95% CI 2.1–44.6) versus single-compartment removal, with risk to bladder, ureter, bowel, and the obturator and pudendal nerves. Source And surgery frequently does not cure the pain: in revision surgery for mesh-related pain, pain reportedly persisted in 42.3% of patients with de novo pain in 6.3%, and release of a sling for voiding dysfunction can reintroduce stress incontinence in up to ~63% of cases. Source

If you or a loved one has been affected by a surgical or breast mesh injury, our team offers a free, confidential consultation. This page is information, not legal or medical advice, and prior results do not guarantee a similar outcome; please also discuss any symptoms with your own physician.

◀ Infection & Life-Threatening Complications · ↑ Top · Material Degradation & Systemic / Immune Reactions ▶

Material Degradation & Systemic / Immune Reactions

Surgical mesh was sold as “permanent” and “inert” — meant to sit quietly in the body forever without changing. In reality, the body treats a synthetic mesh fiber like a permanent splinter, and the immune cells that surround it slowly attack the plastic itself. This cluster explains, in plain English, the injuries that arise from that two-way process: the body damaging the mesh, and the mesh-driven inflammation damaging the body. Each entry below traces the same underlying biology described in our primer on how mesh fails in the body and in The Foreign-Body Response, then follows it to a distinct injury endpoint.

This section is general medical and legal information, not medical or legal advice; it does not create an attorney-client relationship, and outcomes are never guaranteed. Always discuss your own symptoms and any device with your treating physician.

In-Vivo Oxidative Degradation & Cracking of Polypropylene Mesh

Most hernia, prolapse, and incontinence mesh is made of polypropylene — the same family of plastic used in rope and food containers. Marketed as inert, it is not: peer-reviewed explant studies show that inside the body the polymer slowly oxidizes, hardens, becomes brittle, and develops a crust of surface cracks that deepens the longer the mesh stays in (Clavé et al., J Biomed Mater Res, 2010 — “Polypropylene as a reinforcement in pelvic surgery is not inert”; Talley et al., Biomaterials, 2017).

The mechanism — the body corrodes its own implant. Within minutes, blood proteins coat the fiber and immune cells arrive. Because a polypropylene fiber (~100–150 microns) is far too large for any single macrophage to engulf, the macrophages fuse into multinucleated foreign-body giant cells and enter “frustrated phagocytosis,” dumping a respiratory burst of reactive oxygen species — hydrogen peroxide, hypochlorous acid, superoxide, peroxynitrite — onto the surface (Brodbeck & Anderson, Semin Immunol, 2009). Polypropylene is especially vulnerable to these oxidants because of its tertiary carbon-hydrogen bonds. The reaction proceeds by auto-oxidative chain scission: oxidants abstract hydrogen, polymer radicals react with oxygen to form hydroperoxides, and these break down into carbonyl (C=O) groups visible on infrared spectra as a rising carbonyl index. Each scission shortens the polymer, lowering its average molecular weight (Talley et al., 2017; Clavé et al., 2010). Manufacturer antioxidants are sacrificial — they delay but do not prevent degradation, which is time-dependent, with particle shedding rising markedly between roughly 60 and 180 days in animal models (Wynn-Jones et al., J Mech Behav Biomed Mater, 2024).

What the pathologist sees. On an explant, polarized-light and scanning electron microscopy reveal empty fiber “spaces” ringed by giant cells, dense collagen encapsulation, and on the fiber itself a continuous degradation “bark” — an outer crust of cracked, oxidized polymer that thickens with implantation time over an intact core. Scanning electron microscopy shows transverse and longitudinal surface cracks that grow more severe at longer dwell times (Talley et al., 2017; Wynn-Jones et al., 2024). Even titanium-coated and “lightweight” polypropylene meshes show degradation features on human explants (Mary et al., J Biomed Mater Res B, 2024).

What patients notice. The hardening fiber and the contracting scar around it combine to produce chronic pelvic, groin, or abdominal pain; pain with sex (dyspareunia); a “golf ball” sensation of hard tissue; and — when a stiffened, shrinking edge saws through soft tissue — erosion of mesh through the vaginal wall, bladder, or bowel (FDA, Urogynecologic Surgical Mesh Implants).

Devices associated with it. This injury applies to permanent (non-absorbable) polypropylene mesh — transvaginal prolapse mesh, mid-urethral slings, and hernia mesh — the device classes detailed in our devices overview and made by the manufacturers in our C.R. Bard / Davol, Ethicon, Boston Scientific, and Coloplast and Cook records. The FDA-cleared bioabsorbable poly-4-hydroxybutyrate (P4HB) scaffolds GalaFLEX and Phasix are a different polymer with a different mechanism: they are designed to be fully resorbed by hydrolysis over roughly 18–24 months, not to oxidatively crack, and their failure mode is resorption and loss of strength rather than embrittlement (Deeken & Matthews scoping review, Front Surg, 2023). Their use in the breast is off-label and not FDA-cleared for that indication; see our breast-scaffold record. Acellular dermal matrix (AlloDerm and similar) is a biologically derived material that is remodeled rather than oxidized (Red Breast Syndrome and Acellular Dermal Matrix, Aesthet Surg J Open Forum, 2023).

Severity and permanence. Severity ranges from clinically silent to disabling, and the damage is progressive. The oxidative chain-scission of the polymer is an irreversible chemical change — an embrittled, cracked fiber cannot be restored. The FDA describes polypropylene mesh as a permanent implant and states bluntly that “complete removal of mesh may not be possible” and that “mesh contraction or ‘shrinkage’ is associated with vaginal pain that often does not resolve even with mesh removal” (FDA, Urogynecologic Surgical Mesh: Update on Safety and Effectiveness, 2011). In 2019 the FDA ordered manufacturers to stop selling transvaginal mesh for prolapse repair, having found the devices lacked a reasonable assurance of safety and effectiveness (FDA’s Activities: Urogynecologic Surgical Mesh, April 16, 2019).

Particle & Debris Shedding from Degrading Mesh

As polypropylene mesh oxidizes and its surface cracks (see oxidative degradation), tiny flakes and fragments — particles — begin to shed off the fibers. This has been documented on explanted human mesh by electron microscopy and infrared spectroscopy (Costello et al., J Biomed Mater Res B, 2013; Talley et al., degradation-characterization review, 2022). The shed debris is itself pro-inflammatory, feeding the very reaction that produced it.

A self-feeding loop. The foreign-body response follows a stereotyped cascade — protein adsorption, neutrophil influx, macrophage recruitment, giant-cell fusion, then fibrosis (Sheikh et al., Materials, 2015; Brodbeck & Anderson, Semin Immunol, 2009). On explanted human mesh, macrophages surround every fiber and skew toward the pro-inflammatory M1 phenotype; the M2:M1 ratio is significantly reduced versus normal tissue (Nolfi et al., Am J Obstet Gynecol, 2016). Giant cells in frustrated phagocytosis dump oxidants that corrode the plastic — and that corrosion releases more particles, which recruit more cells. The more severely the mesh degrades, the more macrophages and T-lymphocytes accumulate in proportion to the degradation (Farr et al., 2022). Internalized polymer particles perturb macrophage function and increase their mobility (Cao et al., 2023).

What the pathologist sees. Explant histology shows empty round-to-oval clefts where fibers sat, dense mononuclear infiltrate, multinucleated giant cells lining the fibers (occasionally so exuberant it forms a tumor-like mass (Case Rep Pathol, 2018)), granulomas, and dense collagen (Nolfi et al., 2016). Matrix metalloproteinases (pro-MMP-9 and active MMP-9) are elevated versus control tissue — biochemical evidence of ongoing matrix breakdown, highest in erosion cases (Nolfi et al., 2016). On the material itself, electron microscopy shows surface crazing and transverse cracking, infrared spectroscopy shows a new carbonyl peak at ~1,740 cm⁻¹, and calorimetry shows the enthalpy and melt-temperature drop of chain scission (Costello et al., 2013).

What patients notice. As the scar capsule contracts, explanted pelvic mesh has shown 50–70% shrinkage, pulling on anchored tissues (Nolfi et al., 2016). The FDA recognized “vaginal shortening, tightening, and/or pain due to mesh contraction” as a real, previously underappreciated risk (FDA, Update on Safety and Effectiveness, 2011). Patients describe chronic, often worsening pain, stiffness, a pulling or banding sensation, pain with intercourse, and in some cases mesh erosion.

Local versus systemic — an honest distinction. Local distribution is well established: shed particles remain in and migrate within the tissue around the implant, amplifying inflammation in proportion to degradation (Farr et al., 2022). Systemic distribution is biologically plausible but not proven for mesh specifically. The closest human evidence comes from joint prostheses, where polyethylene and metal wear particles migrate to draining lymph nodes (Am J Surg Pathol, 1997); experimentally, polymeric micro/nanoparticles accumulate in distant organs (micro/nanoplastic review, 2021). Importantly, a systematic review of over 104,000 mesh patients found no causal association between polypropylene mesh and systemic autoimmune syndromes; autoimmune-disease rates in mesh patients (1.5–8.1%) matched the general-population background (3.2–9.4%) (systematic review, 2022). The local particle-driven injury is documented; a systemic autoimmune causal link is currently unproven — both truths belong here, and the autoimmune entry explores the contested question further.

Devices and permanence. Polypropylene mesh — hernia, sling, and (historically) transvaginal prolapse — is the studied culprit (Costello et al., 2013). In April 2019 the FDA ordered the remaining manufacturers (Boston Scientific’s Uphold Lite and Xenform, Coloplast’s Restorelle DirectFix Anterior) to stop selling transvaginal prolapse mesh; no FDA-approved transvaginal prolapse mesh is marketed in the U.S. today (FDA, Pelvic Organ Prolapse). By contrast, the bioabsorbable P4HB scaffold GalaFLEX is designed to break down — keeping ~70% of strength at 12 weeks and resorbing into water and CO₂ by 18–24 months — provoking a comparatively mild response that decreases over time rather than oxidative crumbling into shards (Williams et al., history of P4HB, 2016). Acellular dermal matrix is meant to be remodeled rather than to shed particles, though when it fails to integrate it behaves like inert foreign material (histologic comparison, 2018). For permanent polypropylene, explantation can halt further shedding but cannot undo established fibrosis, nerve injury, or particles already dispersed into tissue or lymph nodes.

Calcification of Implanted Mesh

“Calcification” means hard, bone-like mineral — calcium phosphate, the family of mineral in tooth enamel and bone — slowly building up in and around an implanted mesh. The mesh is a permanent foreign object the body can neither dissolve nor expel, so it keeps a low-grade inflammatory reaction running at the mesh surface for as long as the mesh is there (Sheikh et al., 2015). In some people, that chronic reaction and the dying cells within the scar become a seedbed where mineral crystallizes and hardens, turning a soft scar plate into a stiff, gritty, sometimes literally “bony-hard” mass (Mohamedahmed et al., 2023).

An honest scope note up front. Heavy, clinically significant calcification of mesh is a documented but relatively uncommon event, reported chiefly with permanent polypropylene; it is not the usual finding on every explant (Bhama et al., 2022). The far more universal finding is the underlying chronic foreign-body inflammation that calcification, in the right conditions, grows out of.

The mechanism — from scar to stone. The foreign-body response builds a thick fibrous capsule driven by macrophages, giant cells, and the cytokines IL-1β, IL-6, TNF-α, IL-4, IL-13, and the master pro-fibrotic signal TGF-β (Sheikh et al., 2015). TGF-β converts fibroblasts into contractile myofibroblasts expressing alpha-smooth-muscle actin, which both deposit collagen and physically contract — and mechanical strain releases still more TGF-β in “a devastating positive feedback loop” of excess collagen (Witherel et al., 2019). The calcification that grows here is dystrophic calcification — mineral that deposits in damaged or dying tissue even though blood calcium and phosphate are normal (unlike “metastatic” calcification, which requires high blood mineral) (Damrongsak et al., 2010). Dying cells suffer mitochondrial calcium overload; matrix vesicles and apoptotic debris, rich in calcium-binding annexins and phosphate, become the template on which hydroxyapatite crystals first nucleate (Lee et al., 2021). In implant biology this is an active, inflammation-driven process resembling bone formation (Mohamedahmed et al., 2023); extra calcium nearby (e.g., calcium-containing antibiotic beads placed at surgery) can accelerate it (Bhama et al., 2022).

What the pathologist sees, and what shows on imaging. Pathologists confirm calcification with specific stains and analysis rather than by eye: von Kossa and alizarin red highlight the deposits, atomic absorption spectrometry quantifies calcium, and scanning electron microscopy with energy-dispersive X-ray spectrometry confirms a calcium-phosphate / hydroxyapatite composition (Mohamedahmed et al., 2023). Unlike true bone, the mineral is not laid along organized collagen fibrils (Damrongsak et al., 2010). On CT, calcified hernia mesh classically tracks vertically along the linea alba and can be misread as leaking contrast or fistula (Bhama et al., 2022).

What patients notice. A hard ridge or lump they can feel, chronic pain, pulling or tightness, and loss of flexibility. The mineralized, contracted mesh can press on or saw into nearby organs (Mohamedahmed et al., 2023).

Devices. Permanent polypropylene is the material in which mesh dystrophic calcification has actually been reported, both in hernia repair (calcium along the linea alba) and in transvaginal/sacrocolpopexy mesh explants showing the giant-cell and degradation picture (Bhama et al., 2022; Kim et al., 2024). The absorbable scaffold GalaFLEX (P4HB) generally does not calcify — human explant histology from 6 weeks to 63 months shows progressive replacement by organized collagen with no calcification reported (Adams et al., 2025; Deva et al., 2023). For acellular dermal matrix, one breast-reconstruction histopathology study stated that “calcification was never observed” in ADM (Lee et al., 2022). The risk concentrates in the permanent, slowly-degrading synthetic.

Severity and permanence. Calcification converts a compliant implant into a rigid one, creating a stiffness mismatch with soft tissue; in synthetic grafts the calcified material becomes “rigid and bony-hard,” causing failure that requires removal (Mohamedahmed et al., 2023). There are no proven drugs that dissolve or reverse implant calcification once formed (Mohamedahmed et al., 2023). Removal is surgical, technically demanding, and often incomplete — the FDA notes mesh complications can require returning to the operating room over multiple surgeries, with complete removal not always achievable (FDA, Urogynecologic Surgical Mesh Implants).

Autoimmune & Systemic Illness (ASIA / Shoenfeld Syndrome)

When mesh is implanted, the immune system surrounds every fiber and tries, indefinitely, to wall it off and digest it. Locally, that reaction lays down scar that hardens and shrinks (described throughout this cluster). Systemically, a subset of patients develop a body-wide constellation of symptoms — deep fatigue, muscle pain (myalgia), joint pain (arthralgia), brain fog, low-grade fevers, dry mouth and dry eyes, unrefreshing sleep, and sometimes new autoantibodies in the blood — that appears soon after the implant. When this pattern follows exposure to an implanted “adjuvant” material, it has been named ASIA — Autoimmune/Inflammatory Syndrome Induced by Adjuvants, also called Shoenfeld syndrome after the immunologist who described it in 2011 (Watad et al., ASIA basic concepts, 2020).

Where the science actually stands — read this carefully. ASIA is a recognized but still-debated diagnosis. Case reports and case series document patients who became ill after mesh and improved after explant, and improvement-after-removal is one of the formal diagnostic criteria (Watad et al., 2020). But large epidemiologic studies have not confirmed a population-wide causal link, and some reviewers conclude the current literature does not establish that polypropylene causes ASIA (review of Shoenfeld syndrome after polypropylene mesh, ScienceDirect; ASIA pilot-study protocol, 2025). This entry describes both the well-documented local foreign-body disease and the contested systemic syndrome, and does not assert the systemic link as established fact.

The proposed mechanism. The local cascade is the stereotyped foreign-body response: protein adsorption, M1-dominant macrophage activation pouring out IL-1β, TNF-α, IL-6, giant-cell fusion in frustrated phagocytosis, then TGF-β1-driven myofibroblast contraction and fibrosis (Sheikh et al., 2015; T-regulatory cells and TGF-β1 in mesh complications, Acta Biomater, 2022). The ASIA hypothesis proposes that the mesh acts as a chronic adjuvant — non-specifically over-stimulating innate pattern-recognition receptors (Toll-like, NOD-like, C-type lectin) — and that in a genetically predisposed person (certain HLA haplotypes), this can break self-tolerance and produce autoantibodies and overt autoimmune disease (Watad et al., 2020). The same cytokines that run the local reaction, spilling systemically, are proposed to produce the fatigue, myalgia, arthralgia, fever, and cognitive symptoms. Notably, TGF-β was roughly doubled in women with persistent pain even after explant versus those who improved — evidence the profibrotic program can become partly self-driving (dysregulated wound healing in urogynecologic mesh, Int Urogynecol J, 2024).

What the pathologist sees. Explant histology shows a chronic foreign-body granulomatous reaction: empty fiber clefts, a dense inner cellular cuff (~50–100 µm) hugging each fiber surrounded by an outer fibrotic capsule, multinucleated giant cells against the fiber, abundant CD68+ macrophages (~45% right at the 0–50 µm interface), and a surprisingly heavy adaptive immune infiltrate — CD4+ T-helper ~19%, FoxP3+ regulatory T cells ~25%, CD8+ cytotoxic T cells ~14% — with α-SMA-positive myofibroblasts and TGF-β1 in the scar, the degree of fibrosis correlating with reported pelvic-pain score (characterization of FBR to polypropylene in human abdomen, Front Immunol, 2022; Acta Biomater, 2022).

Devices. Permanent polypropylene mesh — non-resorbable, lifelong reaction — is the material named in essentially every published mesh-ASIA case report and series (Front Immunol, 2022; inguinal-hernia mesh ASIA case report, 2021; ASIA pilot protocol, 2025). ASIA has also been reported with silicone breast implants and other implanted adjuvants (Watad et al., 2020). The FDA-cleared bioabsorbable P4HB scaffolds (GalaFLEX / Phasix) are designed to degrade to water and CO₂ over 18–24 months and reportedly trigger an early M1→M2 macrophage shift and mononuclear infiltration that diminishes with time — a time-limited reaction by design rather than a permanent foreign body (P4HB host-response review, 2016). Acellular dermal matrix is decellularized to be repopulated by host cells and carries the lowest persistent foreign-body burden, though porcine ADM provokes a stronger inflammatory response than human ADM (in-vivo comparison of human ADMs, 2021).

Severity and permanence. The local foreign-body disease is, with permanent polypropylene, effectively lifelong — the FDA, finding that serious adverse events are “not rare,” ordered manufacturers to stop selling transvaginal prolapse mesh in 2019 (FDA, Pelvic Organ Prolapse). Removal is partial and risky, and the fibrotic program can persist after explant (TGF-β doubled in those with persistent pain) (Int Urogynecol J, 2024). For systemic ASIA the prognosis is, paradoxically, sometimes better if the device is truly the driver: in reported cases, explantation produced significant improvement in local and systemic symptoms (inguinal-hernia case report, 2021; ASIA pilot protocol, 2025) — but recovery is often only partial, and a patient who has crossed into defined autoimmune disease can carry it independently thereafter (Watad et al., 2020). These are research-stage observations, not a treatment recommendation; any decision about a device belongs with your own physician.

Allergy, Hypersensitivity & Foreign-Body Reaction

When mesh is implanted, the body recognizes the plastic as foreign and mounts a permanent, low-grade reaction against it — the foreign-body reaction. It is not an “allergy” in the everyday sense (like hives from peanuts), but for the patient living through it the distinction can feel academic: the implant becomes a site of chronic inflammation, hardening, scarring, and pain. A small subset of patients, however, appear to react far more violently, and in them a genuine delayed-type (Type IV) hypersensitivity to the polymer — a true antigen-specific, T-cell-mediated immune reaction — is suspected (FDA, Urogynecologic Surgical Mesh Implants; JCI Insight, 2019).

The mechanism — a stalled wound that never resolves. Normal healing runs inflammation → repair → resolution. Around permanent mesh the inflammation phase never shuts off because the immune system can neither digest nor expel the plastic. Blood proteins coat the fiber; macrophages attempt phagocytosis, fail, and enter frustrated phagocytosis, dumping reactive oxygen species and degradative enzymes onto the surface (Brodbeck & Anderson, Semin Immunol, 2009). They then fuse into foreign-body giant cells (Front Immunol, 2022). Critically, the macrophage M1→M2 “calming” switch fails: human and primate studies show macrophages locked in M1-dominant activation (high CD64, HLA-DR, CD86; low M2 marker CD206) with persistently elevated cytokines and no detectable IL-10, the master anti-inflammatory off-switch, and “no substantial attenuation for up to 90 days” in animals plus dense infiltrate beyond one year in human explants (JCI Insight, 2019). The trapped cells secrete IL-1β, IL-6, TNF-α, MCP-1/CCL2, and TGF-β; TGF-β converts fibroblasts into contractile myofibroblasts that lay down disorganized collagen (type I increased ~35% versus controls) and physically pull the scar tight — the basis of clinical mesh contraction (JCI Insight, 2019; mesh-induced fibrosis / T-regulatory cells, Acta Biomater, 2019). The reactive oxygen species also oxidatively degrade the polypropylene, shedding fragments that recruit still more macrophages — a vicious cycle linking this reaction to oxidative degradation and particle shedding.

The true-allergy component. Beyond innate inflammation, the adaptive immune system is engaged long-term: explanted human mesh granulomas contain CD4+ (~19%), CD8+ (~13.5%), and FoxP3+ regulatory T cells (~25%) clustered tightly around the fibers (Front Immunol, 2022). This T-cell involvement is the substrate for genuine Type IV delayed-type hypersensitivity in susceptible patients, tested clinically with a Mesh Allergy Test in which dissolved polypropylene is applied in a Finn chamber and read at 48 hours (ASIA pilot protocol, 2025).

What the pathologist sees. The classic chronic foreign-body granulomatous reaction: empty fiber voids; a palisade of giant cells lining them; a dense inner cuff of CD68+ macrophages mixed with T and B lymphocytes; an outer capsule of disorganized type I/III collagen with α-SMA-positive myofibroblasts; and, in degraded specimens, birefringent polypropylene particles under polarized light with visible surface cracking (Front Immunol, 2022).

What patients notice. Pulling, burning, or stabbing pain; dyspareunia; a “golf ball” of hardness; mesh erosion; and in some patients whole-body symptoms — fatigue, joint and muscle aches, brain fog, rashes — overlapping the contested ASIA picture (FDA, Urogynecologic Surgical Mesh Implants).

Devices. Permanent polypropylene mesh — prolapse kits, mid-urethral slings, and hernia meshes — is the principal offender, with a lifelong reaction; the FDA ordered transvaginal prolapse mesh off the market in April 2019 (FDA’s Activities: Urogynecologic Surgical Mesh). The FDA-cleared bioabsorbable P4HB scaffold GalaFLEX still triggers a foreign-body reaction but, because it resorbs over ~18–24 months, studies report an earlier M1→M2 shift and less myofibroblast-driven contraction — a generally milder, self-limited host response (P4HB prolapse scaffold, Int Urogynecol J, 2024; history of GalaFLEX, 2016). Acellular dermal matrix generally dampens the reaction and capsular contracture, but still provokes inflammation and can present as the delayed inflammatory reaction known as “red breast syndrome”; gamma-irradiated matrices show more inflammation and giant cells (histologic comparison of ADM vs breast capsules, 2016; ADM inflammation, primate model, 2017).

Severity and permanence. The FDA concluded that serious complications of transvaginal prolapse mesh are “NOT rare,” reversing its more reassuring 2008 statement (FDA, Urogynecologic Surgical Mesh Implants). With permanent polypropylene the reaction does not resolve while the mesh remains, removal is difficult and not guaranteed to cure (the FDA notes complications may require multiple surgeries and may not be fully correctable), and contraction-induced vaginal shortening and scar-entrapped nerves are permanent anatomic changes (FDA, Urogynecologic Surgical Mesh Implants). Where a true hypersensitivity/ASIA-type reaction is present, explantation has been reported to produce significant improvement — the closest thing to a reversal for that subgroup (ASIA pilot protocol, 2025).

The Foreign-Body Response (Why the Body Reacts to Mesh)

This is the master injury beneath the entire cluster — the biological reason a permanent synthetic mesh causes trouble at all. When the body cannot dissolve or expel the mesh fibers, it mounts a defensive reaction that never fully shuts off: the foreign-body response (FBR). In its chronic, scar-forming form it underlies much of the pain, stiffness, and mesh-removal surgery patients report. In symptomatic patients this inflammation has been measured still active 4.5 to 93 months — years — after the device went in (Nolfi et al., Am J Obstet Gynecol, 2016).

The cascade, stage by stage.

(a) Protein adsorption (seconds to minutes). A film of host proteins — fibrinogen, fibronectin, vitronectin, albumin, complement — coats the fiber. This layer, not the bare plastic, is what immune cells “read” (Klopfleisch & Jung, J Biomed Mater Res A, 2017).
(b) Acute inflammation (minutes to days). Neutrophils arrive first, then monocytes recruited heavily by the chemokine MCP-1/CCL2, maturing into macrophages at the fiber surface (Kyriakides et al., 2014). Polypropylene produces “rapid and strong myeloid cell accumulation, without substantial attenuation for up to 90 days,” with IgM and complement deposition that increases over time (Klinge group, J Pathol, 2019).
(c) Macrophage polarization (M1/M2). M1 macrophages secrete TNF-α, IL-1β, IL-6, IL-12, IL-23 plus reactive oxygen species; M2 macrophages (induced by IL-4, IL-13, IL-10, TGF-β) secrete TGF-β and the fibroblast mitogen PDGF-BB (Witherel et al., macrophage–fibroblast interactions, 2019). The healthy outcome is a timed M1→M2 hand-off; the mesh outcome is a stuck, M1-skewed state — in symptomatic women the M2:M1 ratio fell to 0.260 vs. 1.772 in controls (P = .001), with TNF-α up 2.13-fold and CXCL10 up 3.38-fold (Nolfi et al., 2016).
(d) Foreign-body giant cell formation. Because the fiber (>100 µm) dwarfs a macrophage (~20 µm), single-cell phagocytosis fails; macrophages enter frustrated phagocytosis and fuse into multinucleated giant cells under IL-4/IL-13 — the histologic hallmark, associated with increased scarring and encapsulation (Witherel et al., 2019; Klopfleisch & Jung, 2017).
(e) Fibroblast / myofibroblast recruitment. TGF-β1 converts fibroblasts into contractile myofibroblasts marked by α-SMA; IL-1β drives collagen and fibronectin; IL-6 drives fibrosis via TGF-β; PDGF-BB multiplies scar cells (Witherel et al., 2019). Myofibroblasts lay down disorganized type I collagen and contract — shrinking and stiffening the mesh and tenting nearby nerves.
(f) Fibrotic encapsulation and chronic inflammation (the end-state). A dense, largely avascular collagen capsule walls the mesh off. With a permanent mesh the stimulus never runs out, so this is not a self-limiting healed scar — it is chronic, lifelong, smoldering inflammation, with active MMP-9 and MMP-2 elevated ~2–3 fold in symptomatic explants (the degradative signature linked to mesh erosion) (Klopfleisch & Jung, 2017; Nolfi et al., 2016).

What the pathologist sees. Empty round/oval “mesh voids” where each fiber dissolved out during processing; a palisade of macrophages and foreign-body giant cells lining each void; a chronic mononuclear infiltrate sometimes with persisting neutrophils (“chronic granulomatous foreign-body reaction with occasional neutrophils”); concentric type I collagen encapsulation; and α-SMA-positive myofibroblasts (Nolfi et al., 2016; Klinge group, 2019). Symptomatic mesh tissue carried significantly more cells than control tissue (682 ± 143 vs. 442 ± 126, P < .001), and the reaction scales with material volume — mesh knots showed ~2-fold more M1 and ~2.3-fold more M2 cells than single fibers (Nolfi et al., 2016).

What patients notice. Chronic pelvic, groin, or vaginal pain; a pulling or tightness; pain with movement or intercourse; the mesh becoming hard and rope-like as the capsule contracts by roughly 50–70%; and in some cases erosion through the vaginal wall or bowel (Nolfi et al., 2016).

Devices. Non-degradable knitted polypropylene — hernia mesh and transvaginal/sling mesh — is the prototype offender that “frequently elicits a chronic foreign-body reaction with resultant fibrosis” (Brown/Badylak group, 2015); PTFE and polyester provoke a comparable or more intense reaction (explant comparison, 2013). The FDA-cleared bioabsorbable P4HB scaffold (GalaFLEX / Phasix) generates a moderate but self-limiting reaction because it degrades over ~12–18 months — head-to-head it produced higher collagen, lower α-SMA myofibroblast differentiation, and no exposures at 24 months versus permanent polypropylene (P4HB 2-year prolapse evaluation, 2024). Acellular dermal matrix aims at host integration rather than permanent encapsulation and shows lower capsular-contracture rates, though histology still scores a genuine, usually milder FBR (DermACELL study, 2014; ADM capsule histology, 2016).

Severity and permanence. Severity ranges from a clinically silent thin capsule to disabling pain, 50–70% contraction, erosion, fistula, and recurrent infection. After 2008 and 2011 safety communications and reclassification to the highest-risk class, the FDA on April 16, 2019 ordered all manufacturers to stop selling surgical mesh for transvaginal prolapse repair, concluding the makers had not shown a reasonable assurance of safety and effectiveness (FDA’s Activities: Urogynecologic Surgical Mesh; FDA press announcement, 4/16/2019). For a permanent synthetic mesh the reaction is as permanent as the mesh — human data confirm inflammation persisting and intensifying beyond one year and out to 7+ years (Nolfi et al., 2016; Klinge group, 2019). Removal can stop new inflammation only by taking out the stimulus, but by then the mesh is fused into dense capsule and ingrown by nerves, so excision is technically difficult, often incomplete, and does not reverse the scar and nerve damage already laid down. The established collagenous capsule and any nerve entrapment are effectively irreversible.

This section is educational and is not a substitute for professional medical care; it does not tell anyone to keep or remove a device. If you have symptoms, talk with your own physician, and remember that prior outcomes do not guarantee a similar result.

If you or a loved one has been affected by a mesh complication, our team offers a free, confidential consultation; you can learn more about the firm and the team behind this guide.

◀ Functional & Organ-System Injuries · ↑ Top · Breast Reconstruction & Scaffold Injuries ▶

Breast Reconstruction & Scaffold Injuries

When a breast is rebuilt after a mastectomy, lifted, or reinforced, surgeons often add a sheet of supporting material — an acellular dermal matrix (ADM, processed donated human or animal skin), a resorbable synthetic scaffold such as a poly-4-hydroxybutyrate (P4HB) mesh, or, less appropriately for the breast, a permanent plastic mesh. The injuries below are the documented ways those reconstructions go wrong: the body treats every implanted sheet as a foreign object it must wall off, and the same biology that is meant to build new supportive tissue can instead drive fluid collections, sterile inflammation, hardening, tissue death, and structural collapse. Each entry explains, in plain English, what the injury is, the cellular mechanism behind it, what a patient actually notices, and how serious and reversible it is. The common thread is the body’s foreign-body response to an implanted material — the same process described in the how-mesh-fails primer — and the materials themselves are catalogued in the devices overview and the breast-scaffold manufacturer record.

This page is educational information, not medical or legal advice; outcomes vary from patient to patient and no result is guaranteed. Discuss any symptoms or device decisions with your own treating physician.

Bioabsorbable Scaffold Failure: P4HB (GalaFLEX) “Internal Bra” Collapse

GalaFLEX is a surgical mesh woven from a man-made absorbable fiber called poly-4-hydroxybutyrate (P4HB). Surgeons implant it as an “internal bra” — a sling placed under the lower part of the breast to hold breast tissue or an implant up after a lift, reduction, or augmentation. The same material is used to reinforce hernia repairs (marketed as Phasix). It is FDA-cleared as a bioabsorbable surgical scaffold, and its use to support the breast is off-label — not an FDA-cleared indication. The selling point is that the mesh is temporary: it is designed to dissolve over roughly 18–24 months while leaving behind a layer of the patient’s own collagen meant to be permanently stronger than the original tissue (Deeken & Matthews, Frontiers in Surgery, 2023 / PMC10130450).

The promise — and the problem — is a race. The implant works only if the body lays down enough new supportive collagen before the fiber loses its strength. The injury here is what happens when the body loses that race: the scaffold resorbs faster than durable host tissue can take over the load. When that happens, the “internal bra” goes slack. Patients experience the breast dropping again (recurrent ptosis), the implant sliding down or sideways (bottoming-out or malposition — see contour deformities), or a hard contracted shell (capsular contracture). Because the support was meant to disappear, by the time failure is obvious there may be little or no mesh left to “fix.”

Mechanism. P4HB does not get “eaten” by cells first; it is broken down chemically by bulk hydrolysis — water diffuses into the polymer and cleaves the chains into 4-hydroxybutyrate, a molecule naturally metabolized through the Krebs cycle and exhaled as carbon dioxide (PMC10130450, 2023). The under-appreciated fact is that molecular-weight loss outpaces visible breakdown. In a porcine model the polymer’s molecular weight fell from roughly 510,000 Da at 6 weeks to about 44,000 Da at 52 weeks — a roughly 90% collapse of the molecular backbone within a year, even while the fibers still looked intact (Martin et al., J Surg Res, porcine model / PMC3679684). In other words, the scaffold can be mechanically near-dead while still appearing present.

The replacement support comes from a foreign-body wound-healing cascade: blood proteins coat the fiber within seconds; mast cells and neutrophils drive acute inflammation; monocytes mature into macrophages (the dominant cell), which polarize from pro-inflammatory “M1” toward pro-repair “M2”; macrophages that cannot engulf the large fibers fuse into multinucleated foreign-body giant cells; and TGF-β drives fibroblast-to-myofibroblast transition, building the intended collagen “bra” (Sheikh et al., Materials, 2015 / PMC5512621). When remodeling goes well, by about 6 weeks mature type I collagen is woven through the scaffold (Adams et al., Aesthetic Surgery Journal, 2025 / PMC12461751). Failure occurs when the two curves cross at the wrong time — in older, irradiated, poorly vascularized, or mechanically overloaded tissue, the 90% strength loss of the polymer arrives before a competent collagen lattice exists to carry the load, and the construct stretches and gives way.

What the pathologist sees. Early specimens show round-to-oval empty spaces where the fibers sat, surrounded by ingrowing fibrovascular tissue and mature type I collagen (PMC12461751). In a failed/contracted explant, the report instead describes a dense, paucicellular fibrous capsule, increased α-SMA-positive myofibroblasts, and persistent giant cells (Pathological Insights on Polypropylene Mesh Complications, PMC10945158).

Severity and permanence. For absorbable P4HB devices, the defining feature is that there is often nothing left to remove. By 18–24 months the scaffold has resorbed, so a failed “internal bra” cannot be “un-failed” by taking the mesh out — the deficit lives in the patient’s own inadequate, often contracted scar. The only remedy is further surgery to redo the repair, which restarts the same race in already-scarred tissue. GalaFLEX and Phasix are the P4HB products central to this entry; their manufacturer record appears in the breast-scaffold section.

Seroma Formation with Breast ADM & Scaffolds

A seroma is a pocket of straw-colored body fluid that collects in the empty “dead space” left behind after breast surgery. When a surgeon reinforces a breast with a sheet of ADM — processed human, pig, or cow skin with the donor cells washed out — or a bioabsorbable P4HB scaffold, the body treats that sheet as a foreign object to wall off, and a thin sheet of material lying between skin and chest wall keeps wound fluid from being reabsorbed.

To the patient, a seroma feels like a swollen, tight, “water-balloon” area on the reconstructed breast. It may be painful, warm, or red (a related sterile reaction is named red breast syndrome). It usually appears in the first days to weeks and, when large, needs drainage with a needle or suction drains. Seroma is not a minor nuisance: a fluid layer under an ADM physically blocks the graft from “taking” and is a breeding ground for infection and implant loss. In a survey of plastic surgeons it was the single most frequently encountered ADM complication (Ibrahim et al., Plast Reconstr Surg Glob Open, PMC4422212).

Mechanism. Seroma is driven by two overlapping processes: ordinary surgical wound exudate, and the foreign-body response. Protein adsorption coats the material within seconds (Sheikh et al., PMC5512621). Acute inflammation — mast cells releasing histamine, neutrophils arriving to clear debris — drives the leaky-capillary phase that is the wound-exudate engine of early seroma (Tanna et al., Plast Reconstr Surg Glob Open, PMC4439592). Macrophages then dominate: pro-inflammatory M1 cells (secreting IL-1β, IL-6, TNF-α) keep capillaries leaky, while reparative M2 cells (induced by IL-4 and IL-13) drive revascularization and matrix deposition. For an ADM to incorporate, this M1→M2 shift must occur and host vessels must invade — but a fluid seroma layer physically separates the matrix from the wound bed and stalls that ingrowth, prolonging inflammation (Sheikh et al., PMC5512621; Tanna et al., PMC4439592). A long-standing seroma develops its own avascular secretory “pseudobursa” lining that keeps secreting fluid so the dead space never closes — the basis of the refractory seroma (Zhang et al., refractory-seroma study, PMC12457137). A material-specific contributor unique to ADM is residual endotoxin retained in the processed dermis, which can trigger a sterile inflammatory flare (Brzezienski & Jarrell, Aesthet Surg J 2020, Oxford Academic).

What the pathologist sees. A benign seroma fluid is serous-to-serosanguinous and protein-rich, with scattered histiocytes, lymphocytes, and neutrophils. Importantly, a late peri-implant seroma must be examined to exclude breast implant–associated anaplastic large cell lymphoma (BIA-ALCL), which shows non-cohesive large CD30-positive pleomorphic cells distinct from the bland reactive picture (Di Napoli et al., PLOS One, PMC5513491). The capsule/pseudobursa shows a dense fibrocollagenous wall, chronic mononuclear infiltrate, foreign-body giant cells, and α-SMA-positive myofibroblasts (Sheikh et al., PMC5512621).

Severity and reversibility. Most seromas are self-limited and resolve with drains or aspiration; the fluid is reversible, but the fibrosis can become permanent, manifesting clinically as capsular contracture. A refractory pseudobursa generally requires surgical capsulectomy because the lining keeps secreting otherwise (PMC12457137). The FDA has never cleared or approved any ADM product specifically for breast reconstruction — such use is off-label, extrapolated from hernia/soft-tissue clearances — and on March 31, 2021 issued a Safety Communication warning that ADM products used in implant-based breast reconstruction differ in complication rates and may carry a higher chance of complications (FDA Safety Communication, March 31, 2021). The FDA also states it has not cleared or approved any device to treat or reduce capsular contracture (FDA, Risks and Complications of Breast Implants).

Red Breast Syndrome (Sterile Inflammatory Erythema of ADM)

Red breast syndrome (RBS) is a sterile inflammation of the breast skin that appears after a surgeon implants a sheet of acellular dermal matrix — a processed graft of donated human or animal skin used as an internal “hammock” to support a tissue expander or implant, usually after mastectomy. The hallmark is a patch of redness (erythema) directly over the footprint of the graft that, to the eye and touch, looks almost exactly like a skin infection (cellulitis) — warm, pink-to-red, sometimes swollen (Lee et al., PRS Glob Open 2019, PMC6571326).

What makes it not an infection is the rest of the picture: typically no fever, no elevated white-blood-cell count, little or no pain, and every bacterial culture comes back negative, and the redness does not improve on antibiotics (Lee et al., 2019, PMC6571326; Kim et al., Arch Plast Surg 2024, PMC12004325). The redness can appear a few days to several weeks after surgery (median onset around 36 days in one cohort) and can take weeks to several months to fade. It is reported in 0%–27% of ADM reconstructions (mean ≈ 6.4%) depending on product and study (Lee et al., 2019, PMC6571326). For the patient, the practical difficulty is the uncertainty: it looks dangerous, triggers rounds of antibiotics and anxiety about losing the reconstruction, and in a minority of cases ends with the graft having to be removed.

Mechanism. RBS is best understood as a localized, visible flare of the foreign-body response: protein adsorption, mast-cell release of IL-4/IL-13, macrophage recruitment, and a dominant M1, IL-1/IL-6/TNF-α phase that produces the vasodilation, warmth, and erythema a clinician sees as the “red breast” (Sheikh et al., 2015, PMC5512621). What ignites it strongly enough to redden the skin is debated, with several proposed triggers:

Retained bacterial endotoxin (the leading molecular trigger). Endotoxin left in the graft from processing is a potent activator of innate immunity. In a large series, grafts associated with RBS contained 167 and 320 endotoxin units per graft (with negative cultures, proving sterility); after the manufacturer began screening grafts for endotoxin in January 2018, the RBS rate fell from 39/15,529 (0.25%) to 0/18,275 (0%), P < 0.0001 (Brzezienski & Jarrell, Aesthet Surg J 2020, Oxford Academic).
Delayed (Type-IV) hypersensitivity / eosinophilic reaction, supported by elevated eosinophil counts in patients with matrix-associated erythema (eosinophilic-dermatoses study, 2024, PMC11122398).
Lymphatic obstruction, where the freshly placed ADM creates a temporary barrier to lymphatic drainage that resolves as new lymphatics form (Lee et al., 2019, PMC6571326).

What the pathologist sees. Because RBS is usually managed clinically rather than biopsied, formal histology is sparse, and one review noted that “no characteristic histologic findings have been described” in many reports (PMC11122398). What pathologists do document on ADM explants: a foreign-body reaction with macrophages and giant cells at the matrix interface; comparatively low-grade chronic inflammation in the ADM capsule (significantly less inflammation and fewer myofibroblasts than ordinary implant capsule — score 0.83 vs. 1.83, P = 0.001) (Suh et al., J Plast Reconstr Aesthet Surg, PMID 27070347); a possible eosinophilic infiltrate; and, in severe operative cases, subcutaneous fat necrosis. The negative microbiology is the defining laboratory finding distinguishing sterile RBS from true cellulitis.

Which devices and severity. The literature states RBS “is not product specific … it can occur with any ADM” (Lee et al., 2019, PMC6571326); AlloDerm (human-derived) is the most frequently implicated (one study reported 26% RBS with AlloDerm versus 0% with DermACELL), and other human and animal matrices (DermACELL, FlexHD, SurgiMend, AlloMend, and others) are also reported. RBS is usually self-limiting and reversible, resolving on its own over weeks to months independent of antibiotics; in one cohort 6 of 8 cases resolved with conservative care (Kim et al., 2024, PMC12004325). A real minority require surgery — debridement or explantation of the graft — and prior radiotherapy is by far the strongest risk factor for the severe form (odds ratio 22.7, P = 0.001) (Kim et al., 2024, PMC12004325).

Capsular Contracture (Periprosthetic Fibrous Capsule)

Whenever a breast implant, mesh, or scaffold is placed, the body builds a wall of scar tissue around it called the capsule. Forming a thin, soft capsule is normal. Capsular contracture is what happens when that wall goes wrong: instead of staying thin and flexible, it thickens, hardens, and squeezes — like a fist slowly closing around the implant. The FDA describes it as “hardening of the breast around the implant” that “causes the tissue to tighten, which can be painful” (FDA, Risks and Complications of Breast Implants).

What the patient experiences, in worsening order: the breast feels firm, then hard; the implant is squeezed into a ball and rides higher on the chest; the breast becomes visibly distorted; and it becomes painful, sometimes badly enough to disturb sleep. For a woman who had reconstruction after a mastectomy, this is a second injury layered on the first. Capsular contracture is, by the FDA’s accounting, one of the most frequent complications experienced by breast-implant patients (FDA, Risks and Complications).

Mechanism. Capsular contracture is the end stage of the foreign-body reaction, which “begins within minutes of implantation” and proceeds through blood–material interaction, provisional matrix formation, acute and chronic inflammation, foreign-body giant cell formation, and fibrous capsule formation (Bachour et al., Current Concepts in Capsular Contracture, PMC8432999). Platelets release the first signaling wave (TGF-β, PDGF, IL-1); macrophages swarm the surface and their programming decides everything — “sustained M1 macrophage activation induces fibrosis,” whereas “M2 macrophage activation leads to less capsular contracture” (Hu et al., PMC11093578). Macrophages that fail to engulf the implant fuse into foreign-body giant cells. In contracted capsules specifically, “Th1/Th17 T cells dominate … and express greater levels of TGF-β, IL-1, IL-6, and IL-17” (Bachour et al., PMC8432999). TGF-β then drives fibroblasts to become myofibroblasts, which both lay down dense collagen and build an internal cable system of α-smooth-muscle actin to physically pull and contract the scar; higher myofibroblast density correlates directly with greater contracture severity (Hu et al., PMC11093578). A recognized accelerant is subclinical bacterial biofilm, which keeps the M1 program switched on indefinitely (see biofilm and chronic inflammation).

What the pathologist sees. The mature capsule has three layers; a contracted capsule shows dense, hypocellular collagen in parallel, aligned fibers (the orientation that lets myofibroblasts squeeze), α-SMA-positive, vimentin-positive, desmin-negative myofibroblasts, greater macrophage and T-cell infiltrates, foreign-body giant cells, and sometimes synovial-like metaplasia (Bachour et al., PMC8432999; Hu et al., PMC11093578; Tevlin et al., PMC6571298). Clinicians grade the patient on the Baker scale (I = soft/natural through IV = hard, painful, abnormal), though its interobserver reliability is “quite poor.”

Which devices. Any non-living implant can drive the cascade, but materials differ sharply. Silicone and saline implants are the primary foreign body; the FDA notes the underlying cause “is not known” though it may be more common after infection, hematoma, and seroma (FDA, Risks and Complications). Polypropylene mesh is the most aggressive scaffold offender — because the fibers “cannot be degraded,” it is permanently surrounded by a contracting fibrotic capsule with “dense collagen encapsulation … and an increased amount of TGF-β1” (Nolfi et al., Host Response to Synthetic Mesh, PMC5201165). ADM works in the opposite direction, producing significantly thinner capsules with significantly fewer myofibroblasts (Tevlin et al., PMC6571298). P4HB / GalaFLEX is absorbable and is associated with “a constructive remodeling response devoid of chronic inflammation or foreign body response,” though identifiable fibers and low-level mononuclear cells can persist for up to 63 months (Adams et al., Aesthetic Surgery Journal, PMC12461751).

Severity and permanence. Baker grades III and IV are considered severe and may require reoperation (FDA, Risks and Complications). Contracture does not resolve on its own and is, in practical terms, permanent unless surgically corrected. The standard treatment is complete capsulectomy with implant exchange — but fixing it is not curative, because the same foreign-body biology can restart around the new implant, with reported recurrence “ranging from 0 to 54%” (Bachour et al., PMC8432999).

Mastectomy Skin-Flap & Nipple-Areola Necrosis

When a breast is removed for cancer and rebuilt in the same operation, the surgeon peels the breast skin — and often the nipple — off the underlying tissue as a thin “flap,” then places an implant or expander, commonly adding an ADM or resorbable scaffold to hold it and give the skin something to drape over. The injury occurs when that thin flap, the nipple, or the wound edges lose enough blood supply to die or simply fail to heal. The skin turns from pink to dusky purple to black, leathery, dead tissue (eschar); the nipple may darken, blister, and slough off; the incision may pull apart (dehiscence) and expose the implant or matrix underneath. Reported rates of skin-flap necrosis run from about 5% in large national audits to 7–30% in immediate-reconstruction series, with partial nipple necrosis reported in roughly 28% of nipple-sparing mastectomies (Robertson et al., skin-flap necrosis review / PMC5357072).

Mechanism. There are two overlapping engines. (a) Ischemic necrosis: the breast skin is fed by a continuous subdermal plexus just beneath the dermis; when the surgeon raises the flap too thin or in the wrong plane, that plexus is divided and the skin is left on marginal collateral flow. When demand outstrips supply, cells switch to anaerobic metabolism, ATP fails, ion pumps collapse, and the tissue dies (coagulative necrosis). Nicotine, diabetes, obesity, prior radiation, and high expander fill volumes all push a marginally perfused flap over the edge; the nipple sits at the watershed end of this circulation, which is why nipple-sparing surgery raises necrosis rates (PMC5357072). (b) The foreign-body response to the matrix: protein adsorption, mast-cell IL-4/IL-13 release, macrophage polarization (M1 IL-1β/IL-6/TNF-α versus reparative M2/IL-10), foreign-body giant cell formation, and TGF-β-driven myofibroblast fibrosis (Sheikh et al., PMC5512621). The two engines compound each other: a dying flap exposes the matrix, exposure invites bacterial colonization, infection drives M1 inflammation, and chronic inflammation plus persistent foreign material delays healing.

What the pathologist sees. Necrotic skin shows coagulative necrosis — loss of nuclei, “ghost” cell outlines, microvascular thrombosis, and a margin of acute inflammation. An explanted ADM no longer looks “acellular”: it becomes “recolonized by fibroblasts and myofibroblasts” along with lymphocytes, macrophages, giant cells, and new vessels (What happens to an ADM after implantation, PubMed 29569868). An explanted polypropylene mesh shows a more aggressive picture — dense mononuclear and giant-cell infiltrate, fibrosis with mesh shrinkage and wrinkling (Wang et al., J Biomed Mater Res A, 2023, PubMed 36583666).

Which devices. Human and animal ADMs (AlloDerm, FlexHD, AlloMax, SurgiMend, Strattice) “vary significantly in source, processing, level of sterility … and preparation methods,” which drives differing complication profiles; the FDA’s March 2021 Safety Communication flagged that certain products carry higher complication rates (FDA Safety Communication, March 31, 2021). P4HB / GalaFLEX elicits a foreign-body reaction during its lifespan but tends toward an M2/remodeling phenotype. Polypropylene is not designed for breast reconstruction and is the most pro-inflammatory, producing surface cracking, contraction, and “persistent strong foreign body reaction with severe fibrosis” (Wang et al., 2023, PubMed 36583666).

Severity and permanence. Mild partial-thickness necrosis may heal with wound care; full-thickness necrosis is irreversible cell death requiring surgical debridement, and an exposed matrix often triggers a cascade of infection → seroma → repeated operations → explantation. The lost skin, nipple, or areola does not regenerate — a lost nipple can only be reconstructed, never biologically restored. The device can be removed, but the necrosis, scarring, and contracture already done are not reversible.

Failure of Breast Reconstruction Requiring Explantation

When a surgeon rebuilds a breast after mastectomy, the implant or expander usually needs internal “scaffolding” — polypropylene mesh, a resorbable mesh such as GalaFLEX, or an ADM. The body walls the device off in scar tissue, and in a meaningful fraction of patients that scar response thickens, tightens, and squeezes. When the scaffold itself becomes the problem — chronically inflamed, infected with a film of bacteria, exposed through the skin, or driving a hard painful capsule that will not relent — the only durable fix is to go back in and take it out. That second surgery is explantation: removal of the implant and, usually, the surrounding scar capsule (capsulectomy) and the failed mesh or matrix. It is a true surgical failure of the reconstruction, not a touch-up. Capsular contracture is the single most common complication of breast-implant surgery, and Baker grade III and IV contractures typically require this reoperation (Bachour et al., PMC8432999; FDA, Risks and Complications of Breast Implants).

Mechanism. The injury is the foreign-body response pushed into a chronic, contractile, fibrotic loop: protein adsorption, acute inflammation (mast-cell IL-4/IL-13), macrophage recruitment and polarization, foreign-body giant cell formation, and TGF-β-driven myofibroblast fibrosis that physically shortens the scar capsule and squeezes the implant (Sheikh et al., PMC5512621). In a healthy outcome the response resolves toward M2 and quiets; in failure it does not. In explanted human polypropylene mesh, macrophages persist with high inflammatory markers, “the NLRP3 inflammasome stays switched on,” and a strong TNF signal with no compensating IL-10 is still measurable more than a year after implantation — the inflammation never resolves (Kalaba et al., Acta Biomater, PMC6413778). A frequent accelerant is subclinical bacterial biofilm, tying low-grade infection directly to the fibrotic failure.

What the pathologist sees. Around mesh fibers: a textbook granulomatous foreign-body reaction — “dense infiltration of mononuclear cells, giant cells, and connective tissue deposition surrounding mesh fibers” (PMC6413778). In the periprosthetic capsule, contracted (Baker III/IV) capsules are significantly thicker, show thick aligned collagen bands (lower angular standard deviation, ~23.8° vs ~29.4°, p=0.0068), and contain more myofibroblasts (α-SMA positive in 39% of contracted vs 12% of uncontracted, p=0.049) (Bui et al., Histological Characterization of Human Breast Implant Capsules, PMC4434852). Where an ADM lined the pocket, the capsule is thinner with fewer myofibroblasts (Tevlin et al., PubMed 31333946); when a graft fails to take, the report reads non-integrated — no neoangiogenesis, no host ingrowth (Pittman et al., non-integrated ADM case report, PMC5918384).

Which devices. Polypropylene mesh never resorbs and sustains a lifelong granulomatous inflammatory response (PMC6413778). P4HB — GalaFLEX and Phasix is fully resorbable over roughly 12–18 months but still elicits a foreign-body response while present and can fail mechanically (in high-risk ventral-hernia use, 60-month data showed 22% recurrence and ~15% reoperation) (Deeken et al., PMC10130450). ADM generally reduces myofibroblasts and capsule thickness but can fail by non-integration or trigger red breast syndrome.

Severity and permanence. This is high-stakes and incompletely reversible. Per FDA labeling data, capsular contracture is reported in up to 51.7% of patients and reoperation in up to 59.7%, and the FDA has not cleared or approved any device to treat or reduce capsular contracture (FDA, Risks and Complications of Breast Implants). It can be treated only surgically and imperfectly — by explantation with capsulectomy — but the underlying biology recurs, with up to 54% of surgically managed cases experiencing contracture again (Bachour et al., PMC8432999). The device can be removed, but the patient cannot be returned to the pre-injury state.

Breast Contour Deformities from Scaffold Failure

When a breast is lifted, reduced, reconstructed, or augmented, surgeons increasingly rely on an “internal bra” scaffold to hold the breast tissue or implant in position — either a permanent plastic mesh (polypropylene) or a resorbable scaffold (GalaFLEX/P4HB or an ADM) meant to dissolve while leaving behind home-grown collagen. When that scaffold fails mechanically — stretches, frays, shrinks, pulls loose, or dissolves before adequate replacement tissue has formed — the breast collapses out of position. Three named deformities result:

Bottoming-out — the lower breast and the crease beneath it (the inframammary fold) slide downward; the nipple points up and most volume falls below the crease.
“Waterfall” (Snoopy) deformity — the implant or scaffold-supported mound stays pinned high while the patient’s own tissue slides down over the front of it and cascades off, creating a double contour (Lin et al., the waterfall effect in breast augmentation, PMC5409900).
Animation deformity — when an implant sits under the chest muscle, each flex yanks the breast sideways and upward into an unnatural moving dent; reported in 75–100% of under-the-muscle reconstructions to some degree (Spear et al., animation deformity in prosthetic breast reconstruction, PMC6378247).

What the patient experiences: visible asymmetry, a crease in the wrong place, skin stretch and thinning, a palpable edge, pain and tightness, movement of the breast with muscle use, and the recognition that this is not self-correcting.

Mechanism. These deformities are the visible end-stage of two intertwined processes: the foreign-body response and the mechanical failure of the scaffold to hold load. The cascade proceeds through acute inflammation, macrophage polarization (M1 IL-1β/IL-6/TNF-α versus M2 IL-10/TGF-β), foreign-body giant cell formation, and TGF-β-driven myofibroblast differentiation — contractile α-SMA-positive cells that lay down collagen and contract the matrix (Witherel et al., macrophages and fibroblasts in foreign body reactions, PMC10494263). Around permanent polypropylene the macrophage population stays predominantly pro-inflammatory and never resolves (FDA, Polypropylene: Medical Device Material Safety Summaries). A parallel route, macrophage-to-myofibroblast transition (MMT), rises in direct proportion to “mesh burden” in a primate polypropylene model (Liang et al., Macrophage-to-Myofibroblast Transition, PMC12637572).

Two opposite failure patterns emerge from the same biology. Too much contraction yields a tight distorting capsule (the substrate for capsular contracture and animation deformity). Too little durable support — a weak, immature, or prematurely-resorbed scaffold — yields tissue laxity: a resorbable scaffold is supposed to be replaced by vascularized neo-collagen over 18–24 months, but if the response generates immature, disorganized, low-density collagen instead, the scaffold dissolves faster than competent tissue forms, the lower pole stretches, the fold migrates downward (bottoming-out), and the soft tissue slides off the fixed mound (waterfall) (PMC12637572; PMC5409900). For permanent polypropylene, the parallel failure is mesh contraction/shrinkage — the FDA lists “migration or shrinkage (contraction) of the mesh” as a recognized adverse event (FDA, Surgical Mesh Used for Hernia Repair) — together with pore collapse that converts the mesh into a stiff, wrinkled scar plate.

What the pathologist sees. A chronic foreign-body-type granulomatous reaction zoned around each fiber: macrophages and aggregates of foreign-body giant cells at the fiber surface; vacuoles where fibers sat, sometimes with fiber fraying and cracks/degradation of the polypropylene filaments (Pathological Insights on Polypropylene Mesh Complications, PMC10945158); a fibrotic zone with α-SMA-positive, vimentin-positive, desmin-negative myofibroblasts (Tevlin et al., PMC6571298); and, in implant capsules, validated scoring of collagen thickness, fiber alignment, and myofibroblast activity, with contracted (Baker III–IV) capsules showing greater alignment, thickness, and myofibroblast activity (Vieira et al., capsular-contracture histology, PMC6280822; Bui et al., PMC4434852).

Which devices. Polypropylene mesh (permanent synthetic) provokes a non-resolving pro-inflammatory response and is subject to FDA-recognized contraction, pore collapse, fiber degradation, and migration (FDA, Surgical Mesh Used for Hernia Repair; PMC12637572). P4HB — GalaFLEX and related resorbable scaffolds (including the SERI class) fail when the regenerated tissue is inadequate at the moment the scaffold loses strength (SERI Surgical Scaffold for Revision Augmentation, ClinicalTrials.gov NCT02030938). ADM reduces capsule thickness when it integrates well but provides no durable lower-pole support when it fails to vascularize, stretches, or is positioned below the native fold (Tevlin et al., PMC6571298).

Severity and permanence. These are functional and disfiguring, not merely cosmetic — bottoming-out is a common reason for revision breast surgery, and animation deformity affects the majority of subpectoral reconstructions to some degree (PMC6378247). None of the three resolves on its own; each requires revision surgery (capsulorrhaphy for bottoming-out, implant-plane change for waterfall, subpectoral-to-prepectoral exchange for animation). Two caveats on “removal”: permanent polypropylene is not cleanly reversible — once encased in giant cells and fibrosis, complete excision is technically difficult and the mesh is often fragmented (PMC10945158) — and the stretched skin and tissue laxity do not fully recoil even after the device is removed, because the elastin and collagen damage is, to a significant degree, permanent (FDA, Polypropylene Material Safety Summary).

This is general medical information, not medical advice, and reading it creates no doctor–patient or attorney–client relationship. Outcomes vary and no result is guaranteed — discuss any symptoms or device decisions with your own physician.

◀ Material Degradation & Systemic / Immune Reactions · ↑ Top · The Big Picture: The Scale of Mesh Litigation in the U.S. and Worldwide ▶

The Big Picture: The Scale of Mesh Litigation in the U.S. and Worldwide

Surgical mesh has generated one of the largest bodies of product-liability litigation in modern American legal history. If you or someone you love has been injured by a mesh device, it helps to understand that you are not facing an isolated problem. Tens of thousands of patients have brought claims, courts have consolidated them into coordinated proceedings, federal juries have returned both plaintiff and defense verdicts, and regulators here and abroad have taken formal action. This section lays out that landscape plainly and accurately — what is on the public record, what was alleged versus what was actually decided, and where the numbers come from.

A note on how we report figures: the largest aggregate dollar amounts in this area (for example, the roughly $8 billion industry-wide pelvic-mesh total) are reported estimates, not single audited numbers, because many individual settlements are confidential. We flag those as estimates, just as the underlying sources do, and we attribute every figure to its source. Litigation facts are stated as matters of public record — what a jury found, what a court ordered, what a company disclosed, or what plaintiffs alleged.

This is educational information, not legal or medical advice; it is not a substitute for professional medical care, and you should consult your own physician about any device in your body. For the device-by-device detail, see the manufacturer sections cross-linked below, the FDA regulatory history, and the international actions.

Two distinct litigation families

Mesh litigation divides into two broad groups, each with its own devices, injuries, and court structure:

Transvaginal / pelvic mesh — mesh implanted through the vagina to treat pelvic organ prolapse (POP) and stress urinary incontinence (SUI). This is the older and larger of the two families.
Hernia mesh — mesh used to repair abdominal, inguinal, ventral, and other hernias. This litigation is more recent and, for several manufacturers, still active.

The injuries at issue overlap with the clinical problems described elsewhere on this page — including mesh erosion, exposure and extrusion, organ perforation, chronic pelvic pain, painful intercourse and sexual dysfunction, infection, migration, contraction and shrinkage, and failure of the repair requiring revision surgery.

Pelvic mesh: 100,000+ lawsuits, seven federal MDLs, ~$8 billion in combined settlements

The pelvic-mesh litigation is, as reported, one of the largest mass-tort proceedings in U.S. history. Surgical mesh implanted vaginally to treat POP and SUI was alleged to erode through tissue and cause chronic pain, infection, organ perforation, painful intercourse, and the need for repeat removal surgeries. Across all manufacturers, more than 100,000 lawsuits were filed, consolidated into seven coordinated federal multidistrict litigations (MDLs) before a single judge.

The seven MDLs were all centralized before U.S. District Judge Joseph R. Goodwin in the Southern District of West Virginia. Each MDL corresponds to one manufacturer or device family. All seven are now closed.

MDL No.	Manufacturer / Defendant	Status
2187	C.R. Bard, Inc. (parent: Becton Dickinson)	Closed
2325	American Medical Systems (Endo)	Closed
2326	Boston Scientific Corp.	Closed
2327	Ethicon, Inc. (Johnson & Johnson)	Closed
2387	Coloplast Corp.	Closed
2440	Cook Medical, Inc.	Closed
2511	Neomedic	Closed

The MDL numbers, manufacturer assignments, the seven-MDL count, the West Virginia venue, and Judge Goodwin’s assignment are confirmed by the court’s own records (U.S. District Court for the Southern District of West Virginia — MDL case information, https://www.wvsd.uscourts.gov/case-info/MDL). For the manufacturer-specific records, see Becton Dickinson / C.R. Bard / Davol, Johnson & Johnson / Ethicon, Boston Scientific, American Medical Systems / Endo, and Coloplast and Cook Medical.

The aggregate settlement figure — roughly $8 billion — is an industry-wide total across all pelvic-mesh manufacturers combined. It should never be attributed to any single company. As reported, companies have paid an estimated $8 billion in transvaginal-mesh settlements and verdicts to more than 100,000 women, and because many settlements are confidential, the true total is likely higher Source.

Reported per-manufacturer settlement components

These are the publicly reported building blocks of the industry total. Each is attributed; confidential settlements are not captured here.

Manufacturer	Reported settlements (attributed)	Source
American Medical Systems / Endo	Reported as the largest single-company exposure, including an $830 million settlement (May 2014) and a $775 million settlement (Aug. 2017), disclosed by the company	Endo press release
C.R. Bard (Becton Dickinson)	$60 million multistate settlement with 48 states over deceptive marketing of surgical-mesh devices (2020)	Nevada Attorney General
Boston Scientific	$188.6 million multistate settlement (announced 2021)	South Carolina Attorney General
Johnson & Johnson / Ethicon	$343.99 million California court judgment (2020) for false and deceptive marketing of pelvic mesh, plus reported multistate settlements	California Attorney General

What courts actually decided: landmark pelvic-mesh outcomes

The record includes both plaintiff verdicts and defense verdicts. Reporting it accurately means distinguishing what a jury found from what plaintiffs alleged.

Scott v. C.R. Bard — In the first pelvic-mesh jury verdict, a Kern County, California, jury returned a verdict for the plaintiffs in July 2012 ($5.5 million total). The verdict was later addressed on appeal by the California Court of Appeal, Fifth Appellate District (California Court of Appeal, Scott v. C.R. Bard, Inc., Fifth Appellate District).
Cisson v. C.R. Bard — The first federal MDL bellwether (MDL 2187, before Judge Goodwin) resulted in a $2 million plaintiff verdict in August 2013, affirmed by the U.S. Court of Appeals for the Fourth Circuit in In re C.R. Bard, Inc. (Cisson), 810 F.3d 913 (4th Cir. 2016) (U.S. Court of Appeals for the Fourth Circuit, In re C.R. Bard, Inc., 810 F.3d 913 (4th Cir. 2016)).
California v. Johnson & Johnson / Ethicon — A primary-source government judgment: the San Diego Superior Court entered a $343.99 million judgment for the State of California in 2020 under California’s Unfair Competition Law and False Advertising Law. As the Attorney General’s office stated, the State alleged that the company “intentionally concealed the risks of its pelvic mesh implant devices” Source.
Engleman v. Ethicon — A Philadelphia Court of Common Pleas jury returned a $20 million plaintiff verdict (April 2017); the matter is documented in the appellate record Source.
Defense verdicts also occurred. Manufacturers won a meaningful subset of trials. In Albright v. Boston Scientific (July 2014), a jury returned a defense verdict — reported as the first transvaginal-mesh trial decided in favor of the defendant Source. Trial results across the litigation were mixed.

For balance and accuracy, note that no verdict or settlement in the records reviewed here was based on a mesh-caused death; one plaintiff (Linda Batiste) died during her litigation, but her verdict was for defective design and injury, not wrongful death Source.

The regulatory backdrop to all of this — the FDA’s 2008 notification, its 2011 “not rare” safety communication, the 2016 reclassification to Class III, and the 2019 order removing the remaining devices from the market — is covered in detail in FDA Action on Surgical Mesh.

Hernia mesh: four active or wound-down federal MDLs

Hernia-mesh litigation is consolidated across four principal federal MDLs, each targeting a different manufacturer and product line. The most authoritative single snapshot of scale is the U.S. Judicial Panel on Multidistrict Litigation (JPML) statistics report dated December 2, 2025, which lists the exact number of actions pending in each MDL. (The JPML publishes these counts monthly; figures change over time, so they are reported here as of that date.)

Manufacturer / MDL	Court / Judge	Actions pending (12/2/2025)	Cumulative
Bard / Davol — MDL 2846	S.D. Ohio — Judge Edmund A. Sargus, Jr.	23,818	25,090
Covidien (Medtronic) — MDL 3029	D. Mass. — Sr. Judge Patti B. Saris	2,205	2,211
Atrium (Getinge) — MDL 2753	D.N.H. — Chief Judge Landya B. McCafferty	322	3,592
Ethicon (J&J) — MDL 2782	N.D. Ga. — Sr. Judge Richard W. Story	1	4,053

All four pending-action counts are taken verbatim from the JPML’s official statistics report Source.

Bard / Davol — MDL 2846 (Southern District of Ohio)

The litigation is centralized as In re Davol, Inc./C.R. Bard, Inc., Polypropylene Hernia Mesh Products Liability Litigation, before Judge Edmund A. Sargus, Jr., per the court’s own MDL page Source. It is one of the largest active mass torts in the country, with 23,818 actions pending as of December 2, 2025 Source.

Three bellwether trials illustrate the mixed record:

Johns v. C.R. Bard (1st bellwether, Sept. 2021) — defense verdict; the jury found for Bard.
Milanesi v. C.R. Bard (2nd bellwether, April 2022) — plaintiff verdict of $255,000 ($250,000 on design-defect plus $5,000 loss of consortium), as reported by Bloomberg Law.
Stinson v. C.R. Bard (3rd bellwether, Nov. 2023) — plaintiff verdict of $500,000; the jury found the defendants “failed to adequately warn the plaintiff and his doctor about the risks” while declining to find malice, as reported by Bloomberg Law.

Separately, a Rhode Island Superior Court jury awarded $4.8 million to Paul Trevino in August 2022 over the Ventralex mesh on a negligence theory Source.

In October 2024, parent company Becton Dickinson announced a settlement resolving the “vast majority” of existing hernia-mesh claims — reported as roughly 38,000 cases — with payments over a multiyear period and no admission of wrongdoing, and with patients retaining the right to opt out and pursue trials. BD did not publicly disclose the deal’s price; per company filings reported by Bloomberg, BD had set aside reserves in the $1.7 billion–$1.9 billion range for its product-liability cases including the mesh litigation, and total payouts were reported as likely to exceed $1 billion Source. Because resolution is administered over time, the JPML docket still showed 23,818 actions pending as of December 2, 2025 Source. The full Bard/Davol record appears in the Becton Dickinson / C.R. Bard / Davol section.

Ethicon (Johnson & Johnson) — Physiomesh — MDL 2782 (Northern District of Georgia)

This MDL is effectively wound down, with only 1 action pending (4,053 cumulative) as of December 2, 2025 Source. In May 2016, Ethicon issued an urgent field safety notice and removed Physiomesh Flexible Composite Mesh from the market — a voluntary market withdrawal, not an FDA recall in the U.S. The withdrawal followed an analysis of unpublished data from German and Danish hernia registries indicating the device was associated with higher rates of recurrence and revision than comparable meshes after laparoscopic ventral hernia repair Source. Ethicon’s hernia-mesh resolutions have been confidential; the court’s MDL page documents the proceeding Source. See the Johnson & Johnson / Ethicon section for more.

Atrium Medical (Getinge) — C-QUR — MDL 2753 (District of New Hampshire)

The C-QUR MDL had 322 actions pending (3,592 cumulative) as of December 2, 2025, in structured wind-down following a global settlement Source. C-QUR is a polypropylene mesh coated with an Omega-3 fish-oil-derived gel; plaintiffs alleged the coating caused inflammatory reactions and could separate during implantation. The device family has a strong primary-source regulatory trail: an October 11, 2012 FDA Warning Letter cited inadequate handling of infection complaints and sterilization problems Source, and in 2015 a federal court entered a permanent injunction against Atrium to stop distribution of adulterated and misbranded products Source. In December 2021, Getinge (Atrium’s parent) announced a $66 million global settlement resolving more than 3,000 C-QUR claims, with no admission of liability Source.

Covidien (Medtronic) — MDL 3029 (District of Massachusetts)

Covidien’s hernia-mesh MDL had 2,205 actions pending as of December 2, 2025, and is the only one of the four federal MDLs without any settlement — it is actively litigating toward bellwether trials Source. The MDL was created by a JPML transfer order filed June 6, 2022, which noted this was the litigation’s second centralization attempt. Per that order, most plaintiffs allege that the polyester used in the defendants’ mesh products “incites inflammation and heightened foreign body response, is more brittle, and is significantly more susceptible to fatigue fracture, breakage, fragmentation, and other mechanical failures than alternative polymers,” with some also alleging defects in the collagen barrier or polylactic microgrips used in certain products Source. The product lines at issue include Parietex, ProGrip, and Symbotex. The Atrium and Covidien records are detailed in the Atrium / Covidien manufacturer section.

Hernia-mesh settlement landscape at a glance

Manufacturer	Status	Reported figure	Source
Bard / Davol (BD)	Global settlement Oct. 2024; “vast majority” of ~38,000 claims; no admission	Reserve $1.7B–$1.9B; total payouts reported to exceed $1B	Claims Journal / Bloomberg
Atrium / C-QUR (Getinge)	Global settlement Dec. 2021; 3,000+ claims; no admission	$66 million	Getinge
Ethicon / Physiomesh (J&J)	Confidential resolutions; MDL wound down (1 pending)	Undisclosed	JPML 12/2/2025
Covidien (Medtronic)	No settlement; actively litigating	None to date	JPML Transfer Order

Regulatory context

The FDA’s own guidance frames the complication landscape for hernia repair, listing the most common adverse events as “pain, infection, hernia recurrence,” adhesions, obstruction, bleeding, fistula, seroma, and perforation — and, for mesh specifically, migration or shrinkage (contraction) of the mesh Source. The FDA has reported that, over a review spanning roughly 22 years, adverse-event reporting produced more than 55,000 reports involving hernia mesh Source. For the full regulatory chronology and how these devices reached the market, see FDA Action on Surgical Mesh and How These Devices Reached the Market.

Why the scale matters to you

The size of this litigation is not, by itself, a measure of whether any one patient has a claim. Every case turns on its own medical facts, the specific device involved, the timing of the injury, and applicable law. What the landscape does show is that mesh injuries are well documented in court records, regulatory files, and the medical literature — and that the questions you may have are questions many others have asked before you. Nothing here predicts or guarantees an outcome in any individual matter, and this page is not a substitute for advice from your own physician or attorney.

If you or a loved one has been affected by a surgical or breast mesh device, our team offers a free, confidential consultation. Reading this page does not create an attorney-client relationship, and prior results do not guarantee a similar outcome. See our important disclaimers for the full context in which this information is offered.

◀ Breast Reconstruction & Scaffold Injuries · ↑ Top · Becton Dickinson / C.R. Bard / Davol — The Documented Record ▶

Becton Dickinson / C.R. Bard / Davol — The Documented Record

If you were implanted with a surgical-mesh device — a hernia patch or a transvaginal mesh kit — there is a meaningful chance it bore the name Bard, Davol, or Avaulta. This section lays out the public, documented record for that corporate family: who owns whom, which products are at issue, what the FDA has formally done, and what juries, courts, and the companies’ own securities filings actually say. We separate allegations (what patients claimed) from adjudicated findings (what a jury found or a court ordered), because that distinction matters — both legally and for understanding your own situation.

This is educational background, not a verdict on your case or your device. For an explanation of the underlying injuries themselves, see Mesh Erosion, Exposure & Extrusion and Infection & Life-Threatening Complications; for the regulatory timeline, see FDA Action on Surgical Mesh: 2008 → 2011 → 2016 → the 2019 Ban.

Who owns whom

The corporate chain is straightforward once laid out:

C.R. Bard, Inc. — a New Jersey medical-device company (SEC CIK 0000009892) that originally manufactured and marketed the products discussed here.
Davol, Inc. — a Bard subsidiary based in Rhode Island, the entity historically associated with Bard’s hernia-mesh products.
Becton, Dickinson and Company (“BD”; NYSE: BDX) — acquired C.R. Bard in December 2017 and now reports all of this litigation as its own product-liability contingency. BD’s annual report confirms the timing: “C.R. Bard, which was acquired by the Company in December 2017.” Source

In plain terms: C.R. Bard and Davol are subsidiaries of Becton Dickinson. When you read “BD,” “Bard,” or “Davol” below, they belong to the same family — and BD today carries the liability.

The products

The litigated devices fall into two distinct product lines, which the companies themselves keep strictly separate in their securities filings — “Women’s Health Product Claims” (pelvic/transvaginal mesh) and “Hernia Product Claims.” Source

Product line	Representative devices	Indication
Pelvic / transvaginal mesh	Avaulta Plus, Avaulta Solo, Align (mid-urethral sling)	Pelvic organ prolapse (POP); stress urinary incontinence (SUI)
Hernia mesh (Kugel generation)	Composix Kugel Hernia Patch	Ventral / incisional hernia repair
Hernia mesh (modern generation)	Ventralight ST, Ventralex, Ventralex ST, 3DMax, Composix, PerFix Plug	Hernia repair

The pelvic devices are constructed from polypropylene; the hernia devices from polypropylene (some with an ePTFE composite or a bioresorbable coating). These devices reached the U.S. market through the FDA’s 510(k) substantial-equivalence premarket pathway, which is explained in How These Devices Reached the Market.

FDA actions and recalls

The Composix Kugel Class I recall (2005–2007). The most serious FDA action in this family’s hernia history was the Class I recall of the Davol/Bard Composix Kugel Hernia Patch (cleared under 510(k) number K003323, product code FTL). Class I is the FDA’s highest recall tier, reserved for products where “there is a reasonable probability that the use of, or exposure to, a violative product will cause serious adverse health consequences or death.” The device’s plastic “memory recoil ring,” meant to spring the folded patch flat inside the abdomen, could break. The FDA recall records state the manufacturer’s reason for recall as: the ring “could break and potentially lead to bowel perforation and or chronic enteric fistula.” Source

The recall began in December 2005 and was expanded into 2007:

FDA recall #	Product	Firm-initiated	Units in commerce
Z-0524-06	Composix Kugel X-Large Patch Oval	Dec 22, 2005	31,761 Source
Z-0359-2007	Composix Kugel Large Oval	Jan 10, 2007	32,581 Source
Z-0360-2007	Composix Kugel Large Circle	Jan 10, 2007	16,603 Source

The harm pathway in these FDA records — bowel perforation and chronic enteric fistula — corresponds to the injuries described in Perforation of Bladder, Bowel or Ureter, Fistula Formation, and, in the most severe cases, Fatal Complications.

The modern hernia devices (Ventralight ST, Ventralex, 3DMax, PerFix Plug) were not subject to a Class I recall; the litigation over those products rests on design-defect and failure-to-warn theories rather than on any recall. Source

Transvaginal (pelvic) mesh — the FDA escalation. The FDA’s escalating action on urogynecologic surgical mesh frames the Avaulta litigation. After 2008 and 2011 safety communications, the agency reclassified surgical mesh for transvaginal POP repair into Class III (high risk) in 2016, and on April 16, 2019 ordered the remaining manufacturers of transvaginal POP mesh “to stop selling and distributing their products immediately,” determining the manufacturers “did not demonstrate reasonable assurance of safety and effectiveness.” Source By the 2019 order Bard’s POP mesh was already off the U.S. market; Bard had stopped selling its Avaulta line around 2012, consistent with the FDA’s January 2012 section 522 postmarket-surveillance orders, after which “most manufacturers elected to stop marketing surgical mesh for transvaginal repair of pelvic organ prolapse.” Source The full timeline is in FDA Action on Surgical Mesh.

The litigation record — pelvic (Avaulta) mesh

Thousands of women alleged that Bard’s Avaulta and Align polypropylene mesh eroded into surrounding tissue and organs, causing chronic pain, painful intercourse, infection, and the need for multiple revision surgeries — allegations that became one of the largest medical-device mass-tort consolidations in U.S. history. The federal cases were centralized as In re: C.R. Bard, Inc., Pelvic Repair System Products Liability Litigation, MDL No. 2187, before Judge Joseph R. Goodwin in the U.S. District Court for the Southern District of West Virginia (now terminated, with residual cases in a New Jersey coordinated proceeding). Source

The following are matters of public court record:

Scott v. C.R. Bard (California, July 2012). The first transvaginal-mesh case to go to trial against a major manufacturer in U.S. state court. A Kern County jury returned a $5.5 million verdict; the jury assigned roughly 40% of fault to the implanting surgeon, leaving Bard’s apportioned share at about $3.6 million. The judgment was affirmed by the California Court of Appeal in November 2014. Source Bard later reported paying its share in March 2015; its securities filing describes the California judgment “of approximately $3.6 million” as having been “affirmed by the appellate court in November 2014.” Source
Cisson v. C.R. Bard (first federal MDL bellwether; verdict August 2013, affirmed January 14, 2016). A federal jury awarded Donna Cisson $250,000 in compensatory damages and $1,750,000 in punitive damages (≈$2 million total) on design-defect and failure-to-warn claims involving the Avaulta Plus. The U.S. Court of Appeals for the Fourth Circuit affirmed the district court judgment on all issues, including the roughly 7-to-1 punitive ratio. A central piece of evidence was the Material Safety Data Sheet for the polypropylene resin, which warned: “Do not use this … material in medical applications involving permanent implantation in the human body.” The affirmed appellate opinion records that internal Bard e-mails showed executives were aware of this warning and, in the court’s words, “sought to prevent their monofilament suppliers from learning of the warning.” Source Cisson is the strongest fully affirmed Bard pelvic-mesh verdict. Bard’s own securities filing independently confirms “a judgment against the company of approximately $2 million, which was upheld by the Fourth Circuit on January 14, 2016.” Source
McGinnis v. C.R. Bard (New Jersey, April 2018) — later overturned. A Bergen County jury awarded $68 million — at the time the largest Bard pelvic-mesh verdict — finding the Avaulta and Align devices defectively designed. Critically, on July 25, 2023, the New Jersey Supreme Court upheld a lower-court ruling that overturned the $68 million verdict, finding Bard was denied a fair trial because it “should have been able to present evidence that the devices were cleared for sale based on equivalence to products already on the market.” A new trial was ordered. This verdict should not be cited as a standing award. Source

Pelvic-mesh settlements (these resolved claims without any admission of liability):

~$200 million to settle roughly 3,000 pelvic-mesh cases, reported in August 2015. Source Bard’s securities filing describes inventory-settlement agreements covering “approximately 11,000 Women’s Health Product Claims” across 2014–2016. Source
$60 million to 48 states and the District of Columbia (September 24, 2020) to resolve allegations that Bard “deceptively marketed transvaginal surgical mesh devices” and “failed to adequately disclose serious, life-altering risks … such as chronic pain, scarring and shrinking of bodily tissue, and recurring infections.” This was a consumer-protection settlement, not a personal-injury resolution. Source

The litigation record — hernia mesh

The modern hernia cases are centralized as In re: Davol, Inc./C.R. Bard, Inc., Polypropylene Hernia Mesh Products Liability Litigation, MDL No. 2846, in the U.S. District Court for the Southern District of Ohio before Chief Judge Edmund A. Sargus, Jr., created August 2, 2018. The court describes the core allegations as “defects in defendants’ polypropylene hernia mesh products [that] can lead to complications when implanted in patients, including adhesions, damage to organs, inflammatory and allergic responses, foreign body [response].” Source A parallel consolidation proceeded in Rhode Island Superior Court. These injuries correspond to Visceral Adhesions from Intraperitoneal Hernia Mesh, Mesh Infection, and The Foreign-Body Response.

Three federal bellwether trials were tried to verdict, with mixed results (all jury verdicts, not settlements):

Bellwether	Device	Verdict date	Outcome	Amount
Johns v. C.R. Bard	Ventralight ST	Sept. 2021	Defense verdict (all counts)	$0
Milanesi v. C.R. Bard	Ventralex	Apr. 2022	Plaintiff verdict — negligent design defect	$255,000
Stinson v. Davol/Bard	PerFix Plug	Nov. 2023	Plaintiff verdict — failure to warn	$500,000

Johns (defense verdict). The first bellwether; the jury found for Bard on all negligence and strict-liability counts, awarding nothing. BD’s securities filing confirms “a complete defense verdict in favor of the Company in September 2021.” Source
Milanesi ($255,000 plaintiff verdict). The jury found for the plaintiffs on the negligent design-defect claim only ($250,000 plus $5,000 loss of consortium), rejecting the strict-liability, failure-to-warn, and misrepresentation claims. Source BD’s filing confirms “a $255 thousand verdict in April 2022.” Source
Stinson ($500,000 plaintiff verdict). The jury found Bard/Davol “failed to adequately warn the plaintiff and his doctor” about the PerFix Plug’s risks, ruling for the plaintiff on negligence and failure-to-warn claims but not on design defect, and found the companies were “not proven to act with malice.” Source
A Rhode Island state bellwether produced a $4.8 million plaintiff verdict in August 2022, which BD reported it planned to appeal. Source

The October 2024 hernia settlement. On October 2, 2024, BD announced an agreement “to resolve the vast majority of its existing hernia litigation,” covering both the Ohio MDL and the Rhode Island consolidation. Reporting put the deal at more than $1 billion to resolve more than 38,000 lawsuits, with payouts over less than five years. Source The exact figure is confidential; BD’s own 8-K states only that the amount is “within the company’s current product litigation reserve,” “will not result in an incremental charge,” and carries “No admission of liability or wrongdoing,” adding that “BD continues to dispute the allegations in these matters.” Source BD’s annual report confirms the residual hernia claim count fell to approximately 6,610 following the settlement. Source

Earlier Kugel settlement. The historically separate Composix Kugel litigation — centralized as MDL No. 1842 in the District of Rhode Island — produced a defense verdict in Whitfield (April 2010) and a $1.5 million plaintiff verdict in Thorpe (August 2010), before a negotiated ~$184 million global settlement announced July 6, 2011 covering roughly 2,600 cases. Source Bard’s filing records that the Composix Kugel products were “voluntarily recalled” beginning December 2005 and that the lawsuits were transferred into the Rhode Island MDL in June 2007. Source

What the securities filings disclose

Becton Dickinson’s own SEC filings quantify the scale of this exposure. After acquiring Bard, BD disclosed in correspondence with the SEC that as of September 30, 2022 it was defending approximately 31,445 product-liability claims involving its hernia-repair devices, with accruals of $2.1 billion and $2.5 billion as of September 30, 2022 and 2021, and pre-tax charges of approximately $21 million, $361 million, and $378 million during 2022, 2021, and 2020. Source BD’s most recent annual report records additional pre-tax charges of approximately $297 million, $218 million, and $58 million in fiscal years 2025, 2024, and 2023. Source These are the company’s own disclosures to its investors — a useful, neutral measure of the documented record’s scale. For how this Bard/BD record fits within the broader national and global picture, see The Big Picture.

The record above is drawn entirely from court opinions, FDA databases, and the companies’ own securities filings. Where a jury or court reached a finding, we have said so; where patients or attorneys general alleged misconduct, we have labeled it an allegation; and where a verdict was later overturned, we have flagged it. This material is general legal and medical information, not legal or medical advice, and reading it creates no attorney-client relationship; prior results do not guarantee a similar outcome, and any questions about your own implant or symptoms should be directed to your own physician. If you or a loved one was implanted with a Bard, Davol, or Avaulta mesh device and you are trying to understand what happened, our team offers a free, confidential consultation — and you can also learn more about who we are in About Attorney 911.

◀ The Big Picture: The Scale of Mesh Litigation in the U.S. and Worldwide · ↑ Top · Johnson & Johnson / Ethicon — The Documented Record ▶

Johnson & Johnson / Ethicon — The Documented Record

Ethicon, Inc. is the surgical-device subsidiary of Johnson & Johnson, one of the largest medical-products companies in the world. Through Ethicon (and its women’s-health unit, historically branded “Gynecare”), Johnson & Johnson designed, manufactured, and sold a large family of polypropylene surgical-mesh devices used in pelvic and hernia repair. This section sets out the public, documented record for those products: what they were, what regulators did, and what courts, juries, and government enforcers actually found. It is presented as a neutral reference, not an accusation — allegations are labeled as allegations, and adjudicated findings are labeled as findings.

If you have one of these devices, this page is educational only and is not a substitute for the advice of your own physician. Nothing here tells you to remove or keep any implant — that is a medical decision for you and your doctor. For the broader scale of this litigation, see The Big Picture.

Corporate identity and chain of ownership

Johnson & Johnson — the publicly traded parent company.
Ethicon, Inc. and Ethicon US, LLC — Johnson & Johnson subsidiaries that designed, manufactured, and marketed the surgical-mesh devices. The “Gynecare” name was Ethicon’s women’s-health brand.
The Physiomesh hernia product was manufactured in Germany by Johnson & Johnson Medical GmbH and sold worldwide through Ethicon and Johnson & Johnson (MDL 2782 Order, Doc. 690, N.D. Ga.).

By way of contrast, a different corporate family — C.R. Bard and Davol — are subsidiaries of Becton Dickinson; their record is covered separately in Becton Dickinson / C.R. Bard / Davol.

The products

Ethicon’s pelvic-mesh line treated two conditions — pelvic organ prolapse (POP) and stress urinary incontinence (SUI):

Product	Use	Notes
Gynecare Prolift / Prolift +M	POP repair kit	The largest of Ethicon’s polypropylene pelvic meshes
Gynecare Prosima	POP repair kit
Gynemesh / Gynemesh PS	POP repair mesh	Derived from the same Prolene polypropylene used in earlier hernia repairs
Gynecare TVT, TVT-O, TVT-Secur, TVT Abbrevo, TVT-Exact	Mid-urethral slings for SUI	“Tension-free vaginal tape” family

A separate Ethicon product line addressed hernia repair:

Physiomesh Flexible Composite Mesh — a multi-layer, polypropylene-based laparoscopic hernia mesh, sold worldwide between April 2010 and May 2016 (MDL 2782 Order, Doc. 690, at 2).

According to the California Attorney General, Johnson & Johnson sold more than 470,000 pelvic-mesh products nationally between 2008 and 2014, and roughly 2 million women worldwide received the implants (California Department of Justice press release).

Injuries associated with these products

In litigation, government complaints, and adverse-event reports, the harms attributed to Ethicon pelvic mesh have included mesh erosion and exposure, chronic pelvic pain, dyspareunia and loss of sexual function, neuropathic pain and nerve injury, urinary dysfunction and recurrent infection, and the difficulty or impossibility of fully removing implanted mesh — often requiring repeated revision surgeries. The California Attorney General’s complaint described the concealed and minimized risks as including “permanent pain with intercourse,” “loss of sexual function,” “chronic pain,” and “permanent urinary or defecatory dysfunction” (California DOJ press release).

For Physiomesh, the U.S. Judicial Panel on Multidistrict Litigation summarized plaintiffs’ allegations that defects “can lead to complications when implanted in patients, including herniation through the mesh, recurrent hernia formation and/or rupture, and deformation of the mesh,” and that “the multi-layer coating in Physiomesh prevented adequate incorporation of the mesh” (JPML Transfer Order, MDL No. 2782). Reported individual injuries included bowel obstruction and erosion, adhesions, fistula formation, mesh migration, and infection. These are allegations as framed in the consolidated litigation.

FDA regulatory history

The FDA actions specific to Ethicon products and the broader transvaginal-mesh category form a timeline (the full category history is covered in FDA Action on Surgical Mesh):

Date	FDA / company action
Oct. 20, 2008	FDA issued its first Public Health Notification on transvaginal mesh, citing more than 1,000 adverse-event reports received 2005–2007 (FDA — Urogynecologic Surgical Mesh Implants).
July 2011	FDA Safety Communication update stating serious complications are “not rare” and that it had “not found conclusive evidence” that transvaginally placed mesh improves clinical outcomes (FDA).
Jan. 2012	FDA issued Section 522 postmarket surveillance orders to mesh manufacturers (FDA).
June 2012	Ethicon withdrew four Gynecare products (Prolift, Prolift +M, Prosima, and TVT-Secur) from the U.S. market. This was a market withdrawal, not a formal FDA recall, and Ethicon did not recall devices already implanted (FDA).
Jan. 2016	FDA reclassified transvaginal POP mesh to Class III (high risk), requiring premarket approval applications (FDA).
Apr. 16, 2019	FDA ordered all remaining transvaginal POP mesh off the U.S. market after manufacturers “did not demonstrate a reasonable assurance of safety and effectiveness” (FDA).

It is important to be precise: Ethicon characterized its June 2012 action as a commercial discontinuation rather than a safety recall, and the company did not retrieve devices already sold or implanted. Calling that step a “recall” would be inaccurate.

Physiomesh. Physiomesh reached the U.S. market through the FDA’s 510(k) substantial-equivalence premarket pathway, with clearance effective April 9, 2010 (510(k) number K093932), as a Class II device with three Ethicon predicate devices (MDL 2782 Order, Doc. 690, at 9–11). In late May 2016, Ethicon issued an Urgent Field Safety Notice and withdrew the laparoscopic Physiomesh from the worldwide market. The stated reason, per Health Canada’s recall record, was that “the recurrence/reoperation rates after laparoscopic ventral hernia repair using Ethicon Physiomesh Composite Mesh were higher than the average rates of the comparator set of meshes” in two European registries (Health Canada recall record). The FDA’s MAUDE adverse-event database contains numerous reports filed for Physiomesh (FDA MAUDE database).

A peer-reviewed nationwide cohort study using the Danish Ventral Hernia Database later quantified Physiomesh’s elevated reoperation-for-recurrence risk, reporting a hazard ratio of 3.45 (95% CI 2.16–5.51) for primary hernias versus a comparator mesh (Baker JJ, Öberg S, Rosenberg J, Annals of Surgery, PMID 34520420).

The litigation record — pelvic mesh (MDL 2327 and state courts)

Federal pelvic-mesh cases against Ethicon were consolidated as MDL No. 2327, In re Ethicon, Inc., Pelvic Repair System Products Liability Litigation, before Judge Joseph R. Goodwin in the Southern District of West Virginia. At its peak, more than 40,870 lawsuits were pending against Ethicon in that MDL (U.S. District Court, S.D.W.V. — MDL 2327).

Outcomes were mixed, and the record includes both plaintiff and defense results. The following are matters of public record, reported as such:

Case (court / year)	Device	Result (as reported)
Lewis v. Ethicon (S.D.W.V., MDL 2327 bellwether, 2014)	Gynecare TVT	Defense win — directed verdict for Ethicon
Huskey v. Ethicon (S.D.W.V., 2014)	TVT-O	Plaintiff verdict — $3.27 million
Gross v. Gynecare/Ethicon (N.J., 2013)	Prolift	Plaintiff verdict — ~$11.1 million ($3.35M compensatory + $7.76M punitive); affirmed on appeal (Gross v. Gynecare, N.J. App. Div., A-0011-14)
Hrymoc v. Ethicon (N.J., 2017)	Prolift + TVT-O	Plaintiff verdict — $15 million; reversed and remanded on appeal
Kaiser v. Johnson & Johnson & Ethicon (N.D. Ind., 2018)	Prolift	Jury awarded $35 million; reduced to $20 million under Indiana’s punitive cap; affirmed by the Seventh Circuit (Kaiser v. Johnson & Johnson, 7th Cir. No. 18-2944, Justia)

The Gross verdict in detail. Linda Gross v. Gynecare, Ethicon, Inc. & Johnson & Johnson was the first pelvic-mesh case tried in New Jersey’s coordinated proceeding. In February 2013 a jury awarded $3.35 million in compensatory damages and, after a separate phase, $7.76 million in punitive damages. As the appellate opinion records, the jury found Ethicon liable for failure to provide adequate warnings to the implanting surgeon and for fraudulent misrepresentation to the patient — but the same jury rejected the claim that the Prolift was defectively designed and the claim of misrepresentation to the surgeon (Gross v. Gynecare, N.J. App. Div., A-0011-14). That distinction — what a jury accepted versus rejected — is part of the documented record.

The Kaiser appeal. In affirming the (reduced) verdict, the Seventh Circuit held that the 510(k) process did “not directly conflict with Indiana law,” so the design-defect claim was not preempted, and that a reasonable jury could conclude Ethicon breached its duty to warn surgeons (Kaiser v. Johnson & Johnson, 7th Cir.).

A separate coordinated program in the Philadelphia Court of Common Pleas produced additional verdicts, including awards in Engleman ($20 million, April 2017) and Beltz ($2.16 million). The Beltz award is documented in the appellate record (In re Pelvic Mesh Litigation, Appeal of Ethicon, CourtListener); the Engleman award was reported by news of record (The Philadelphia Inquirer, Apr. 28, 2017). These are individual jury awards entered at trial; some were subject to post-trial motions or appeal, and prior results do not predict any future outcome.

Disposition of MDL 2327. All cases in the federal MDL have been resolved, with remaining matters handled through New Jersey multicounty litigation and court-supervised qualified settlement funds administered by appointed settlement masters (U.S. District Court, S.D.W.V. — MDL 2327). Johnson & Johnson did not publicly disclose a single aggregate dollar figure for these pelvic-mesh settlements.

The litigation record — Physiomesh hernia mesh (MDL 2782)

Federal Physiomesh cases were centralized on June 2, 2017 as MDL No. 2782 in the Northern District of Georgia before Judge Richard W. Story (JPML Transfer Order). The litigation grew to more than 3,700 cases (N.D. Ga. — In re Ethicon Physiomesh MDL 2782).

In a significant pretrial ruling on November 25, 2020, Judge Story granted plaintiffs’ motion to exclude FDA 510(k) and regulatory evidence from the first bellwether trial, writing that 510(k) clearance “is of little or no evidentiary value” and that admitting it could mislead jurors into thinking clearance “constitutes a certification of safety” (MDL 2782 Order, Doc. 690, at 11, 18–19).

The litigation resolved by a global confidential settlement announced in September 2021, covering roughly 3,729 cases; the court appointed a Special Master and established a Qualified Settlement Fund to administer the resolution. No dollar amount was disclosed — the settlement terms are confidential, and no public jury verdict (plaintiff or defense) was ever entered in MDL 2782, because the matter settled before any bellwether reached trial (MedTech Dive). Later batches of cases were settled confidentially, including the dismissal of more than 200 additional cases in December 2023 (MedTech Dive).

Government enforcement actions

Several state attorneys general pursued Johnson & Johnson and Ethicon over the marketing of pelvic mesh. These are matters of public record:

Multistate (41 states and the District of Columbia), October 2019. Johnson & Johnson and Ethicon agreed to a $116.86 million settlement (often rounded to “nearly $117 million”) resolving claims under state consumer-protection laws, with injunctive terms requiring the company to stop describing the mesh as “FDA approved” where inaccurate (Connecticut Attorney General press release); (Texas Attorney General press release).
California — People v. Johnson & Johnson. Following a bench trial, the court entered a judgment of $343,993,750 (Jan. 30, 2020) for violations of California’s Unfair Competition Law and False Advertising Law. On appeal (April 11, 2022), the California Court of Appeal reduced the penalty to approximately $302 million after striking penalties tied to unrecorded oral statements, while rejecting Johnson & Johnson’s argument that the penalty was excessive (California Court of Appeal opinion, People v. Johnson & Johnson, Apr. 11, 2022) (California DOJ press release). This was a court (bench) judgment, not a jury verdict.
Washington — State of Washington v. Johnson & Johnson. On the eve of trial in April 2019, Johnson & Johnson (Ethicon) agreed to a $9.9 million settlement under the state Consumer Protection Act; the AG’s office reported that approximately 14,000 Washington women had received the devices (Washington Attorney General press release).
Kentucky. In February 2023, the Kentucky Attorney General’s office reported a settlement of approximately $9.9 million with Ethicon over the alleged failure to disclose transvaginal-mesh risks (Kentucky Office of the Attorney General announcement, Feb. 2023).

What this record does and does not establish

The documented harms attributed to Ethicon pelvic mesh are severe and frequently permanent — repeated revision surgeries, chronic pain, and mesh that “could not be completely extracted.” At the same time, the record is mixed: some juries found for Ethicon (for example, the Lewis bellwether), and some plaintiff verdicts were reduced or reversed on appeal. Where juries found liability, the prevailing theories most often included negligent or defective design, failure to warn, and fraudulent misrepresentation; in attorney-general actions, state consumer-protection and false-advertising violations. The causes of these harms remain the subject of individual proof, and outcomes varied case by case.

This summary reports only what courts, regulators, and government enforcers have stated on the public record. It does not assert that any company “lied” or “covered up” — it reports what was alleged, what was found, and what was settled.

If you or a loved one received a Johnson & Johnson / Ethicon mesh device and are dealing with complications, our team offers a free, confidential consultation. The firm behind this guide brings decades of experience representing seriously injured Texans in Texas and federal courts — see About Attorney 911. This is attorney advertising and legal information, not legal or medical advice, and reading it does not create an attorney-client relationship; prior results do not guarantee a similar outcome.

◀ Becton Dickinson / C.R. Bard / Davol — The Documented Record · ↑ Top · Boston Scientific — The Documented Record ▶

Boston Scientific — The Documented Record

Boston Scientific Corporation (NYSE: BSX), headquartered in Marlborough, Massachusetts, is one of the world’s largest medical-device makers. Among its many product lines were a family of transvaginal surgical mesh devices used to treat two common conditions in women: stress urinary incontinence (SUI) and pelvic organ prolapse (POP). This section lays out the documented public record for those devices — the products, the FDA’s actions, the jury verdicts, the corporate settlements disclosed in Boston Scientific’s own SEC filings, and the allegations that were raised in court. This material is provided for general education and information only; it is not legal or medical advice. Throughout, we are careful to separate what a jury actually found from what plaintiffs merely alleged, and to present the company’s denials alongside the claims against it.

If you were implanted with one of these devices and are trying to understand what happened to your body, the patient-focused explanations in Mesh Erosion, Exposure & Extrusion and Chronic Pelvic Pain (Fibrotic Foreign-Body Injury) may help you put a name to your symptoms. For the broader regulatory story, see FDA Action on Surgical Mesh: 2008 → 2011 → 2016 → the 2019 Ban and The Big Picture.

The products

Boston Scientific’s transvaginal mesh lines included, among others, the Pinnacle (Pelvic Floor Repair Kit), Advantage / Advantage Fit (mid-urethral slings), Obtryx (transobturator mid-urethral sling), Uphold / Uphold LITE (vaginal support system), and Xenform soft-tissue repair matrix. The polypropylene-based slings were marketed for SUI; the kits and support systems were marketed for POP.

The federal multidistrict litigation (MDL 2326)

Federal lawsuits over these devices were consolidated as In re: Boston Scientific Corp. Pelvic Repair System Products Liability Litigation, MDL No. 2326, in the U.S. District Court for the Southern District of West Virginia, before U.S. District Judge Joseph R. Goodwin. The court’s own docket page records the MDL as established in 2012 and later closed (terminated February 11, 2021) (U.S. District Court, S.D. W. Va., MDL 2326). A later federal order recounting the history noted that “[a]pproximately 26,000 of these cases were filed against Boston Scientific Corporation” within the consolidated proceedings (Goodnight v. Boston Scientific Corp., No. 0:18-cv-62370 (S.D. Fla.), govinfo.gov).

The injuries at the center of these cases are the same foreign-body and structural-failure complications described elsewhere in this guide: mesh erosion into the vagina, chronic pelvic pain, painful intercourse (dyspareunia), infection, urinary dysfunction, and the need for multiple corrective (“revision”) surgeries.

The jury verdicts (public record)

Several juries returned verdicts against Boston Scientific. The figures below are matters of public record; where a trial court later reduced an award, both numbers are stated, because the reduction is part of the record too.

Case	Court / jurisdiction	Verdict date	Device(s)	Jury award (gross)	Post-trial outcome
Barba v. Boston Scientific	New Castle County Superior Court, Delaware (C.A. No. N11C-08-050 MMJ)	May 28, 2015	Pinnacle + Advantage Fit	$100M ($25M compensatory + $75M punitive)	Reduced to $10M by Judge Mary Johnston, Oct. 9, 2015
Salazar v. Boston Scientific	Dallas County District Court, Texas (No. DC-12-14349)	Sept. 8, 2014	Obtryx sling	$73.5M ($23M compensatory + $50M punitive)	Reduced to ~$34M under Texas punitive-damages cap
Eghnayem v. Boston Scientific (4 plaintiffs)	U.S. Dist. Ct., S.D. Florida (after MDL 2326 transfer)	Nov. 13, 2014	Pinnacle Pelvic Floor Repair Kit	~$26.7M combined (each more than $6M)	Affirmed, 11th Cir., Oct. 19, 2017
Tyree / Campbell / Blankenship / Wilson (4 plaintiffs)	U.S. Dist. Ct., S.D. West Virginia (MDL 2326)	Nov. 20, 2014	Obtryx slings	$18.5M combined (incl. $4M punitive)	Verdict upheld

Salazar v. Boston Scientific (Texas, ~$73.5M, reduced to ~$34M). A Dallas County jury found Boston Scientific negligent in both the design and the marketing of its Obtryx sling and found gross negligence, awarding Martha Salazar $23 million in compensatory and $50 million in punitive damages. Salazar had been implanted to treat incontinence; the jury found the company “failed to warn doctors and their patients of the serious complications” (The Boston Globe, Sept. 9, 2014). The trial court later reduced the verdict to roughly $34 million, cutting the punitive award to about $11 million, because Texas statute caps punitive damages (Bloomberg, Oct. 3, 2014). As reported, plaintiff’s counsel noted the reduction was “simply as a matter of Texas law, and does not in any way reflect negatively on the jury’s findings” (Bloomberg, Oct. 3, 2014).

Barba v. Boston Scientific (Delaware, $100M, reduced to $10M). A New Castle County, Delaware jury awarded Deborah Barba $25 million compensatory and $75 million punitive, finding negligence, breach of warranty, fraud, and Delaware consumer-protection violations in the design and marketing of the Pinnacle and Advantage Fit devices (Bloomberg, May 28, 2015). On October 9, 2015, Judge Mary Johnston reduced the verdict to $10 million ($2.5M compensatory plus $7.5M punitive) while affirming the underlying findings of defect and failure to warn and denying a new trial (Barba v. Boston Scientific Corp., Del. Super. Ct. (Justia)).

Eghnayem v. Boston Scientific (Florida, ~$26.7M, affirmed on appeal). Four Florida women — Amal Eghnayem, Mania Nuñez, Margarita Dotres, and Juana Betancourt — each implanted with the Pinnacle Pelvic Floor Repair Kit for prolapse, had their cases consolidated in MDL 2326 and transferred to the Southern District of Florida for trial. After an eight-day trial, the jury found for each plaintiff that the Pinnacle was defectively designed, that its instructions to physicians were defective, and that the company was negligent and failed to warn, awarding each more than $6 million (combined ~$26.7 million; no punitive damages). The plaintiffs’ documented complications included “pain, infection, mesh erosion, dyspareunia and mesh shrinkage” (Eghnayem v. Boston Scientific Corp., 873 F.3d 1304 (11th Cir. 2017), Justia). The Eleventh Circuit affirmed the judgment on October 19, 2017, upholding the consolidation, the exclusion of Boston Scientific’s FDA 510(k)-clearance evidence at trial, and the failure-to-warn verdicts (Goodnight v. Boston Scientific Corp. (S.D. Fla.), recounting the Eghnayem history, govinfo.gov).

Tyree v. Boston Scientific (West Virginia federal, $18.5M). A federal jury in the Southern District of West Virginia, within MDL 2326, awarded four women implanted with Obtryx slings a combined $18.5 million, including $4 million in punitive damages (Goodnight v. Boston Scientific Corp. (S.D. Fla.), govinfo.gov).

A note on the record: these were personal-injury verdicts. We did not locate, in the primary sources, a confirmed wrongful-death award attributable to a specific Boston Scientific mesh plaintiff, and we do not assert one.

What Boston Scientific disclosed to the SEC

Because Boston Scientific is a publicly traded company, its mesh exposure is documented in its own filings with the U.S. Securities and Exchange Commission. The company states in those filings that every settlement was “entered into solely by way of compromise and without any admission or concession by us of any liability or wrongdoing” (Boston Scientific FY2015 Form 10-K, SEC EDGAR).

The litigation reserve the company set aside for these matters peaked and then drew down as cases settled:

As of	Accrual for legal matters (probable & estimable)	Source
Dec. 31, 2014	$1.577 billion	FY2015 10-K
Dec. 31, 2015	$1.936 billion (peak)	FY2015 10-K
Dec. 31, 2023	$377 million	FY2024 10-K
Dec. 31, 2024	$326 million	FY2024 10-K

The FY2015 Form 10-K states: “Our accrual for legal matters that are probable and estimable was $1.936 billion as of December 31, 2015 and $1.577 billion as of December 31, 2014, and includes certain estimated costs of settlement, damages and defense” (Boston Scientific FY2015 Form 10-K, SEC EDGAR). The FY2024 Form 10-K reports the accrual had fallen to “$326 million as of December 31, 2024, and $377 million as of December 31, 2023,” and notes the company “did not record any litigation-related net charges (credits) in 2024” (Boston Scientific FY2024 Form 10-K, SEC EDGAR). The company ran large litigation charges through earnings in the peak years — $1.036 billion in 2014 and $1.105 billion in 2015, both of which the filings attribute in part to “transvaginal surgical mesh product liability cases and claims” (FY2015 Form 10-K, SEC EDGAR). Boston Scientific does not publish a single cumulative “total mesh” figure, so any one all-in number is an aggregation rather than a stated line item.

On claim volume, the filings disclose that “over 35,000” mesh cases or claims had been asserted as of February 23, 2016, growing to “approximately 54,500” by October 20, 2021, of which approximately 50,500 had been resolved as final through master settlement agreements (Boston Scientific FY2015 Form 10-K; Boston Scientific Q3 2021 Form 10-Q, SEC EDGAR).

Settlements (public record)

April 2015 — ~$119 million / ~2,970 cases. Boston Scientific disclosed it “entered into an initial master settlement agreement with certain plaintiffs’ counsel to settle 2,970 pending cases and claims … for approximately $119 million,” referencing within that group the reduced Salazar judgment (Boston Scientific FY2015 Form 10-K, SEC EDGAR).
March 2021 — $188.6 million multistate Attorneys General settlement. Boston Scientific agreed to pay $188.6 million to 47 states and the District of Columbia to resolve allegations that it deceptively marketed its transvaginal mesh by failing to disclose the full range of serious complications, including “chronic pain, voiding dysfunction, and new onset of incontinence.” The settlement included no admission of liability and required marketing, physician-training, and clinical-trial disclosure reforms (California Department of Justice press release; MedTech Dive, Mar. 24, 2021). Boston Scientific’s own filing ties this to its reserves, noting it “reached settlements with 48 states, including Mississippi, and the District of Columbia,” finalized in March 2021 (Boston Scientific Q3 2021 Form 10-Q, SEC EDGAR).
March 2023 — A$105 million Australian class action. The Federal Court of Australia approved a A$105 million class-action settlement for Australian women implanted with Boston Scientific pelvic mesh and slings; the settlement involved no admission of liability, and the court made no liability finding (Fowkes v Boston Scientific Corporation [2023] FCA 230, AustLII).

FDA regulatory actions

The federal regulatory history is covered in full in FDA Action on Surgical Mesh; the key milestones that touched Boston Scientific’s devices are:

July 2011 — Safety Communication. The FDA warned that serious complications associated with surgical mesh for transvaginal repair of POP are “not rare,” updating its earlier characterization (FDA, Urogynecologic Surgical Mesh: Update on the Safety and Effectiveness of Transvaginal Placement for Pelvic Organ Prolapse (July 2011)).
2016 — Reclassification. The FDA reclassified transvaginal mesh for POP into Class III (high-risk), requiring premarket-approval applications (FDA, FDA’s Activities: Urogynecologic Surgical Mesh).
April 16, 2019 — Order to stop selling. The FDA ordered the remaining manufacturers of transvaginal POP mesh to stop selling and distributing their products immediately, finding they “have not demonstrated a reasonable assurance of safety and effectiveness.” The order named Boston Scientific’s Uphold LITE Vaginal Support System and Xenform Soft Tissue Repair System and Coloplast’s Restorelle DirectFix Anterior (FDA, Urogynecologic Surgical Mesh Implants). Boston Scientific’s filing confirms that it “ceased global sales and distribution of surgical mesh products indicated for transvaginal pelvic organ prolapse” as a result (Boston Scientific Q3 2021 Form 10-Q, SEC EDGAR).

Importantly, the 2019 order applied to transvaginal POP mesh; mid-urethral slings for SUI (such as the Obtryx and Advantage lines) were not swept up in that same order.

The “counterfeit resin” allegations — presented as allegations

One strand of the litigation drew particular attention: claims, raised in a federal racketeering (RICO) complaint and amplified by a 2018 CBS 60 Minutes broadcast, that Boston Scientific used polypropylene resin of questionable provenance after its U.S. supplier stopped selling resin for permanent human implantation. These were allegations in a complaint and reporting of those allegations — they were not adjudicated findings, and Boston Scientific has denied them.

What plaintiffs alleged. Plaintiffs alleged that Boston Scientific, facing a supply cutoff, sourced replacement Marlex-type polypropylene from a Chinese supplier and that the material differed from the original; the complaint asserted racketeering, fraud, and related claims. As reported, plaintiffs characterized the sourcing as improper and described internal communications they contended showed the company knew of differences in the material (CBS News / 60 Minutes, Apr. 17, 2019). We present these only as plaintiffs’ allegations as reported, not as established fact.
Boston Scientific’s denial. Boston Scientific rejected the allegations, stating that testing showed “the resin currently used in our products matches a formulation from the original U.S. produced resin,” that this finding “was also reviewed by the U.S. Food and Drug Administration (FDA) and was part of the basis of their conclusions,” and that the broadcast “resurfaced outdated and previously disproven allegations.” The company stated that “[n]early one million women have been successfully treated with our transvaginal mesh products” (Boston Scientific official response, news.bostonscientific.com).
What the FDA reported. As reported, the FDA reviewed the resin change and stated it “did not find any indication that the change in [plastic] resin led to an increase in adverse events” (CBS News / 60 Minutes, Apr. 17, 2019).

In short: the resin allegations are serious and were widely reported, but Boston Scientific denies them and the FDA reported no finding that the resin change increased adverse events. We label them as allegations throughout, and a reader should treat them that way.

Where this fits

Boston Scientific is one of several manufacturer families whose mesh devices generated large-scale litigation in the United States and abroad. For comparison, see the records compiled for Johnson & Johnson / Ethicon, American Medical Systems / Endo, Coloplast and Cook Medical, and Becton Dickinson / C.R. Bard / Davol, and the overall scale of mesh litigation.

If you or a loved one was implanted with a Boston Scientific mesh device and has suffered erosion, chronic pain, or other complications, our team offers a free, confidential consultation. You can learn more about who we are on the About Attorney 911 page. This page is attorney advertising and is provided for general information; reading it does not create an attorney–client relationship, no outcome is guaranteed, and it is not a substitute for the advice of your own physician — if you have a mesh device and are experiencing symptoms, talk to a qualified doctor about your individual situation.

◀ Johnson & Johnson / Ethicon — The Documented Record · ↑ Top · American Medical Systems / Endo — The Documented Record ▶

American Medical Systems / Endo — The Documented Record

This section sets out the documented public record for the pelvic-mesh devices made by American Medical Systems, Inc. (AMS) and its parent, Endo International plc. By dollar value, Endo/AMS accrued one of the largest settlement totals among the pelvic-mesh manufacturers — accruing roughly $2.6 billion to resolve more than 48,000 U.S. mesh claims — and, unlike several competitors, it did so almost entirely through negotiated settlements rather than through litigated jury verdicts. Endo later carried its remaining mesh exposure into a 2022 Chapter 11 bankruptcy, where existing and future mesh claims were channeled into dedicated trusts. Everything below is drawn from court dockets, FDA.gov, SEC filings, company disclosures, and court-approved bankruptcy administration records, and is presented as public record. This page provides educational information only — not legal or medical advice — and prior results do not guarantee a similar outcome. For the broader scale of this litigation, see The Big Picture.

Corporate identity and chain of ownership

American Medical Systems, Inc. (Minnetonka, Minnesota) manufactured transvaginal surgical mesh devices used to treat pelvic organ prolapse (POP) and stress urinary incontinence (SUI). The ownership chain is a matter of public record:

Endo acquired AMS in 2011. Endo announced it would “acquire 100 percent of the shares of AMS for $30 per share or a total cash consideration of $2.9 billion in cash.” (Endo press release, Apr. 11, 2011, via PR Newswire) — Source
Endo divested the AMS urology business — but not the mesh business — to Boston Scientific in 2015. Boston Scientific agreed “to acquire the American Medical Systems urology portfolio, which includes the Men’s Health and Prostate Health businesses, for $1.6 billion in up-front cash and a potential additional $50 million milestone.” Critically, “The AMS women’s health business for treating pelvic organ prolapse and female stress urinary incontinence is not included in the transaction.” (Boston Scientific SEC Form 8-K press release, Mar. 2, 2015) — Source
Endo wound down the mesh business. In February 2016, Endo announced it would wind down and close its Astora Women’s Health division, ending its manufacture of pelvic mesh. (Endo press release, Apr. 11, 2011, via PR Newswire) — Source

Because the women’s-health business and its liabilities stayed with Endo/AMS (later renamed Astora), it was Endo — not Boston Scientific — that paid the AMS mesh settlements and later carried the mesh claims into bankruptcy. For Boston Scientific’s own separate record, see Boston Scientific — The Documented Record.

The products

Device family	Indication	FDA pathway
Perigee, Apogee	Pelvic organ prolapse (POP) repair	510(k) substantial-equivalence premarket clearance
Elevate	Pelvic organ prolapse (POP) repair	510(k) substantial-equivalence premarket clearance

The AMS Perigee and Apogee POP systems reached the market through the 510(k) substantial-equivalence premarket pathway — clearance based on substantial equivalence to legally marketed predicate devices rather than original premarket clinical trials. (FDA 510(k) Summary, AMS Perigee System, clearance K040623) — Source. For how that pathway works, see How These Devices Reached the Market.

FDA actions on transvaginal (POP) mesh

The FDA’s regulatory posture toward transvaginal POP mesh escalated steadily over a decade. These are documented agency actions, drawn from the FDA’s own activities timeline:

Date	FDA action
Oct. 20, 2008	Public Health Notification on “Serious Complications Associated with Transvaginal Placement of Surgical Mesh” for POP and SUI repair
July 13, 2011	Updated Safety Communication; the agency determined serious complications from transvaginal POP mesh are “not rare”
Sept. 8–9, 2011	Obstetrics & Gynecology Devices Panel considered reclassifying POP mesh from Class II to Class III
Jan. 5, 2016	FDA finalized orders reclassifying transvaginal POP mesh from Class II to Class III (high-risk), requiring Premarket Approval (PMA) — “the agency’s most stringent device review pathway”
July 13, 2018	FDA ordered the last posterior-compartment (rectocele) transvaginal POP mesh off the market
Apr. 16, 2019	FDA ordered remaining manufacturers to stop selling and distributing transvaginal POP mesh immediately after PMAs failed to show reasonable assurance of safety and effectiveness

All dates above: FDA, “FDA’s Activities: Urogynecologic Surgical Mesh”.

In its July 13, 2011 Safety Communication, the FDA updated its earlier 2008 characterization and stated that serious complications associated with transvaginal POP mesh are “not rare,” citing a roughly five-fold increase in adverse-event reports between 2008 and 2010. (FDA, July 2011 Safety Communication) — Source. On the 2016 reclassification, the agency confirmed it moved POP mesh “into class III, which require premarket approval (PMA) applications, the agency’s most stringent device review pathway,” and the Federal Register notice records that order. On the 2019 stop-sale order, FDA stated it “ordered the manufacturers of all remaining surgical mesh products indicated for the transvaginal repair of pelvic organ prolapse (POP) to stop selling and distributing their products in the U.S. immediately”; FDA’s Dr. Jeffrey Shuren said the agency “couldn’t assure women that these devices were safe and effective long term.” (FDA announcement, Apr. 16, 2019, via PR Newswire) — Source. The full regulatory arc is traced in FDA Action on Surgical Mesh.

The injuries at issue

FDA patient guidance lists the complications that drove the litigation over POP mesh: “Mesh erosion through the vagina (also called exposure, extrusion, or protrusion) … Pain … Infection … Pain during sexual intercourse (dyspareunia),” and notes that “Erosion of mesh through the vagina is the most commonly reported mesh-specific complication,” sometimes requiring a return to the operating room “to remove part or all of the mesh.” (FDA, POP Surgical Mesh Considerations) — Source.

Plaintiffs in the AMS litigation alleged that the polypropylene Perigee, Apogee, and Elevate devices were defectively designed and inadequately warned, causing erosion, migration, infection, chronic pelvic pain, painful intercourse, and urinary problems, and that the mesh frequently could not be fully removed. These are allegations made in the litigation, not adjudicated findings. The injuries cross-link to detailed entries on this page, including Mesh Erosion, Exposure & Extrusion, Chronic Pelvic Pain, Dyspareunia & Sexual Dysfunction, and Urinary Dysfunction. Endo’s court-approved bankruptcy claims notice independently catalogs the relevant harms as “Claims for pelvic pain, infection, bleeding, among others.” — Source.

The litigation vehicle: MDL No. 2325

The federal AMS mesh cases were consolidated in a multidistrict litigation:

Item	Detail
Case name	In re: American Medical Systems, Inc., Pelvic Repair System Products Liability Litigation
MDL number	MDL No. 2325 (docketed 12-md-02325)
Court	U.S. District Court, Southern District of West Virginia (Charleston)
Presiding judge	Hon. Joseph R. Goodwin
Status	Closed (Terminated Dec. 21, 2020)

The court’s own docket records the case name, judge, and that the MDL is “Closed (Terminated 12/21/2020).” (U.S. District Court, S.D. W. Va. — MDL No. 2325) — Source. Judge Goodwin presided over the cluster of pelvic-mesh MDLs (AMS, Boston Scientific, Ethicon, Bard, Coloplast, Cook) consolidated in the same district. For scale, the overall mass tort across these MDLs exceeded 100,000 filed lawsuits — among the largest in U.S. history. (S.D. W. Va. MDL dockets) — Source.

Settlements vs. verdicts — an important distinction

AMS/Endo resolved its MDL 2325 exposure overwhelmingly through negotiated global settlements, not through litigated jury verdicts, and the MDL closed in December 2020 with cases “compromised and settled.” The large single-plaintiff jury verdicts that circulate in transvaginal-mesh coverage were entered against other manufacturers — for example, against Ethicon (Johnson & Johnson), C.R. Bard, and Boston Scientific — and should not be attributed to AMS/Endo. No confirmed individual jury verdict against AMS/Endo appears in the public record reviewed here. Those other manufacturers’ records are covered separately at Johnson & Johnson / Ethicon, Becton Dickinson / C.R. Bard / Davol, and Boston Scientific.

The settlements (roughly $2.6 billion accrued)

Endo resolved its mesh exposure through a sequence of master settlement agreements, each entered, in the company’s words, “solely by way of compromise and settlement” and expressly “not in any way an admission of liability or fault.”

Date	Amount	Claims resolved	Character	Source
June/July 2013	~$54.5 million	Undisclosed	Settlement	Endo Health Solutions Q2 2013 Form 10-Q (SEC)
2014 (MDL)	Up to $830 million	~20,000 claims	Settlement	Endo Form 8-K press release (2014), SEC
Sept. 30, 2014	$400+ million (additional); total accrual to ~$1.6 billion	10,000+ additional claims	Settlement	Endo 8-K, EX-99.1 (Sept. 30, 2014)
Aug. 7, 2017	$775 million (reserve)	~22,000 U.S. claims + known international	Settlement	Endo 8-K, Q2 2017 earnings (EX-99.1), SEC
Cumulative	~$2.6 billion	>48,000 U.S. claims since 2013	All settlements	Endo PR Newswire (Aug. 7, 2017)

The June 2013 (~$54.5M) tranche. Endo’s own SEC filing records that AMS “paid approximately $54.5 million” into an escrow settlement fund under a Master Settlement Agreement executed in June 2013, resolving an inventory of filed and unfiled pelvic-mesh claims. (Endo Health Solutions Q2 2013 Form 10-Q, Legal Proceedings) — Source.

The 2014 (~$830M) tranche. AMS agreed to pay “up to $830 million” to resolve an estimated 20,000 claims, as reflected in Endo’s SEC filings. (Endo Form 8-K press release, 2014) — Source.

The Sept. 30, 2014 master settlements (total accrual to ~$1.6 billion). Endo’s SEC-filed press release is the authoritative source for the figure most often quoted as Endo’s mesh liability:

“Endo previously established a pre-tax product liability reserve of approximately $1.2 billion. As a result of these additional agreements described above, the Company expects to increase its pre-tax product liability accrual for all known, pending and estimated future claims primarily related to vaginal mesh products to approximately $1.6 billion in total.” — Endo 8-K, EX-99.1, Sept. 30, 2014

The same filing states the agreements “were entered into solely by way of compromise and settlement and are not in any way an admission of liability or fault,” and that AMS had “paid approximately $200 million into qualified settlement funds.” Then-CEO Rajiv De Silva stated the company was “very pleased to resolve substantially all of the remaining U.S. vaginal mesh litigation claims facing our AMS business.” — Source.

Note that the ~$1.6 billion figure has two distinct meanings in this record and should not be conflated: it is (1) Endo’s total pre-tax mesh product-liability accrual as of Sept. 30, 2014, and (2), separately, the up-front cash value of the 2015 AMS urology divestiture to Boston Scientific. They are different facts.

The Aug. 7, 2017 ($775M) closing tranche. Endo’s release describes the final round:

“the Company intends to increase its mesh product liability accrual by $775 million, which is expected to cover approximately 22,000 U.S. mesh claims, as well as all known international mesh product liability claims and other mesh-related matters.” — Endo PR Newswire, Aug. 7, 2017

With this round, Endo reported it had paid or set aside more than $2.6 billion to settle over 48,000 cases filed since 2013. (Endo PR Newswire, Aug. 7, 2017) — Source.

Endo’s Chapter 11 bankruptcy and the treatment of mesh claims

After committing roughly $2.6 billion to mesh settlements between 2013 and 2017 — funded in installments through 2019 — Endo filed for Chapter 11 bankruptcy in 2022, which the company attributed to combined opioid, generic ranitidine, and transvaginal mesh liabilities.

Item	Detail	Source
Petition date	Aug. 16, 2022	endoclaims.com
Court / case	U.S. Bankruptcy Court, S.D.N.Y.; Case No. 22-22549 (JLG)	S.D.N.Y. Bankruptcy opinion
Claims bar date	July 7, 2023, 5:00 p.m. ET	endoclaims.com
Plan confirmed	March 2024 (Fourth Amended Joint Chapter 11 Plan)	Endo PR Newswire, Mar. 19, 2024
Plan effective	April 2024; assets sold to new entity Endo, Inc.	Stretto — Endo GUC Trust
Mesh treatment	Mesh Claims Distribution Sub-Trust within the Endo GUC Trust	Endo GUC Trust Distributions FAQ

The court-approved claims notice confirms the filing and that mesh was a covered liability: “On August 16, 2022, Endo International plc and certain of its affiliates filed for chapter 11 bankruptcy in the United States Bankruptcy Court for the Southern District of New York,” covering products including “transvaginal mesh.” — Source. The plan confirmation release records that “substantially all of the Company’s assets are being sold to a new entity, Endo, Inc., over 95% of which is owned by holders of the Company’s first lien debt.” — Source.

How mesh claims were treated. Under the confirmed plan, mesh personal-injury claims were not paid in full by the reorganized company. They were channeled into the Endo GUC Trust and then to a dedicated Mesh Claims Distribution Sub-Trust, which holds a fixed slice of a finite estate. According to the Endo GUC Trust’s own official Distributions FAQ, the entire GUC Trust began with $60 million in cash (with $10 million withheld), and the mesh sub-trust’s allocation was: $2 million in initial cash, 1.75% of “Transferred Litigations” and “Transferred Insurance Rights,” and a 50% interest in a dedicated “Mesh Products Liability Tower” of insurance — with recoveries “over time” and “nothing … currently … predicted with any certainty.” (Endo GUC Trust Distributions FAQ) — Source. The bankruptcy court’s published opinion describes the trust’s beneficiaries as including “thousands of women implanted with defective vaginal mesh products” and victims of the opioid crisis. (U.S. Bankruptcy Court, S.D.N.Y., opinion) — Source. Mesh claimants must “attach medical records necessary to show that you were implanted with a mesh product, and medical records necessary to show that you were injured by a mesh product” to participate. (Endo GUC Trust Distributions FAQ) — Source.

Bottom line

One of the largest mesh payers. Endo/AMS accrued roughly $2.6 billion to resolve more than 48,000 U.S. mesh claims — overwhelmingly through settlement, not jury verdict. — Source
Forum. MDL 2325, S.D. W. Va., before Judge Joseph R. Goodwin; closed Dec. 21, 2020. — Source
FDA escalation. 2008 notification → 2011 “not rare” finding → 2016 Class III reclassification (PMA required) → 2019 stop-sale order. — Source
Bankruptcy. Endo filed Chapter 11 on Aug. 16, 2022 (S.D.N.Y.); the plan became effective in 2024, with mesh claims channeled into a dedicated sub-trust of the Endo GUC Trust. — Source

If you or a loved one received an AMS or Endo pelvic-mesh device — including a Perigee, Apogee, or Elevate system — and have questions about your situation, our team offers a free, confidential consultation. You can learn more about the firm at About Attorney 911. This page is educational information, not medical or legal advice, and reading it creates no attorney-client relationship; prior results do not guarantee a similar outcome; always consult your own physician about your care.

◀ Boston Scientific — The Documented Record · ↑ Top · Coloplast and Cook Medical — The Documented Record ▶

Coloplast and Cook Medical — The Documented Record

Two more device makers were swept into the wave of federal surgical-mesh litigation in Charleston, West Virginia, and each tells a distinct story. Coloplast Corp. sold synthetic (polypropylene) transvaginal mesh and produced one of the documented plaintiff jury verdicts, plus billions of Danish kroner in publicly disclosed litigation reserves. Cook Medical is the outlier: its pelvic-repair products were biologic grafts made from pig intestine, and its consolidated litigation ended with no jury verdicts at all. This section lays out what the public court record, regulators, and the companies’ own investor disclosures actually establish — and, just as importantly, what they do not.

This page is legal and medical information, not advice; reading it creates no attorney-client relationship, and no outcome is ever guaranteed. Always consult your own physician about your care.

For context on how these cases fit into the broader picture, see The Big Picture: The Scale of Mesh Litigation and the FDA Action on Surgical Mesh timeline.

Coloplast Corp. — Transvaginal Mesh (MDL 2387)

Corporate identity. Coloplast is a Danish medical-device company; its U.S. operating entity, Coloplast Corp., is headquartered in Minnesota. Its transvaginal mesh products were designed to treat pelvic organ prolapse (POP) and stress urinary incontinence (SUI).

The products at issue. The Coloplast pelvic-mesh line named in the litigation included roughly a dozen device lines — among them the Novasilk synthetic flat mesh, the Restorelle / SmartMesh family, the Exair prolapse-repair system (all for POP), and the Aris transobturator sling, Supris suprapubic sling, T-Sling, Minitape, and Omnisure (for SUI) (U.S. District Court, S.D. W. Va. — MDL 2387 case page). Several of these devices are non-absorbable polypropylene; plaintiffs alleged that the material provoked a foreign-body reaction. See The Foreign-Body Response and Material Degradation & Systemic Reactions.

The litigation: MDL No. 2387. Coloplast’s federal mesh cases were consolidated as In re Coloplast Corp., Pelvic Repair System Products Liability Litigation, MDL No. 2387 (docketed 2:12-md-02387), in the U.S. District Court for the Southern District of West Virginia, Charleston Division, before District Judge Joseph R. Goodwin (WVSD — MDL 2387 case page). The litigation was transferred to that court by the Judicial Panel on Multidistrict Litigation in 2012, and the court’s own case page lists the matter’s status as “Closed (Terminated 12/18/2020).” Coloplast was one of several manufacturers whose mesh cases Judge Goodwin oversaw in the same courthouse.

Injuries plaintiffs alleged. Across the litigation, plaintiffs alleged that Coloplast’s polypropylene mesh caused a recurring set of injuries. As described in the trial record of the affirmed Redding verdict, mesh erosion occurs when “the mesh destroys the tissue either of the vagina . . . or it does the same to the tissue of the bladder or the urethra,” and mesh exposure is when a doctor can see “the suture or some graft material in the vagina” (Redding v. Coloplast Corp., 11th Cir. opinion). Plaintiffs also alleged chronic pelvic pain, vaginal bleeding, infection, drainage, painful intercourse (dyspareunia), urinary dysfunction, and the need for revision/removal surgeries. These map to several injuries described elsewhere on this page:

Mesh Erosion, Exposure & Extrusion
Infection & Life-Threatening Complications
Chronic Pelvic Pain and Dyspareunia & Sexual Dysfunction
Urinary Dysfunction

The legal theories raised included design defect, manufacturing defect, negligence, failure to warn, negligent misrepresentation, and fraud — in Redding, the plaintiff “raised 16 claims, including counts of design defect, manufacturing defect, defective product, negligence, failure to warn, and fraud” (Redding 11th Cir. opinion). These are allegations and legal theories; the only adjudicated outcome of record is the one verdict below.

A note on deaths: the FDA has reported that, more broadly, transvaginal POP mesh has been associated with serious complications including death, and the agency logged 77 death reports among roughly 11,274 medical-device reports between January 2008 and October 2018 (MedTech Dive reporting on the FDA’s April 2019 order). No primary source reviewed for this page attributes a specific death or a wrongful-death verdict to a named Coloplast device.

The documented jury verdict: Redding v. Coloplast Corp. — $2.5 million (affirmed on appeal)

The principal documented jury verdict against Coloplast is Virginia Redding v. Coloplast Corp. The case is a matter of public record, set out in the published opinion of the U.S. Court of Appeals for the Eleventh Circuit.

Field	Detail
Case	Virginia Redding v. Coloplast Corp., No. 22-13218 (11th Cir.)
Trial court	U.S. District Court, Middle District of Florida (D.C. Docket No. 6:19-cv-01857-CEM-DAB); originally filed in MDL 2387 and transferred in 2019
Devices	Novasilk mesh (anterior pelvic prolapse) and Supris sling (stress urinary incontinence)
Trial began	April 14, 2022
Jury verdict	$2.5 million for the plaintiff
Appellate result	Affirmed, June 20, 2024

According to the published opinion, the two Coloplast devices were implanted in December 2009; by 2014 a new, roughly one-centimeter erosion was diagnosed, and the plaintiff underwent two mesh-removal surgeries — the second involving a hysterectomy — after which “Redding’s pain and bladder problems have not improved.” A jury awarded her “$2.5 million in damages.” The sole issue Coloplast pressed on appeal was Florida’s four-year statute of limitations; the Eleventh Circuit held her claims “were not time barred” and “affirm[ed] the district court’s denial of Coloplast’s renewed motion for judgment as a matter of law” (Redding v. Coloplast Corp., 11th Cir. opinion). Per the opinion, Coloplast did not appeal the underlying defect findings or the damages amount, so the verdict stands.

Settlements and disclosed litigation reserves

The 2014 settlement (~$16 million). News of record reported in March 2014 that Coloplast agreed to pay about $16 million to settle roughly 400 vaginal-mesh lawsuits, with claimants receiving approximately $40,000 each (Bloomberg). The $16 million aggregate is well-corroborated; the exact per-claimant figure should be treated as approximate, as reports differ.

The company’s own disclosures. Far larger than the publicized settlement is the exposure Coloplast disclosed to investors in its own stock-exchange announcements:

Date	Disclosure (Coloplast’s own words / figures)	Source
May 2, 2014	A DKK 1 billion provision for U.S. litigation, covering roughly 7,000 legal claims, plus DKK 500m of product-liability insurance	Coloplast announcement, GlobeNewswire
Sept. 22, 2015	An additional DKK 3 billion provision; total expected costs of DKK 4.5 billion before tax	Coloplast announcement, GlobeNewswire

In the 2014 announcement, Coloplast stated the provision related to “transvaginal surgical mesh products designed to treat pelvic organ prolapse and stress urinary incontinence,” and its CFO emphasized the company “does not admit any liability or that its devices are unsafe” (Coloplast, May 2, 2014). In September 2015, the company’s CEO said that “with the knowledge available to us today it is our best estimate that the DKK 4,5bn will cover the total costs of all claims” (Coloplast, Sept. 22, 2015). Read together, these disclosures show Coloplast reserving roughly DKK 4.5 billion before tax for U.S. mesh litigation — a figure the company stated was its best estimate to cover the total costs of all claims, well beyond the publicized $16 million/400-case settlement.

FDA regulatory actions touching Coloplast

Date	FDA action	Coloplast relevance
2011	Safety Communication warning that complications with transvaginal POP mesh are “not rare” and that mesh repair is not clearly more effective than non-mesh repair	Applies to all transvaginal POP mesh, including Coloplast
Jan. 2012	Section 522 postmarket-surveillance orders to transvaginal POP mesh manufacturers	Coloplast among the ordered manufacturers
2016	Reclassification of transvaginal POP surgical mesh to Class III (high-risk)	Triggered a premarket-approval (PMA) requirement
April 16, 2019	Order to stop selling and distributing all transvaginal POP mesh in the U.S.	Coloplast’s Restorelle DirectFix Anterior was a named device

On April 16, 2019, the FDA ordered the two remaining manufacturers of transvaginal POP mesh to halt U.S. sales. Per the FDA’s announcement, “Coloplast filed a PMA for its device, Restorelle DirectFix Anterior,” and the FDA “determined that the manufacturers, Boston Scientific and Coloplast, have not demonstrated a reasonable assurance of safety and effectiveness for these devices” (FDA press announcement, April 16, 2019; see also the FDA’s urogynecologic surgical mesh activities page).

Precision matters here. The April 2019 action was a stop-sale / market-withdrawal order for transvaginal POP mesh, not a “recall” of already-implanted devices. The Coloplast device named was the Restorelle DirectFix Anterior (a POP device). Coloplast’s SUI slings (such as Aris and Supris) were not part of this POP-specific order. The full regulatory sequence is laid out in the FDA history section.

Cook Medical — Biologic Pelvic Grafts (MDL 2440)

Corporate identity. Cook Medical is the device business of the privately held Cook Group (Bloomington, Indiana). For litigation purposes, the JPML defined “Cook” to include a family of affiliated entities — among them Cook Incorporated, Cook Biotech Incorporated, Cook Group Incorporated, and Vance Products Incorporated (d/b/a Cook Urological) (JPML Transfer Order, MDL No. 2440, n.1, CourtListener docket).

What made Cook different. Cook is the only pelvic-mesh MDL defendant whose products are biologic — grafts made from porcine (pig) small-intestinal submucosa (SIS) rather than synthetic polypropylene. The products were originally branded Surgisis, later rebranded Biodesign, together with the Stratasis urethral slings, used to treat POP and SUI. Cook stressed that these are “biologic grafts made from pig small intestinal submucosa, not metallic or polymeric screens,” and argued they are “not ‘surgical mesh,’ as defined by the FDA” (JPML Transfer Order, MDL 2440, CourtListener docket). On the biology of porcine SIS grafts, see the peer-reviewed literature (Journal of Medical Case Reports, PMC).

The litigation: MDL No. 2440. The Judicial Panel on Multidistrict Litigation centralized Cook’s pelvic-mesh cases by Transfer Order of June 11, 2013, creating In re Cook Medical, Inc., Pelvic Repair System Products Liability Litigation, MDL No. 2440, in the Southern District of West Virginia (Charleston), again before Judge Joseph R. Goodwin (WVSD — MDL 2440 case page). The Panel found the cases shared “factual issues arising from allegations that defects in surgical products manufactured by Cook to treat pelvic organ prolapse and stress urinary incontinence cause injuries to women who are implanted with the products,” and declined to treat Cook’s biologic-versus-synthetic distinction as a reason to keep the cases separate at the venue stage, calling that “a question of liability more appropriately addressed to the court which oversees those claims” (JPML Transfer Order, MDL 2440, CourtListener docket).

The products as pleaded. The MDL court’s operative Short Form Complaint (Pretrial Order #14) lists the devices a plaintiff could identify, including the “Biodesign® or Surgisis® Tension-Free Urethral Sling,” the “Stratasis™ Urethral Sling,” and the “Biodesign® or Surgisis® Anterior” and “Posterior Pelvic Floor Graft,” among others (PTO #14, Short Form Complaint, WVSD). Plaintiffs incorporated a Master Complaint pleading 17 counts — including negligence, strict liability (manufacturing defect, failure to warn, design defect), fraud, breach of warranty, and a claim for punitive damages (PTO #14, WVSD). The injuries alleged for the porcine product included a latent inflammatory response, infection, scarring, chronic pain, and dyspareunia — the kinds of foreign-body and infection injuries described in Foreign-Body Granuloma, Mesh Infection, and Dyspareunia & Sexual Dysfunction. These remained allegations; the litigation produced no verdict.

Caseload. MDL 2440 was by far the smallest of the pelvic-mesh MDLs. Contemporaneous figures vary by date, but the most reliable statement is Judge Goodwin’s own: in 2015 the mesh MDLs collectively held “approximately 70,000 cases currently pending, nearly 400 of which are in the Cook MDL, MDL 2440” (Demarcus v. Cook, Civil Action No. 2:13-cv-20350 (S.D. W. Va. June 4, 2015)).

The defining outcome: no verdicts, bellwethers dismissed

The single most important documented fact about MDL 2440 is that it produced no jury verdicts — for either side. Judge Goodwin set up a thirty-case discovery pool and selected four bellwether cases for early trial. In his own words:

“From the group of thirty discovery pool cases, I picked four bellwether cases. Well before trial, all four bellwether cases were dismissed by the plaintiffs with prejudice.” (Demarcus v. Cook, S.D. W. Va. (June 4, 2015))

The four bellwether cases (reported as Ailey, Lingo, Hovey, and Watkins) were dismissed with prejudice in 2015, before any Cook pelvic-mesh case reached a jury (WVSD — MDL 2440 case page). In a surviving case, Demarcus v. Cook, the court granted Cook summary judgment because the plaintiff lacked case-specific causation evidence: “Without evidence of specific causation, the plaintiff cannot show that she has suffered an injury . . . Cook’s Motion on all of the plaintiff’s claims is GRANTED,” and the case was “DISMISSED with prejudice” (Demarcus v. Cook). The causation challenge — central to a biologic device with a contested injury mechanism — is part of why Cook fared comparatively well at the dispositive-motion stage.

Settlement record

MDL 2440 wound down through private, case-by-case settlements and dismissals rather than a single announced global deal. The court’s case-info page lists the MDL’s status as “Closed (Terminated 8/6/2019)” (WVSD — MDL 2440 case page). No specific aggregate Cook pelvic-mesh settlement dollar figure is disclosed in the public court record or in any primary source reviewed for this page. Unlike its synthetic-mesh co-defendants, Cook has no publicly confirmed settlement total — a fact worth stating plainly: any specific dollar figure attributed to a “Cook mesh settlement” should be regarded as unverified.

That absence stands in contrast to the publicly reported figures for the synthetic-mesh manufacturers covered elsewhere on this page (for example, the disclosures by Becton Dickinson / C.R. Bard, Johnson & Johnson / Ethicon, Boston Scientific, and American Medical Systems / Endo). Industry-wide, mesh manufacturers were reported to have “settled thousands of claims privately for approximately $8 billion” (Reuters).

FDA regulatory backdrop for Cook

The same FDA timeline that affected synthetic mesh forms the regulatory backdrop here: the 2011 Safety Communication on serious complications of transvaginal POP mesh (FDA urogynecologic surgical mesh activities); the 2016 reclassification of transvaginal POP surgical mesh to Class III, on the FDA’s finding that the devices “present a potential unreasonable risk of illness or injury” (Federal Register, 81 FR 365 (Jan. 5, 2016)); and the April 16, 2019 stop-sale order (FDA press announcement).

An important caveat for Cook. The April 2019 stop-sale order named only synthetic devices — Boston Scientific’s Uphold LITE and Xenform, and Coloplast’s Restorelle DirectFix Anterior. Cook’s porcine Surgisis/Biodesign grafts were not among the named products in that action. The precise regulatory treatment of Cook’s biologic SIS grafts under the 2016 reclassification framework is best confirmed against the Federal Register final order itself.

The bottom line on these two manufacturers

Coloplast sold synthetic transvaginal POP and SUI mesh; its litigation produced a documented $2.5 million plaintiff jury verdict (Redding, affirmed by the Eleventh Circuit in 2024) and the company disclosed reserves of roughly DKK 4.5 billion before tax for U.S. mesh litigation. Its Restorelle DirectFix Anterior was a device named in the FDA’s 2019 stop-sale order.
Cook Medical’s pelvic products were biologic porcine grafts; its MDL ended with no jury verdicts, its four bellwether cases dismissed with prejudice, and no publicly disclosed aggregate settlement figure. Cook’s devices were not named in the 2019 FDA stop-sale order.

Every figure above is drawn from a primary or neutral source — published court opinions, the federal court’s own case pages, the Federal Register, FDA.gov, the companies’ own investor disclosures, and news of record. Whether a particular product caused a particular person’s injury is a fact-specific medical and legal question that depends on that person’s records and treating physicians.

If you or a loved one was implanted with a Coloplast or Cook pelvic-mesh device and believe you may have been harmed, our team offers a free, confidential consultation. You can also read more about our firm and the attorneys behind this guide. This page is legal and medical information, not advice, and reading it creates no attorney-client relationship; prior results do not guarantee a similar outcome, and you should always consult your own physician about your care.

◀ American Medical Systems / Endo — The Documented Record · ↑ Top · Atrium Medical (Getinge) and Covidien (Medtronic) — The Documented Record ▶

Atrium Medical (Getinge) and Covidien (Medtronic) — The Documented Record

This section documents the public record for two hernia-mesh manufacturers whose products are the subject of large federal multidistrict litigation (MDL): Atrium Medical Corporation, maker of the C-QUR omega-3-coated mesh line, now part of Sweden’s Getinge AB; and Covidien, maker of the polyester-based Parietex line, now part of Medtronic plc. Both companies’ products reached the U.S. market through the FDA’s 510(k) substantial-equivalence premarket pathway, the standard route for moderate-risk (Class II) devices. Everything below is stated as public record — FDA actions, court filings, and corporate disclosures — and carefully distinguishes what plaintiffs alleged from what a court or agency actually found or ordered. Where a settlement exists, it is described as a settlement, not a verdict; importantly, neither company’s hernia-mesh MDL has produced a jury verdict. This material is for general education and is not legal or medical advice.

For background on how these devices are cleared and monitored, see How These Devices Reached the Market and FDA Action on Surgical Mesh. For the broader litigation context, see The Big Picture.

Atrium Medical (Getinge AB) — C-QUR Omega-3 Hernia Mesh

Corporate chain. Atrium Medical Corporation was headquartered in Hudson, New Hampshire. In 2011 it was acquired by the Getinge Group for $680 million, becoming a subsidiary of Sweden-listed Getinge AB (through Maquet). In later litigation the responding defendants were named as “Atrium Medical Corp., Maquet Cardiovascular, LLC, Getinge USA, Inc., and Getinge AB.” Source

The product. C-QUR is a polypropylene surgical mesh coated with an omega-3 fatty-acid (O3FA) fish-oil gel, marketed as a bioabsorbable barrier intended to reduce adhesions in hernia repair. The FDA cleared C-QUR Mesh on March 31, 2006 through the 510(k) pathway (clearance K050311), determining it “substantially equivalent” to a legally marketed predicate device under that pathway. Source The product family in commerce included C-QUR Mesh, C-QUR V-Patch, C-QUR TacShield, C-QUR FX, C-QUR Mosaic, and C-QUR Film, among others. Source

What plaintiffs alleged

In the federal litigation, plaintiffs alleged that the omega-3 coating was unstable after implantation and could degrade, slip off, or separate from the underlying polypropylene mesh, provoking a harmful reaction. The Judicial Panel on Multidistrict Litigation summarized the common theory in its own words: the actions “share common factual questions arising out of allegations that defects in defendants’ C-Qur mesh products incite an allergic or inflammatory response that causes severe complications.” Source The plaintiffs’ master complaint listed alleged complications including “severe pain, organ damage, graft rejection, graft migration, fistula, complex seroma, sinus tract formation, delayed wound closure, infection, sepsis, and death.” Source

These are allegations. Because no C-QUR case was tried to a verdict, no court found the product defective and no court attributed any death to it. The alleged injury types overlap with those discussed in Visceral Adhesions from Intraperitoneal Hernia Mesh, Mesh Infection, Bacterial Biofilm & Chronic Inflammation, and Functional & Organ-System Injuries.

A peer-reviewed clinical study in the journal Hernia (Springer, 2018) of the C-QUR V-Patch in ventral hernia repairs reported a surgical-site infection rate of 7.7% and a recurrence rate of 2.4% overall, with the infection rate rising to 19.0% when the mesh was placed intraperitoneally and a mesh-explantation rate of 2.4% (cohort of roughly 168 patients). Source

FDA enforcement record (the strongest, primary-source material)

The regulatory record concerning Atrium is documented in primary FDA and Department of Justice filings:

FDA Warning Letter, October 11, 2012. Following an inspection of Atrium’s Hudson, New Hampshire facility, the FDA issued a Warning Letter citing, among other things, that C-QUR infection complaints “were closed without obtaining any results,” “thirty five (35) confirmed instances of hair being found in your sterile medical devices,” and inadequate sterilization validation across six product families. Source
2013 recalls. Atrium conducted a Class 2 recall of the C-QUR Edge Mesh (FDA recall record) because the omega-3 coating could adhere to the package’s inner liner after exposure to high humidity; a broader 2013 recall series addressed the same humidity/packaging issue across the C-QUR V-Patch, TacShield, Edge, and standard meshes. The recall did not result in the product being pulled from the market. Source
Consent decree of permanent injunction, February 2015. After the company failed to correct the 2012 deficiencies, the United States filed suit and the U.S. District Court for the District of New Hampshire entered a permanent injunction halting manufacture and distribution of C-QUR hernia mesh at the Hudson facility until the FDA confirmed compliance. The Department of Justice described the basis as allegations that the company “introduced adulterated and misbranded medical devices into interstate commerce.” Source

The MDL and the global settlement

The C-QUR cases were centralized as MDL No. 2753, In re: Atrium Medical Corp. C-QUR Mesh Products Liability Litigation, in the U.S. District Court for the District of New Hampshire before Chief Judge Landya B. McCafferty, consolidated in December 2016. Source The litigation grew substantially; a JPML statistics report listed 3,308 pending cases as of September 2022. Source

No jury ever decided the C-QUR claims. The first designated bellwether, Barron v. Atrium (No. 1:16-cv-742-LM), settled on the morning of its pretrial conference in July 2021, before any jury heard evidence. Source

The litigation resolved by a global settlement, announced by parent company Getinge AB on December 8, 2021. Getinge’s own press release is the authoritative source: it stated that Atrium “entered into a settlement agreement related to the MDL mesh litigation,” recorded a concluding additional provision of SEK 600 million (on top of a SEK 1.8 billion provision booked in 2018 for the same litigation), noted “about 3,200 plaintiffs in the MDL,” set a claims cutoff of November 30, 2021, and stated that “the settlement is not an admission of liability or wrongdoing by the company.” Source

On the dollar figure. Getinge reports its provisions in Swedish kronor (SEK). U.S. business press reported the resolution as a set-aside of more than $66 million to resolve the more than 3,000 New Hampshire claims; that USD figure is press reporting, not a number stated in Getinge’s release. Source Settlement administration was handled through a court-established Qualified Settlement Fund and a court-appointed Special Master; individual per-claimant amounts are set under a confidential master settlement agreement and are not part of the public court record. Source

Covidien (Medtronic plc) — Parietex Polyester Hernia Mesh

Corporate chain. Covidien is the manufacturer of the Parietex hernia-mesh line; it is wholly owned by Medtronic plc, which acquired Covidien in 2015. The mesh itself was made by Covidien’s French subsidiary Sofradim Production SAS. The federal litigation names a slate of related entities — “Covidien LP, Covidien Holding Inc., Covidien, Inc., Covidien plc, Tyco Healthcare Group, Tyco International, Sofradim Productions SAS, Medtronic, Inc., and Medtronic USA, Inc. (together, Covidien).” Source

The products. Unlike most competitors, which use polypropylene, the Parietex line is built on monofilament polyester. Cleared through the 510(k) pathway, the line includes the original Parietex (1999), Parietex Composite (polyester with an absorbable collagen-film barrier), Parietex/Parietene ProGrip (self-fixating mesh with resorbable polylactic-acid micro-grips), and Symbotex Composite — the product in the lead bellwether case. Source

What plaintiffs allege

The JPML’s transfer order is the most authoritative statement of the plaintiffs’ theory:

“Plaintiffs in these personal injury actions allege that they were implanted with various Covidien hernia mesh products to treat a hernia, and, consequently, they suffered injury. Most plaintiffs allege that the polyester used in defendants’ hernia mesh products incites inflammation and heightened foreign body response, is more brittle, and is significantly more susceptible to fatigue fracture, breakage, fragmentation, and other mechanical failures than alternative polymers. In many actions, plaintiffs also allege defects in the collagen barrier or polylactic microgrips used in some Covidien hernia mesh products.” Source

The court found the actions “share factual issues arising from common allegations that defects in defendants’ hernia mesh products can lead to complications.” Source The alleged complications — chronic pain and foreign-body sensation, adhesions and bowel obstruction, mesh migration and structural failure, infection, organ perforation, fistula, and the need for revision surgery — track the general hernia-mesh complication profile described by the FDA. Source These overlap with the injuries covered in Visceral Adhesions from Intraperitoneal Hernia Mesh, Infection & Life-Threatening Complications, and Functional & Organ-System Injuries. These remain allegations; no Covidien hernia-mesh case has been tried.

The litigation’s design-defect theory draws on comparative polymer literature, including a peer-reviewed study that reported macroporous polyester mesh “induced the greatest [foreign body response] and lasting chronic inflammatory response” relative to polypropylene meshes. Source

FDA actions and recalls

Parietex and Symbotex were cleared as Class II devices through the 510(k) substantial-equivalence pathway. Source Several narrow recalls are documented in the FDA recall database; none broadly removed Parietex, ProGrip, or Symbotex from the market:

Date	Product	Class	Reason (FDA summary)
Oct. 2018	Parietex Composite Parastomal Mesh	Class 2	Parastomal mesh failure years after repair, in some cases leading to hernia recurrence Source
Jan. 2021	Parietex Hydrophilic Anatomical Mesh	Class 2	Mislabeling — package indicated one side but contained the device for the opposite side Source
Feb. 2023	Parietex Composite Mesh, Horseshoe-Shaped (PCO2H3)	Class 2	Manufacturing defect — the collagen film was placed on the opposite side of the mesh Source

The 2018 parastomal recall is the one most relevant to the litigation because it acknowledged real-world mesh failure leading to hernia recurrence; the 2021 and 2023 recalls were narrower manufacturing or labeling defects. Source The FDA’s MAUDE database contains numerous adverse-event reports for Parietex products describing complications such as chronic pain, mesh migration, adhesions, infection, and recurrence requiring revision surgery. Source

Litigation status: no verdict, no settlement

The Covidien cases are centralized as MDL No. 3029, In re: Covidien Hernia Mesh Products Liability Litigation (No. II), No. 1:22-md-03029-PBS, in the U.S. District Court for the District of Massachusetts before the Hon. Patti B. Saris, created June 6, 2022. The Panel chose Massachusetts because Covidien LP is headquartered there and a large coordinated proceeding (more than 4,700 cases at the time) was already pending in Massachusetts state court. Source The federal docket has continued to grow, with JPML records reflecting roughly 2,400 pending federal actions by mid-2026. Source

As a matter of public record, as of mid-2026 there is no global settlement and no jury verdict in the Covidien/Medtronic hernia-mesh litigation. The first bellwether — a Symbotex case in which plaintiffs allege the mesh caused a bowel obstruction requiring surgical removal — is scheduled for trial on July 13, 2026, after the court denied Covidien’s motion for summary judgment on certain warning and fraud claims. Source

A note on a frequently confused figure. A widely reported hernia-mesh settlement of more than $1 billion (announced in October 2024 to resolve roughly 38,000 cases) belongs to a different manufacturer — C.R. Bard / Davol, a subsidiary of Becton Dickinson, in a separate MDL in the Southern District of Ohio. The company did not disclose an exact figure. Source That settlement does not apply to Covidien/Medtronic and is mentioned here only to prevent the two from being conflated. For the Bard/Davol record, see Becton Dickinson / C.R. Bard / Davol — The Documented Record.

These records are presented for patient education and to help readers understand the documented regulatory and litigation history of these device families. They are not medical or legal advice, and reading them does not create an attorney-client relationship; prior results do not guarantee a similar outcome. Nothing here should be read as a direction to remove or keep any implanted device — that is a decision for you and your own physician, whom you should consult about your individual care. If you or a loved one has been affected by a hernia-mesh complication, our team offers a free, confidential consultation. You can learn more about us in About Attorney 911.

◀ Coloplast and Cook Medical — The Documented Record · ↑ Top · Breast Scaffolds & Acellular Dermal Matrix — GalaFLEX, Phasix, SERI, AlloDerm, Strattice ▶

Breast Scaffolds & Acellular Dermal Matrix — GalaFLEX, Phasix, SERI, AlloDerm, Strattice

If you had breast surgery — a lift (mastopexy), an augmentation, or reconstruction after mastectomy — your surgeon may have placed a sheet of mesh or processed tissue inside the breast to support the lower pole, cradle an implant, or reinforce thin skin. Surgeons often call this an “internal bra.” The materials come in two broad families: bioabsorbable synthetic scaffolds (GalaFLEX, GalaFLEX 3D, Phasix — all made from the polymer poly-4-hydroxybutyrate, or P4HB; and SERI, made from silk) and acellular dermal matrix (ADM) — sheets of human or pig skin that have been stripped of cells (AlloDerm, Strattice, and related products).

This section explains what these products are, what the FDA has and has not said about using them in the breast, what the peer-reviewed medical literature reports about their complications, and what is — and is not — happening in the courts. This is general educational information, not medical or legal advice, and no outcome is guaranteed; always consult your own physician about your specific situation. Several of these products are made by subsidiaries of Becton, Dickinson and Company (BD); the broader BD/C.R. Bard/Davol record is covered separately in Becton Dickinson / C.R. Bard / Davol — The Documented Record. For the underlying breast-injury patterns referenced throughout, see Breast Reconstruction & Scaffold Injuries.

The one fact to anchor on. On November 9, 2023, the FDA told health-care providers in writing that, while these are surgical mesh products “cleared for the repair and reinforcement of soft tissue where weakness exists,” “the safety and effectiveness of surgical mesh in breast surgery, including in augmentation or reconstruction, has not been determined by the FDA,” and that there are “no surgical mesh products cleared or approved by the FDA for use in breast surgery, including in augmentation or reconstruction.” Source Use of any of these products in the breast is therefore off-label.

GalaFLEX, GalaFLEX 3D & Phasix — the P4HB scaffolds (Becton Dickinson)

GalaFLEX and Phasix are FDA-cleared bioabsorbable surgical scaffolds knitted from monofilament poly-4-hydroxybutyrate (P4HB) fibers. GalaFLEX’s own 510(k) Summary describes it as “a sterile, knitted, resorbable mesh, constructed of non-dyed monofilament fibers made from poly-4-hydroxybutyrate (P4HB).” Source Phasix uses “a fully resorbable poly-4-hydroxybutyrate (P4HB) polymer material.” Source The same P4HB material is sold for hernia and abdominal-wall repair under the Phasix brand and for soft-tissue support under the GalaFLEX brand.

Who makes them. Through a chain of acquisitions, these products now roll up to Becton, Dickinson and Company:

Entity	Role	Event
Tepha, Inc.	Original maker of the GalaFLEX family and the P4HB polymer	BD acquired Tepha on July 27, 2021 Source
Galatea Surgical, Inc.	Tepha’s aesthetic/plastic-surgery commercial arm for GalaFLEX	Now a BD subsidiary
C.R. Bard / Davol Inc.	Maker of Phasix Mesh	BD completed its ~$24 billion acquisition of C.R. Bard on December 29, 2017 Source
Becton, Dickinson and Company (BD)	Current owner of the entire P4HB portfolio	—

BD’s own 2021 release confirms the integration: “Tepha’s GalaFLEX® portfolio, also based on the novel P4HB polymer, is included in the acquisition,” and “Tepha’s proprietary polymer is used in BD’s current Phasix™ Mesh products.” Source

What the FDA actually cleared — surgical mesh. Every P4HB clearance in this family is regulated under 21 CFR 878.3300, “Surgical Mesh,” Class II, under product code OOD (with the closely related absorbable-mesh code OXF). These are surgical-mesh product codes; sutures are regulated separately. The FDA’s clearance letters and the FDA Product Classification database make this explicit.

510(k)	Trade name	Clearance date	Applicant	Regulation / code	Predicate device(s)
K140533	GalaFLEX Mesh	May 21, 2014	Tepha, Inc.	878.3300, Surgical Mesh, Class II, OOD	TephaFLEX Mesh; SERI Surgical Scaffold (K123128) Source
K142818	Phasix Mesh	Feb. 18, 2015	Davol, Inc. (subsidiary of C.R. Bard)	878.3300, Surgical Mesh, Class II, OOD	TephaFLEX Mesh Source
K161092	GalaSHAPE 3D	July 21, 2016	Tepha, Inc.	878.3300, Surgical Mesh, Class II, OOD	GalaFLEX scaffold (K140533) Source
K162922	GalaFORM 3D	Jan. 17, 2017	Tepha, Inc.	878.3300, Surgical Mesh, Class II, OOD	GalaSHAPE 3D; GalaFLEX scaffold Source
K233999	GalaFLEX LITE Scaffold	Apr. 9, 2024	Tepha, Inc.	878.3300, Surgical Mesh, Class II, OOD	TephaFLEX Light Mesh (K113721); reference: Phasix Mesh Source

The FDA’s clearance letter for GalaFLEX states verbatim: “Regulation Name: Surgical Mesh — Regulatory Class: Class II — Product Code: OOD.” Source Its cleared Indications for Use never mention the breast: GalaFLEX is indicated “as a transitory scaffold for soft tissue support … This includes reinforcement of soft tissue in plastic and reconstructive surgery, and general soft tissue reconstruction.” Source For background on how the 510(k) substantial-equivalence premarket pathway works, see How These Devices Reached the Market: 510(k), MAUDE Reporting & Expert Review.

The November 9, 2023 FDA Letter to Health Care Providers. The FDA’s letter, “Labeling Updates for BD Mesh Products,” names nine P4HB products — Phasix Mesh; Phasix ST Mesh; Phasix Plug and Patch; Phasix ST Mesh with Open Positioning System (OPS); Phasix ST Mesh with Echo 2 Positioning System; GalaFLEX Lite Scaffold; GalaFLEX Scaffold; GalaFLEX 3D Scaffold; and GalaFLEX 3DR Scaffold. The FDA wrote that it “is aware of increased use of surgical mesh products in breast surgery,” that the safety and effectiveness of such use “has not been determined by the FDA,” and that BD “has updated their labeling for these products, including updated warnings and precautions.” Critically for patients, “The FDA is not recommending reoperation or removal of implanted surgical mesh in asymptomatic patients.” Source The FDA noted it had communicated about this issue at its General and Plastic Surgery Devices Panel of March 25–26, 2019, and that “the panel’s recommendations have not changed.” Source Trade press reported the same FDA position contemporaneously. Source

This is a labeling action, not a recall. As of mid-2026 there is no FDA Class I or Class II recall of the GalaFLEX or Phasix P4HB products; the FDA’s action was the labeling update and the Letter to Health Care Providers. Source

What the peer-reviewed literature reports. The published evidence is almost entirely retrospective (Level IV) case series with short follow-up and no randomized controlled trials, and several studies disclose manufacturer financial relationships — important context when reading the rates below. With that caveat:

A 2025 systematic review and meta-analysis in the Journal of Personalized Medicine (13 studies; 636 reconstruction cases) reported periprosthetic infection 3.8%, seroma 1.3%, capsular contracture 0.9%, and — the most clinically significant signal — device explantation of 10.3%, “Higher in patients with: radiation history, advanced age, elevated BMI, smoking, larger mastectomy specimens.” Source
A 2024 meta-analysis in Aesthetic Surgery Journal Open Forum (31 studies) reported a seroma meta-rate of 3%, infection 4%, reoperation 10%, and explantation 3%, and stated plainly that “No mesh device has gained FDA-approved indication for breast reconstruction.” Source
A 2024 Plastic and Reconstructive Surgery cohort (Movassaghi et al., 105 patients / 194 breasts) reported that “10.3% of devices required explantation,” rising to 28.6% in irradiated breasts (P < 0.01). Source
A 2024 long-term aesthetic-surgery cohort in Aesthetic Surgery Journal (Sinclair & Adams, 248 patients) reported an 8.0% overall complication rate and a 2.8% unplanned reoperation rate; the companion meta-analysis noted this series documented an encapsulated mesh fragment that “remained palpable long-term, requiring surgical removal.” Source

These signals map onto the injuries described in Bioabsorbable Scaffold Failure: P4HB (GalaFLEX) “Internal Bra” Collapse, Seroma Formation with Breast ADM & Scaffolds, and Failure of Breast Reconstruction Requiring Explantation.

The resorption / transient-support point. Because P4HB dissolves, long-term lower-pole support depends on the patient’s own ingrown tissue, not the scaffold. Even device-favorable authors concede that “lower pole support at one year postoperatively and afterward was primarily dependent on neovascularized connective tissue ingrowth rather than the P4HB scaffold itself,” with “complete resorption … within 18–24 months through hydrolysis.” Source Preclinical hernia-model work on the same P4HB material found it “retains only 70% of its strength after 12 weeks,” with resorption “essentially complete in 12 to 18 months.” Source

The inflammatory-response question is genuinely contested. Manufacturer-aligned histology has reported “no evidence for chronic inflammation or a foreign body response” and “a constructive tissue remodeling process,” though that study acknowledged it was “limited by the size of the 10-patient cohort.” Source The same body of literature also reports that “P4HB elicits a stronger and faster M2 macrophage response than polypropylene mesh,” with the M2 pathway described as beneficial by proponents and as a concern by critics. Source We present this as a documented scientific dispute, not a settled conclusion; see The Foreign-Body Response (Why the Body Reacts to Mesh).

Litigation — active but early. Individual breast-mesh complaints have reportedly been filed in Rhode Island state court (where BD’s surgical-mesh operations are headquartered) against Becton Dickinson and several subsidiaries, including Davol Inc., C.R. Bard Inc., Tepha Inc., and Galatea Surgical Inc. Plaintiffs allege injuries such as nerve pain, swelling, breast ptosis, seroma, and inflammation, asserting causes of action including negligence, strict product liability, failure to warn, breach of warranty, and fraud, and the core theory that the products were marketed for breast surgery “despite the lack of FDA clearance or approval for that specific use.” Source These are allegations that have not been proven in court. Importantly: no multidistrict litigation (MDL), no class action, and no settlement or verdict has been reported in any GalaFLEX/Phasix breast-mesh case. A separate, much larger litigation involving BD’s polypropylene hernia mesh (a different product line) — the MDL In re: Davol, Inc./C.R. Bard, Inc., Polypropylene Hernia Mesh Products Liability Litigation, No. 2:18-md-02846 (S.D. Ohio) — produced bellwether jury verdicts and a 2024 settlement that BD announced would resolve the vast majority of its hernia cases. Source Those hernia outcomes are defendant history only and must not be confused with the breast-mesh claims; the hernia record is detailed in Becton Dickinson / C.R. Bard / Davol — The Documented Record.

SERI Surgical Scaffold — silk-derived (Serica / Allergan / AbbVie / Sofregen)

SERI Surgical Scaffold was a bioresorbable surgical mesh made from purified silk fibroin protein of the Bombyx mori silkworm. It originated with Serica Technologies, was acquired by Allergan (later part of AbbVie), and the product line was sold to Sofregen Medical in 2016. Source

Regulatory status. SERI was cleared via the 510(k) pathway as a general soft-tissue surgical mesh — 510(k) K123128, decision date April 25, 2013, product code OXF, 21 CFR 878.3300, Class II — never as a PMA-approved device and never cleared specifically for breast surgery. Its cleared indication covered “reinforcement of soft tissue in plastic and reconstructive surgery, and general soft tissue reconstruction,” with no breast indication named. Source

FDA enforcement. On May 29, 2015, the FDA issued Allergan Medical a Warning Letter finding that the company was promoting SERI for breast-surgery uses beyond its cleared indication — including “breast revision surgery, breast reductions, muscle flap reinforcement, and mastopexy with or without augmentation” — and that these breast claims would constitute a major change to the device’s intended use for which the firm lacked clearance, rendering the device adulterated and misbranded. Source Separately, a 2013 FDA Class 2 recall addressed a packaging/sterility defect (“outer pouch seal of dual packaging may be compromised and sterility may not be assured”), not an injury-based withdrawal. Source

Complications. Allergan’s own manufacturer-sponsored two-stage breast-reconstruction trial (Fine et al., 103 patients / 161 breasts) reported per-breast rates of tissue/skin necrosis 8.1%, seroma 5.0%, wound dehiscence 5.0%, breast redness 5.0%, and capsular contracture 2.5%, with “52.2% of breasts” experiencing at least one predefined adverse event (most mild) and 98.8% SERI retention at two years. Source A peer-reviewed case report separately documented a “delayed erythematous skin reaction” with SERI-assisted direct-to-implant reconstruction — relevant to Red Breast Syndrome (Sterile Inflammatory Erythema of ADM). Source

Market status. SERI is no longer available: its final owner, Sofregen, began discontinuing it on March 31, 2021 for inventory/shelf-life reasons, and “as of December 31, 2021, SERI Surgical Scaffold is no longer commercially available.” Source

Litigation. In Wendy Knecht v. Max R. Lehfeldt, M.D. and Allergan, Inc. (No. BC641979, Los Angeles Superior Court, filed Nov. 28, 2016), the plaintiff alleged her surgeon used SERI and Natrelle tissue expanders off-label without her knowledge and that the devices “failed and caused her injuries and disfigurement that required three additional surgeries”; the matter resolved by settlement rather than a verdict. In Gianna Krstic v. Allergan, Inc. and Sofregen Medical, Inc. (U.S. District Court for the District of Massachusetts), a federal judge in February 2021 denied the defendants’ motion to dismiss, allowing the plaintiff’s negligence and fraudulent-concealment claims — that silk netting “hardened within her body” after a paid Allergan consultant allegedly used it without her knowledge — to proceed; no settlement or verdict was reported at the time of that ruling. Source

AlloDerm & Strattice — acellular dermal matrix (LifeCell / Allergan / AbbVie)

Acellular dermal matrices (ADMs) are sheets of human or animal skin processed to remove cells while preserving the collagen scaffold; in implant-based reconstruction they act as a sling or “internal bra” supporting the tissue expander or implant. AlloDerm is a human-derived ADM (first commercialized by LifeCell in 1993); Strattice is a non-cross-linked porcine (pig-skin) ADM introduced by LifeCell in 2008. Both came to LifeCell, which Allergan acquired and which became part of AbbVie when AbbVie acquired Allergan in 2020. Source Strattice’s labeling describes it as “a surgical mesh that is derived from porcine skin.” Source

Off-label in the breast. As the FDA stated at its March 25–26, 2019 advisory panel, “no surgical mesh device, whether synthetic, animal collagen derived or human collagen derived, is cleared or approved for use in breast surgery.” Source On March 31, 2021, the FDA issued a Safety Communication warning that certain ADM products used in implant-based breast reconstruction may carry a higher chance of complications, stating that “the FDA has not cleared or approved any ADM product for use in breast reconstruction.” Drawing on the Mastectomy Reconstruction Outcomes Consortium (MROC) data, the FDA found “significantly higher major complication rates of explantation, reoperation, and infections two years after surgery” with certain brands (the human ADMs FlexHD and AlloMax) relative to others; the FDA did not recommend reoperation or removal of implanted ADM as a preventive measure. Source

Reported complications. A 2024 systematic review and network meta-analysis in BMC Cancer (51 studies; 7,667 patients; 11,988 breasts) reported the following pooled per-product rates, with AlloDerm as the human-ADM reference and Strattice within the porcine-ADM group:

ADM	Infection	Seroma	Explantation	Capsular contracture
AlloDerm (human, reference)	9.0%	6.6%	8.0%	0.4%
Porcine ADMs (e.g., Strattice)	11.1%	10.3% (highest)	5.1%	2.5% (highest)

Source

For Strattice specifically, published breast-reconstruction series report overall complication rates ranging from roughly 8.6% (Salzberg et al., 54 patients) to 10.8% (Mitchell, 103 patients), with Mitchell finding complications, implant/expander loss, and dehiscence “significantly higher in irradiated breasts.” Source A direct comparison found Strattice “associated with higher rates of skin erythema post-operatively (16.7% versus 4.5%; P = 0.044)” — relevant to Red Breast Syndrome (Sterile Inflammatory Erythema of ADM), described in the literature as “a self-limited, non-infectious erythema historically linked to acellular dermal matrices.” Source A separate case report documented a delayed type IV hypersensitivity reaction to porcine ADM “masquerading as infection” that led to multiple debridements. Source

FDA adverse-event reports. Court filings in Strattice litigation cite the FDA’s own tally that “the FDA received at least 450 Medical Device Reports … from September 1, 1990, through September 30, 2020 involving Strattice. Six reports involve death,” plus more than 340 injury reports and at least 107 malfunctions — figures that are device-wide (largely hernia/abdominal use), not breast-specific. Source

Litigation. Strattice’s most developed litigation is a hernia-based New Jersey Multicounty Litigation before Judge John C. Porto, where the first trial — Theresa Blakely v. LifeCell Corp., Allergan, Inc. & Allergan USA Sales, Inc. — ended in a defense verdict on March 22, 2024 (the jury cleared LifeCell of liability in a recurrent-hernia case). Source An off-label breast/”internal bra” litigation track against Strattice (and other scaffolds) has reportedly been the subject of inquiry, but no confirmed Strattice breast-reconstruction settlement or jury verdict could be located in a primary source, and as of 2026 there are reportedly no large-scale breast-mesh settlements. We do not state any unverified breast-mesh recovery figure for these products.

What this means for a patient — and where the record stands

Pulling the threads together, the documented, attributable facts are these:

No surgical mesh or ADM — synthetic, silk, human, or porcine — is FDA-cleared or approved for breast surgery. The FDA has said this directly and repeatedly. Source Use of these products in the breast is off-label.
The published complication signals that survive scrutiny include roughly 10% device explantation in P4HB reconstruction (rising to about 28.6% in irradiated breasts), reoperation around 10%, documented seroma and skin-erythema/Red Breast Syndrome with ADMs, and elevated complications in patients who had radiation. Source
The inflammatory/foreign-body and cancer-surveillance questions for P4HB are genuinely disputed in the scientific literature and should be read as an open debate, not a settled finding. Source
Breast-mesh litigation is real but early: individual suits exist, but there is no MDL, class action, settlement, or verdict in any breast-mesh case. The only confirmed BD dollar outcomes are in the separate hernia-mesh litigation. Source

Crucially, the FDA has not recommended that asymptomatic patients have implanted mesh removed or undergo reoperation. Source This page is educational and is not a substitute for medical care, and no result or outcome is guaranteed: if you are concerned about a breast scaffold or ADM, talk with your own physician about your specific situation and follow-up — do not start, stop, or change any treatment based on this page alone. For the underlying device science, see What Surgical Mesh and Breast Scaffolds Actually Are; for the injury patterns, see Breast Reconstruction & Scaffold Injuries.

If you or a loved one has been affected by a breast scaffold or ADM complication, our team offers a free, confidential consultation. To learn about the attorneys behind this guide, see About Attorney 911 — The Manginello Law Firm, PLLC.

◀ Atrium Medical (Getinge) and Covidien (Medtronic) — The Documented Record · ↑ Top · FDA Action on Surgical Mesh: 2008 → 2011 → 2016 → the 2019 Ban ▶

FDA Action on Surgical Mesh: 2008 → 2011 → 2016 → the 2019 Ban

For more than a decade, the U.S. Food and Drug Administration (FDA) escalated its regulatory response to surgical mesh used in the vagina to repair pelvic organ prolapse (POP) — moving from an early warning, to a finding that serious complications are “not rare,” to reclassifying the devices as high-risk, and finally, in April 2019, ordering the last two manufacturers to stop selling them. This section lays out that timeline in plain English, with every regulatory milestone drawn from the FDA’s own published record. It matters to patients because the regulatory history explains what the FDA itself concluded about these devices — and because women who were implanted before the 2019 order are still living with the consequences the FDA described.

A note on scope before the timeline: the FDA’s most severe actions applied to mesh placed transvaginally to repair pelvic organ prolapse (POP). They did not apply to mesh slings used for stress urinary incontinence (SUI), nor to mesh placed abdominally (sacrocolpopexy) for prolapse — those remain separately regulated and on the market. Keeping that distinction straight is essential to understanding what the FDA did and did not do. The broader documented harms catalogued in the injury sections of this guide — erosion, perforation, chronic pelvic pain, and contraction — are the same complications the FDA repeatedly cited in these communications.

The FDA Timeline at a Glance

Date	FDA Action	What It Said / Did
Oct. 20, 2008	Public Health Notification	Warned of complications from transvaginal POP/SUI mesh; called them “rare”
July 13, 2011	Safety Communication	Reversed course — serious complications are “not rare”; no clear benefit over non-mesh repair
Jan. 2012	522 postmarket study orders	Ordered manufacturers to study real-world safety
Jan. 5, 2016	Two final orders	Reclassified transvaginal POP mesh from Class II to Class III; required premarket approval (PMA)
July 13, 2018	Stop-sale order (rectocele)	Ordered last posterior-compartment POP mesh off the market
Apr. 16, 2019	Stop-sale order (all remaining)	Ordered Boston Scientific and Coloplast to stop selling all transvaginal POP mesh immediately

Source: FDA’s Activities: Urogynecologic Surgical Mesh, FDA.gov.

October 20, 2008 — The Public Health Notification (“Although Rare…”)

The FDA’s first formal alert was the Public Health Notification: Serious Complications Associated with Transvaginal Placement of Surgical Mesh in Repair of Pelvic Organ Prolapse and Stress Urinary Incontinence, issued October 20, 2008 and signed by Daniel G. Schultz, MD, then Director of the FDA’s Center for Devices and Radiological Health. The notification stated that “Over the past three years, FDA has received over 1,000 reports from nine surgical mesh manufacturers of complications that were associated with surgical mesh devices used to repair POP and SUI.” The FDA characterized those complications, at the time, as rare: “Although rare, these complications can have serious consequences.” (FDA Public Health Notification, Oct. 20, 2008, FDA web archive)

The 2008 notification listed the complications that would come to define the mesh-injury landscape:

“erosion through vaginal epithelium, infection, pain, urinary problems, and recurrence of prolapse and/or incontinence”
“bowel, bladder, and blood vessel perforation during insertion”
“vaginal scarring and mesh erosion led to a significant decrease in patient quality of life due to discomfort and pain, including dyspareunia” (painful intercourse)

It also made an early, candid acknowledgment that some harms may not be fixable: “implantation of surgical mesh is permanent, and that some complications associated with the implanted mesh may require additional surgery that may or may not correct the complication.” (FDA Public Health Notification, Oct. 20, 2008)

July 13, 2011 — The Reversal: Complications Are “Not Rare”

The pivotal moment came on July 13, 2011, when the FDA issued UPDATE on Serious Complications Associated with Transvaginal Placement of Surgical Mesh for Pelvic Organ Prolapse: FDA Safety Communication. In it, the FDA expressly reversed its 2008 framing:

“The FDA is issuing this update to inform you that serious complications associated with surgical mesh for transvaginal repair of POP are not rare. This is a change from what the FDA previously reported on Oct. 20, 2008. Furthermore, it is not clear that transvaginal POP repair with mesh is more effective than traditional non-mesh repair … and it may expose patients to greater risk.” — FDA Safety Communication, July 13, 2011 (FDA web archive)

The reversal rested on a sharp rise in adverse-event reports and on a systematic review of the published scientific literature (1996–2011). The FDA reported that “from Jan. 01, 2008 through Dec. 31, 2010, the FDA received 2,874 additional reports of complications … with 1,503 reports associated with POP repairs and 1,371 associated with SUI repairs,” adding that it was “concerned that the number of adverse event reports remains high.” (FDA Safety Communication, July 13, 2011)

Period	Adverse-event reports (POP + SUI)	Source
2005–2007	“over 1,000”	2008 PHN
Jan. 1, 2008 – Dec. 31, 2010	2,874 (1,503 POP; 1,371 SUI)	2011 Safety Communication

Key findings stated by the FDA in the 2011 communication and its companion white paper, Urogynecologic Surgical Mesh: Update on the Safety and Effectiveness of Transvaginal Placement for Pelvic Organ Prolapse (July 2011):

No proven benefit over non-mesh repair. The literature review “showed that transvaginal POP repair with mesh does not improve symptomatic results or quality of life over traditional non-mesh repair.” (FDA, July 13, 2011)
Erosion is the most common complication. “[E]rosion of mesh through the vagina is the most common and consistently reported mesh-related complication … In some cases, even multiple surgeries will not resolve the complication.” (FDA, July 13, 2011) — see Mesh Erosion, Exposure & Extrusion.
Mesh contraction newly recognized. “Mesh contraction (shrinkage) is a previously unidentified risk … Reports in the literature associate mesh contraction with vaginal shortening, vaginal tightening and vaginal pain.” (FDA, July 13, 2011) — see Mesh Contraction / Shrinkage.
A class-wide concern, not one brand. “The complications associated with the use of surgical mesh for POP repair have not been linked to a single brand of mesh.” (FDA, July 13, 2011)
Mesh is often unnecessary. “[I]n most cases, POP can be treated successfully without mesh thus avoiding the risk of mesh-related complications.” (FDA, July 13, 2011)

The FDA’s July 2011 white paper also reported seven deaths associated with transvaginal POP mesh repairs in adverse-event reports from 2008–2010 — three directly related to the mesh-placement procedure (two bowel perforations and one hemorrhage) and four from post-operative medical complications. (FDA white paper, July 2011) See Fatal Complications.

How these devices reached the market in the first place — through the 510(k) premarket pathway, a substantial-equivalence review rather than an independent demonstration of safety and effectiveness — is explained in How These Devices Reached the Market.

2011–2014 — Advisory Panel, 522 Studies, and Proposed Reclassification

Following the 2011 communication, the FDA convened its Obstetrics and Gynecology Devices Panel on September 8–9, 2011, which led the agency to consider reclassifying transvaginal POP mesh “from Class II (low- to moderate-risk devices) to Class III (high-risk devices).” Beginning January 3, 2012, the FDA issued postmarket-surveillance (“522”) study orders; as of February 17, 2013 it had issued “95 postmarket study orders to 34 manufacturers” of POP mesh and “14 postmarket study orders to seven manufacturers” of SUI mini-slings. On April 29, 2014, the FDA issued proposed orders to reclassify the devices and require PMA applications. (FDA’s Activities: Urogynecologic Surgical Mesh); (Federal Register, May 1, 2014)

January 5, 2016 — Reclassification to Class III and the PMA Requirement

On January 5, 2016, the FDA published two companion final orders in the Federal Register (Vol. 81, No. 2). The first reclassified the devices; the order’s own summary states its basis:

“The Food and Drug Administration (FDA or the Agency) is issuing a final order to reclassify surgical mesh for transvaginal pelvic organ prolapse (POP) repair from class II to class III. FDA is reclassifying these devices based on the determination that general controls and special controls together are not sufficient to provide reasonable assurance of safety and effectiveness for this device, and these devices present a potential unreasonable risk of illness or injury.” — Obstetrical and Gynecological Devices; Reclassification of Surgical Mesh for Transvaginal Pelvic Organ Prolapse Repair, Final order, 81 Fed. Reg. 353–61 (PubMed record of the Federal Register final order, NLM 26742182); (Federal Register, Jan. 5, 2016)

The companion order set the practical consequence: because Class III devices require the agency’s most stringent review, manufacturers now had to obtain premarket approval (PMA) — an affirmative demonstration of “a reasonable assurance of safety and effectiveness” for each device — to keep it on the market. Manufacturers were required to file PMAs by July 5, 2018. (Federal Register — PMA effective-date order, Jan. 5, 2016)

This was a significant change. As described in How These Devices Reached the Market, transvaginal POP mesh had largely reached the market through the 510(k) substantial-equivalence pathway, which requires a showing that a device is substantially equivalent to an already-marketed predicate device rather than original clinical safety and effectiveness data. The 2016 reclassification meant manufacturers now had to prove safety and effectiveness directly. (The 2016 reclassification applied only to transvaginal POP mesh; SUI slings remained Class II.) (FDA’s Activities: Urogynecologic Surgical Mesh)

On July 13, 2018, the FDA ordered “the manufacturer of the last mesh surgical products on the market for the transvaginal repair of pelvic organ prolapse in the posterior compartment (rectocele) to stop selling and distributing their products.” (FDA’s Activities: Urogynecologic Surgical Mesh)

April 16, 2019 — The Order to Stop Selling

After the July 2018 PMA deadline, only two companies — Boston Scientific and Coloplast (see Coloplast and Cook Medical) — had filed applications to keep their transvaginal POP mesh on the market. The FDA convened its Obstetrics and Gynecology Devices Panel on February 12, 2019, which concluded that, to support a favorable benefit-risk profile, the effectiveness of transvaginal POP mesh “should be superior to native tissue repair at 36 months” with comparable safety. (FDA’s Activities: Urogynecologic Surgical Mesh)

On April 16, 2019, the FDA reviewed the two companies’ PMAs and “decided not to approve these PMAs because the data submitted did not provide a reasonable assurance of safety and effectiveness.” The agency “ordered the two manufacturers of the three mesh surgical products on the market for the transvaginal repair of pelvic organ prolapse to stop selling and distributing their products immediately.” (FDA’s Activities: Urogynecologic Surgical Mesh)

The three products ordered off the market:

Manufacturer	Device
Boston Scientific	Uphold LITE Vaginal Support System
Boston Scientific	Xenform Soft Tissue Repair System
Coloplast	Restorelle DirectFix Anterior

Source: FDA’s Activities: Urogynecologic Surgical Mesh.

The order applied only to mesh for transvaginal repair of POP. It did not cover mesh for stress urinary incontinence or transabdominal (sacrocolpopexy) repair. The FDA also advised that the order did not call for removal of mesh already implanted: women satisfied with their surgery and without complications were told there was no need to take additional action, but to continue routine follow-up and to notify their health care providers if symptoms such as “persistent vaginal bleeding or discharge, pelvic or groin pain, or pain during sexual intercourse” developed. (FDA — Pelvic Organ Prolapse (POP))

In the agency’s later assessment of the manufacturers’ final 522 study results (Boston Scientific, Aug. 16, 2021; Coloplast, Oct. 17, 2022), the FDA found the devices “had similar effectiveness and safety outcomes to native tissue repair at 36 months,” but stated that it “maintains that these devices do not have a favorable benefit-risk profile,” citing “potential additional risks compared to native tissue repair, including mesh exposure and erosion.” (FDA’s Activities: Urogynecologic Surgical Mesh) The practical result: there are no FDA-approved surgical mesh products for transvaginal repair of pelvic organ prolapse marketed in the United States.

Major Mesh Recalls (Hernia and Pelvic Devices)

Separate from the POP regulatory timeline, the FDA’s recall and enforcement databases document several specific mesh-product actions. An important legal distinction runs through this area: a recall is an FDA-classified safety action with a recall number and class, while a market withdrawal is a manufacturer’s business decision to stop selling a product. Some widely discussed products were withdrawn from the market without ever being the subject of an FDA safety recall.

Bard / Davol Composix Kugel Hernia Patch — FDA Class I Recall (2005–2007). This patch used a “memory recoil ring” to spring the mesh flat inside the abdomen; the ring could break. The FDA classified the recalls as Class I — its most serious category. The FDA’s recall records describe the reason as the “Memory recoil ring could break and potentially lead to bowel perforation and or chronic enteric fistula.” The recalls spanned multiple product codes and waves (FDA recall numbers Z-0524-06 through Z-0762-06 and Z-0359-2007, Z-0360-2007), recalling firm “Davol, Inc., Sub. C. R. Bard, Inc.” (openFDA Device Recall database, product “Kugel”); (FDA recall-detail record, “Class 1 Device Recall Davol Composix Kugel Hernia Patch”) These complications are discussed in Perforation of Bladder, Bowel or Ureter and Fistula Formation. C.R. Bard later recognized a $184 million charge in its SEC filings to resolve the related Kugel litigation. (C.R. Bard Form 8-K, June 30, 2011, SEC EDGAR)
Atrium Medical C-QUR Mesh — FDA Class II Recall (2013) + DOJ Consent Decree (2015). The openFDA enforcement database records four C-QUR recalls, all Class II, all initiated July 19, 2013, addressing a packaging/humidity defect: “Coated mesh can adhere to the inner packaging liner due to exposure to high humidity conditions” (recall numbers Z-1936-2013 through Z-1939-2013). (openFDA Device Enforcement database, Atrium “mesh”) Separately, in October 2012 the FDA issued a Warning Letter to Atrium citing, among other issues, “35 confirmed instances of human hair being found in sterilized meshes.” (FDA Warning Letter — Atrium Medical Corporation, Oct. 11, 2012, FDA web archive) In February 2015, the U.S. District Court for the District of New Hampshire entered a consent decree of permanent injunction against Atrium, related Maquet entities, and named executives; the U.S. Department of Justice stated the “corporate defendants shall pay the United States $6 million in equitable disgorgement.” (U.S. DOJ press release, Feb. 2015) See Atrium Medical (Getinge) and Covidien (Medtronic).
Ethicon Physiomesh Flexible Composite Mesh — Market Withdrawal, not an FDA safety recall (2016). In May 2016, Ethicon issued a worldwide market withdrawal of the laparoscopic Physiomesh after hernia-registry data showed higher recurrence and re-operation rates than comparable meshes. This was a business/market withdrawal, not an FDA-classified safety recall — the openFDA database contains no safety-recall classification for the Ethicon device itself (only a 2015 third-party repackager registration deficiency, Z-2242-2015 and Z-2243-2015). (openFDA Device Recall database, “Physiomesh”)
Ethicon Gynecare Prolift — Voluntary discontinuation, not an FDA safety recall (2012). In June 2012, Ethicon told the FDA it would discontinue four transvaginal devices (Gynecare Prolift, Prolift+M, TVT Secur, and Prosima), citing commercial reasons. This was a product discontinuation/withdrawal, not a safety recall; the only Prolift entry in the openFDA recall database is a 2007 labeling-correction recall over a mislabeled outer box (Z-0795-2007). (openFDA Device Recall database, “Prolift”) A peer-reviewed systematic review of the FDA approval process noted that “Johnson & Johnson brought the Gynecare Prolift (K071512) to market in 2005, 3 years before it received regulatory approval.” (Heneghan et al., systematic review of the U.S. FDA approval process for transvaginal mesh, PMC5728256) See Johnson & Johnson / Ethicon — The Documented Record.

Product	What the FDA record shows	FDA safety recall on file?
Bard/Davol Composix Kugel	Class I recall (recoil-ring breakage → bowel perforation/fistula), 2005–2007	Yes — Z-0524-06 … Z-0360-2007
Atrium C-QUR	Class II recall (2013 humidity/packaging) + DOJ consent decree	Yes (Class II) — Z-1936-2013 … Z-1939-2013
Ethicon Physiomesh	Worldwide market withdrawal (2016)	No safety recall for the device
Ethicon Gynecare Prolift	Voluntary discontinuation (2012); 2007 mislabeling correction only	No safety recall (labeling correction only)
Boston Scientific Uphold LITE / Xenform; Coloplast Restorelle DirectFix	FDA-ordered off market Apr. 16, 2019 (PMAs not approved)	Stop-sale order, not a numbered recall

Sources: openFDA Device Recall/Enforcement databases; FDA’s Activities: Urogynecologic Surgical Mesh.

What the Record Means for Patients

The throughline of the FDA’s record is documented and primary-sourced: the agency moved from calling transvaginal POP-mesh complications “rare” in 2008, to finding they are “not rare” in 2011, to reclassifying the devices as high-risk in 2016, to ordering them off the U.S. market entirely in 2019 after the manufacturers’ applications “did not provide a reasonable assurance of safety and effectiveness.” (FDA’s Activities: Urogynecologic Surgical Mesh) Regulators in other countries took parallel and sometimes broader steps, summarized in What the Rest of the World Did.

This page is educational information, not medical or legal advice, and is not a substitute for professional medical care. The FDA’s own guidance is that women already implanted with mesh should continue routine follow-up and contact their own physician if they develop symptoms — and nothing here should be read as telling any reader to remove or keep a device; that is a decision for you and your doctor.

◀ Breast Scaffolds & Acellular Dermal Matrix — GalaFLEX, Phasix, SERI, AlloDerm, Strattice · ↑ Top · How These Devices Reached the Market: 510(k), MAUDE Reporting & Expert Review ▶

How These Devices Reached the Market: 510(k), MAUDE Reporting & Expert Review

Most surgical mesh and breast scaffolds did not reach the U.S. market through the FDA’s most stringent review. They entered through a federal premarket pathway called 510(k), in which a manufacturer demonstrates that its device is “substantially equivalent” to a device already legally on the market. This section explains, in plain English and from primary government sources, three things every patient should understand: (1) what the 510(k) substantial-equivalence pathway actually is, (2) what the FDA’s adverse-event database (MAUDE) does and does not tell us, and (3) what expert bodies, medical societies, and FDA advisory panels have concluded about these devices. Understanding how a device was reviewed helps explain why complications can surface only after years of widespread use — a recurring theme across the injuries catalogued on this page and the FDA’s escalating actions on transvaginal mesh.

A word of caution before the data: numbers in this section describe reports, clearances, and expert findings — not proof that any particular device caused any particular person’s injury. Causation is a medical and legal question that depends on individual facts. Nothing here is medical advice; if you have a mesh or scaffold implant, discuss your situation with your own physician. Prior results and the experiences in these records do not guarantee a similar outcome.

The 510(k) Substantial-Equivalence Pathway, Explained Neutrally

The 510(k) pathway — formally Premarket Notification under Section 510(k) of the Federal Food, Drug, and Cosmetic Act — is the marketing route the FDA uses for most moderate-risk (Class II) medical devices, as well as certain Class I and Class III devices. It is distinct from the more demanding Premarket Approval (PMA) process reserved for the highest-risk devices.

Here is how the FDA itself describes it:

A 510(k) is a comparison submission, not a stand-alone clinical safety-and-effectiveness trial. The FDA defines it as a submission “made to FDA to demonstrate that the device to be marketed is as safe and effective, that is, substantially equivalent (SE), to a legally marketed device.” Source
The statute “requires device manufacturers intending to market a device to notify the FDA at least 90 days in advance,” a process the FDA calls Premarket Notification, or 510(k). Source
To find substantial equivalence, the FDA “first establishes that the new and predicate devices have the same intended use and any differences in technological characteristics do not raise different questions of safety and effectiveness.” Source

The device used for comparison is the predicate. As the FDA explains, “The legally marketed device(s) to which equivalence is drawn is commonly known as the ‘predicate,'” and “any legally marketed device may be used as a predicate.” Source

“Cleared” is not “Approved” — a distinction that matters

When a device passes the 510(k) review, the FDA issues an order finding it substantially equivalent and stating “that the device can be marketed in the U.S.” Source The device is then said to be “cleared.” That is different from being “FDA-approved,” a term that properly applies only to devices that survive the PMA process. This is why, throughout this page, the bioabsorbable breast scaffolds described in the breast-scaffold manufacturer record are referred to as FDA-cleared surgical mesh/scaffolds (under product codes such as OOD), and why their use in the breast is described as off-label rather than FDA-cleared for that indication.

Pathway	What the manufacturer must show	Result
510(k) Premarket Notification	Substantial equivalence to a legally marketed predicate device	Device is cleared for marketing
PMA (Premarket Approval)	Independent reasonable assurance the device is safe and effective for its intended use	Device is approved

The 510(k) pathway is the lawful, long-standing premarket route Congress created for moderate-risk devices — a defined regulatory standard of substantial equivalence. What follows are attributed critiques of that pathway published by two authoritative government and scientific bodies. These are their findings, in their words — not the conclusions of this firm.

Two Authoritative Critiques: GAO (2009) and the IOM/National Academies (2011)

GAO-09-190 (January 2009)

At the direction of Congress under the FDA Amendments Act of 2007, the U.S. Government Accountability Office (GAO) studied the 510(k) process and published GAO-09-190, Medical Devices: FDA Should Take Steps to Ensure That High-Risk Device Types Are Approved through the Most Stringent Premarket Review Process, on January 15, 2009. Source

Key findings, attributed to GAO:

Volume. Over FY2003–FY2007, the FDA “reviewed 13,199 submissions for class I and II devices via the 510(k) process, clearing 11,935 (90 percent).” Source
High-risk devices clearing via 510(k). The FDA “reviewed 342 submissions for class III devices through the 510(k) process, clearing 228 (67 percent) of these submissions.” Source
The reclassification gap (the central finding). “FDA cleared submissions for 24 types of class III devices through the 510(k) process. As of October 2008, 4 of these device types had been reclassified to class II, but 20 device types could still be cleared through the 510(k) process.” Source
GAO’s recommendation. “GAO recommends that FDA expeditiously take steps to issue regulations for class III device types currently allowed to enter the market via the 510(k) process by requiring PMAs or reclassifying them to a lower class.” Source

Importantly for accuracy: GAO’s data describe the situation as of October 2008, and GAO later closed this recommendation as implemented in December 2019, after the FDA completed reclassification or PMA requirements for the affected Class III device types. Source

IOM / National Academies (July 2011)

In July 2011 the Institute of Medicine (IOM) of the National Academies released Medical Devices and the Public’s Health: The FDA 510(k) Clearance Process at 35 Years, published by the National Academies Press. Source The FDA acknowledged the report and convened a public meeting on its recommendations. Source

The IOM committee’s findings, attributed to that committee:

What substantial equivalence does and does not establish. “The 510(k) process determines only the substantial equivalence of a new device to a previously cleared device, not the new device’s safety and effectiveness.” The committee framed the operative question as: “Is this device substantially equivalent to some other device whose safety and effectiveness may never have been assessed?” — in contrast to the PMA question, “Is this device reasonably safe and effective for its intended use?” Source
“Predicate creep.” “Current 510(k) decisions have been built on a chain of predicates dating back to devices on the market in 1976,” yet “[b]ecause data systems in the FDA are inadequate, the agency does not have the ability to trace the supporting decisions.” The committee warned that “[i]ncremental design changes are difficult to define and if poorly controlled can lead to device ‘creep,’ in which there is the potential for a marketed device to differ significantly from a device cleared.” Source
The “safety paradox.” A device can be “superior to its predicate and still be substantially equivalent to it,” but conversely “a product that was truly inferior to the current state of the art could still enter the market.” Source
Limited clinical testing. “In practice, clinical data play a very small role in the 510(k) process,” and “only 8% of 510(k) submissions for non–in vitro diagnostic devices contain clinical data” (a 2011-era figure). Source
Recommendation. The committee recommended that the FDA “gather the information needed to develop a new regulatory framework to replace the 35-year-old 510(k) clearance process.” Source

A New England Journal of Medicine editorial by Drs. Gregory Curfman and Rita Redberg supported the IOM committee’s recommendation that “the 510(k) process be replaced with an evaluation of safety and effectiveness.” Source

Two points of fairness and precision: the IOM’s conclusions are the findings of an expert committee, not an FDA admission — the FDA did not adopt the recommendation to replace the 510(k) program. And the design-change and degradation concerns the IOM raised in the abstract are explored, for mesh specifically, in the section on material degradation and immune reactions.

MAUDE: What the FDA’s Adverse-Event Database Can and Cannot Tell You

When a device may have caused or contributed to a death, serious injury, or malfunction, reports are filed with the FDA and collected in the Manufacturer and User Facility Device Experience (MAUDE) database — a searchable record of Medical Device Reports (MDRs). MAUDE is a powerful window into real-world experience, but the FDA is emphatic about its limits.

How it works. The online database “contains the last ten years of MDR data” and “will be updated every month to include reports received through the last day of the previous month,” with deeper historical files going back to the early 1990s. Source Reports come from manufacturers, importers, user facilities, and voluntary reporters. Source

The FDA’s own limitations (these must accompany any use of the numbers):

“MDR data is not intended to be used either to evaluate rates of adverse events, evaluate a change in event rates over time, or to compare adverse event occurrence rates across devices.” Source
“The submission of an MDR itself does not necessarily demonstrate that the device caused or contributed to the adverse outcome or event.” Source
“[A]lthough MDRs are a valuable source of information, this passive surveillance system has limitations,” and “[e]stablishing a causal relationship is especially difficult if circumstances surrounding the event have not been verified or if the device in question has not been directly evaluated.” Source

A peer-reviewed analysis of the very MAUDE data underlying the FDA’s transvaginal-mesh reclassification reinforced these caveats, finding the database “has limitations, including the potential submission of incomplete, inaccurate, untimely, unverified, or biased data,” that “true adverse event rates could not be accurately calculated because the number of total cases was unknown,” that “47% of medical device reports did not identify a reporter source,” and that there were “at least 64 duplicated MDRs.” Source

In short: a high report count signals a documented safety signal worth investigating — not a proven rate of harm.

What MAUDE shows for the most-litigated mesh category

For transvaginal/pelvic mesh, the FDA’s own July 2011 analysis searched MAUDE and “identified 2,874 Medical Device Reports (MDRs) for urogynecologic surgical meshes,” of which “1,503 were associated with pelvic organ prolapse (POP) repairs, and 1,371 were associated with stress urinary incontinence (SUI) repairs,” over 2008–2010. Source The most frequently reported complications mapped directly to the injuries catalogued elsewhere on this page — “vaginal mesh erosion (also called exposure, extrusion or protrusion), pain (including painful sexual intercourse known as dyspareunia), infection, urinary problems, bleeding, and organ perforation,” along with “recurrent prolapse, neuro-muscular problems, vaginal scarring/shrinkage and emotional problems.” Source (See mesh erosion, organ perforation, and chronic pelvic pain.)

A later peer-reviewed analysis counted 43,970 urogynecologic-mesh MDRs from August 2000 through January 2019, with 97.8% filed after the FDA’s 2011 Public Health Notification. Source The same study illustrates why raw counts must be read with care: of 645 death reports, 49.3% identified no cause of death and only about 0.6% could be directly attributed to the initial surgery. Source

MAUDE reports for bioabsorbable breast scaffolds (GalaFLEX and Phasix)

GalaFLEX and Phasix are FDA-cleared bioabsorbable poly-4-hydroxybutyrate (P4HB) surgical scaffolds (FDA product code OOD) that are frequently used off-label in breast surgery — an off-label use that is not FDA-cleared for the breast indication. Peer-reviewed studies of P4HB scaffolds in breast and plastic surgery exist and are discussed in bioabsorbable scaffold failure. Their MAUDE footprint can be reviewed directly in FDA systems.

The FDA MAUDE database can be queried by brand name to retrieve current report counts and the underlying detail records for GalaFLEX and Phasix; because those counts shift with each monthly update and are not a measure of any rate, readers should generate them live rather than rely on a static figure. (FDA MAUDE / openFDA Device Adverse Event API, device.brand_name search)

The substance of these reports — including infection, capsular contracture, mesh extrusion, migration, and revision/explant surgery — is reflected in the underlying FDA MAUDE detail records. For example, one MAUDE report describes a patient who “developed left breast infection 10 days post-op with mrsa,” with “temperature at 102f, requiring urgent removal of breast implant and mesh.” Source Another describes recurrent, grade IV capsular contracture leading to explantation of the scaffold. Source

One report cluster warrants careful, attributed handling. A 2022 MedWatch report (submitted, per the manufacturer’s own narrative, by a former company employee) alleged that P4HB material can activate a “pro-oncogenic” immune response in breast-cancer patients. The manufacturer’s response narrative disputed any causal relationship, stating that “a pro-oncogenic immune response is not a clinically anticipated outcome” and that its review “identified no increased concern”; that same response confirmed that “MDRs have been submitted in an abundance of caution … for reports of cancer recurrence associated with the indicated plastic surgeon in women with breast cancer, post-mastectomy,” while noting “[t]he surgeon did not identify any causal relationship between the cancer patient’s experiencing recurrence and the galaflex implant.” Source This is an unproven allegation paired with the manufacturer’s documented rebuttal — exactly the kind of MAUDE entry that should never be read as an established fact. These scaffold complications are discussed clinically in bioabsorbable scaffold failure and in the breast-scaffold manufacturer record.

Hernia and abdominal mesh in MAUDE

Hernia mesh is among the highest-volume mesh categories in MAUDE. The general surgical-mesh product code FTL and a broad generic-name search on “mesh” return very large report counts that span many different devices, manufacturers, and event types over decades — they emphatically do not represent a rate and should not be read as one. Because these counts change with each monthly database update, readers should generate them live rather than rely on a static figure. (FDA openFDA Device Adverse Event API, product code FTL and generic_name “mesh”) The clinical failure modes behind such reports are detailed in structural-failure injuries and visceral adhesions from intraperitoneal hernia mesh.

How to Look It Up Yourself

MAUDE is a public, searchable record, and patients and clinicians can query it directly:

MAUDE web interface — searchable by brand name, manufacturer, product code, event type, and date range. Each report has a stable detail page identified by its MDR Report Key. Source
openFDA Device Adverse Event API — a machine-readable, monthly-updated mirror at api.fda.gov/device/event.json. openFDA carries its own caution that users “should assume all results are unvalidated.” Source

What Medical Societies and FDA Advisory Panels Have Concluded

Expert review did not end with clearance. Over more than a decade, FDA advisory panels and the major medical societies took clear, public positions on surgical mesh — and a critical distinction runs through all of them.

The hard line: transvaginal POP mesh vs. the SUI midurethral sling. The regulatory and scientific record sharply separates two different polypropylene products. Transvaginal mesh for pelvic organ prolapse (POP) was escalated by the FDA from a 2008 advisory, to a 2011 “serious adverse events are NOT rare” finding, to Class III reclassification in 2016, to an order in 2019 directing manufacturers to stop selling and distributing the affected POP-mesh devices. The mesh midurethral sling for stress urinary incontinence (SUI) is a different device that the FDA never ordered off the market and that the relevant medical societies continue to call the standard of care. A factually careful page keeps these two products separate. The full FDA chronology is detailed in the section on FDA action on surgical mesh.

FDA advisory-panel findings

At the September 8–9, 2011 Obstetrics and Gynecology Devices Panel, the FDA considered the recommendation that transvaginal POP mesh “be reclassified from Class II … to Class III,” while the panel “also recommended that surgical mesh for SUI and surgical mesh for abdominal repair of POP remain in Class II.” Source On the SUI sling specifically, the panel record states “[t]he safety and effectiveness of multi-incision slings was well-established in clinical trials,” with an average reported mesh-erosion rate “at one year following SUI surgery with mesh … [of] approximately 2 percent.” Source

The February 12, 2019 Ob-Gyn Devices Panel then addressed the evidentiary bar for POP mesh: it “concluded that to support a favorable benefit/risk, surgical mesh for transvaginal repair of prolapse should be superior to native tissue repair at 36 months.” Source

Medical-society position statements

AUGS and SUFU. The joint statement of the American Urogynecologic Society (AUGS) and the Society of Urodynamics, Female Pelvic Medicine and Urogenital Reconstruction (SUFU) defends the SUI midurethral sling — not POP mesh — stating that “[t]he polypropylene mesh midurethral sling is the recognized worldwide standard of care for the surgical treatment of stress urinary incontinence” and that “[t]he procedure is safe, effective, and has improved the quality of life for millions of women.” Source The societies also expressly warned that media and advertising attention had “resulted in confusion, fear, and an unbalanced negative perception regarding the midurethral sling,” emphasizing that “[t]he midurethral sling was not the subject of the 2011 FDA Safety Communication.” Source
ACOG. In Committee Opinion No. 694 (developed jointly with AUGS), the American College of Obstetricians and Gynecologists addressed management of mesh and graft complications, cautioning on referral and on over-treatment that “[m]esh removal surgery should not be performed unless there is a specific therapeutic indication.” Source ACOG and AUGS also issued a Practice Bulletin on pelvic organ prolapse published in Obstetrics & Gynecology. Source

The bottom line on expert review. Multiple independent layers of authority — the FDA’s 2011 finding, its 2016 Class III reclassification, the 2019 order to stop selling and distributing the affected POP-mesh devices, and the FDA’s standing post-2019 view — align against transvaginal POP mesh, while the SUI sling, abdominal/sacrocolpopexy mesh, and other indications occupy a different regulatory category. The 510(k) clearance history, the MAUDE signal, the GAO and IOM critiques, and these society statements together help explain why the documented record on certain mesh products is what it is — and why patients deserve neutral, primary-sourced information rather than marketing.

This page is legal and medical information, not advice; reading it does not create an attorney-client relationship, and prior results do not guarantee a similar outcome. Always consult your own physician about your implant and care. If you or a loved one has been affected by a surgical mesh or breast-scaffold complication and you have questions about your situation, our team offers a free, confidential consultation.

◀ FDA Action on Surgical Mesh: 2008 → 2011 → 2016 → the 2019 Ban · ↑ Top · What the Rest of the World Did: UK, Australia, Scotland, Canada & the EU ▶

What the Rest of the World Did: UK, Australia, Scotland, Canada & the EU

The United States was not alone in confronting surgical mesh. Over the same decade that the U.S. Food and Drug Administration was escalating its own response (see FDA Action on Surgical Mesh), regulators, parliaments, and courts in the United Kingdom, Scotland, Australia, New Zealand, Canada, and across the European Union reviewed the same devices and reached strikingly similar conclusions: that non-absorbable synthetic mesh implanted through the vagina to treat pelvic organ prolapse (POP) and stress urinary incontinence (SUI) carried serious, sometimes irreversible complications. The result was a wave of suspensions, restrictions, and effective bans — and, in two countries, formal national apologies and a landmark class-action settlement.

This section reports those actions as a matter of public record, attributed to each regulator, government body, court, or news organization of record. For patients, it matters because it shows that concerns about these devices were documented and acted upon by independent authorities in multiple countries. This is educational information, not medical or legal advice. A consistent thread runs through every jurisdiction: most actions targeted transvaginal/pelvic mesh specifically, and many expressly left hernia mesh and certain abdominally placed mesh on the market — a distinction the official sources are careful to draw, and one that also runs through the injuries described elsewhere on this page.

The United Kingdom: the Cumberlege “First Do No Harm” Review and the 2018 NHS England Pause

The July 2018 NHS England “high vigilance restriction.” On 10 July 2018, the UK Government and NHS announced a national “pause” in the use of surgical mesh and tape for stress urinary incontinence and for vaginally inserted prolapse mesh, implemented as a “high vigilance restriction period.” The Department of Health and Social Care described it as a regime of “strict rules for the use of vaginal mesh” Source. The NHS England / NHS Improvement letter to acute-trust chief executives and medical directors instructed that “all cases should be postponed if it is clinically safe to do so,” while excepting cases of genuine clinical urgency such as cancer procedures, subject to a multidisciplinary-team decision and informed consent Source.

The Government emphasized that this was not a ban: “These procedures have not been banned and during this pause, they will continue to be used when there is no viable alternative and after close and comprehensive consultation between patient and clinician” Source. The restriction was tied to six conditions that had to be met before it could be lifted — including that surgeons be appropriately trained and operate regularly, that every procedure be reported to a national database and register, that complication reporting be linked to that register through the MHRA, that specialist centres be accredited, and that NICE guidelines on mesh for SUI be published Source. At the time of the pause, the NHS letter recorded that approximately 7,245 tape procedures for SUI had been performed in England in 2016/17, a figure that had fallen 48% since 2008/9 Source.

The Cumberlege Review — “First Do No Harm.” The pause was recommended by Baroness Julia Cumberlege, chair of the Independent Medicines and Medical Devices Safety (IMMDS) Review, which had been announced in February 2018 to examine three interventions — Primodos hormone pregnancy tests, sodium valproate, and pelvic mesh. The Review published its report, “First Do No Harm,” on 8 July 2020 Source. The Review reported that its panel “met and listened to over 700 people, mostly women,” and chose its title because the work “has been about people who have suffered avoidable harm” Source.

The Review’s central finding about the healthcare system, in its own words, was that the system “is disjointed, siloed, unresponsive and defensive,” and that “when, belatedly, it has decided to act it has too often moved glacially” Source. Describing the harm reported by women, the Review wrote that they had “spoken of excruciating chronic pain feeling like razors inside their body, damage to organs, the loss of mobility and sex life and depression and suicidal thoughts” Source — injuries this page examines in detail under chronic pelvic pain, mesh erosion, and psychological sequelae. The Review also recorded that patients “spoke of being ‘gaslighted’ and of not being believed, particularly in relation to pelvic mesh and the suffering of pain” Source.

The report made nine strategic recommendations, supplemented by 50 Actions for Improvement. They included a Government apology; the appointment of an independent Patient Safety Commissioner; the creation of a Redress Agency and separate redress schemes for each intervention; networks of specialist mesh-treatment centres; substantial revision of the MHRA’s adverse-event reporting and device regulation; a central patient-identifiable device database; and improved transparency of payments to clinicians Source. The UK Government issued an apology on behalf of the healthcare system, accepted the Patient Safety Commissioner, and commissioned a network of specialist mesh-complication centres in England Source.

For context, transvaginal prolapse (POP) mesh had already been restricted in the UK before the 2018 SUI pause: following the 2017 Scottish Independent Review and a change in NICE guidance, the IMMDS report records that “transvaginal POP mesh surgery has been restricted to research trials only” Source. The recognized complications of pelvic mesh, as listed by the UK Patient Safety Commissioner, include “pain, erosion, voiding dysfunction, infection, recurrent UTIs, fistulae, organ perforation, bleeding, vaginal scarring, neuromuscular alterations, lower urinary tract symptoms and bowel complications” Source.

Date	UK event
Dec 2017	Transvaginal POP mesh restricted to research only after NICE guidance change Source
Feb 2018	IMMDS Review announced, chaired by Baroness Cumberlege Source
10 July 2018	NHS England “high vigilance restriction” — effective pause on SUI/vaginal mesh Source
8 July 2020	“First Do No Harm” published — 9 recommendations + 50 Actions Source

Scotland: the Mesh Suspension and Effective Halt

Scotland acted before the rest of the UK, in a three-stage sequence. On 17 June 2014, the then Cabinet Secretary for Health, Alex Neil MSP, announced an independent review and “requested that Health Boards consider suspending routine use of synthetic mesh for these procedures until the review reported its findings” Source. Because the 2014 measure was a request rather than a legal mandate, it was not uniformly observed, which is part of why a firmer instruction followed.

The Independent Review published its final report in March 2017. It “did not go as far as banning implants, but concluded that mesh must not be routinely offered as a treatment and that women should have access to clear advice to help them make informed choices,” and recorded that NHSScotland claims relating to vaginal implants in women with SUI and POP “increased to 426 as at February 2017” Source.

On 12 September 2018, Health Secretary Jeane Freeman told the Scottish Parliament: “I have today asked the chief medical officer to instruct health boards immediately to halt the use of transvaginal mesh altogether,” pending a high-vigilance restricted-use protocol and individual sign-off by the medical director Source. The Scottish Government described the action as a “halt in use of transvaginal mesh” Source. As The Scotsman later reported, mesh “have not been used in vaginal surgeries in Scotland since 2018,” while transabdominal mesh remained “under active review and subject to high vigilance procedures” Source. The Scottish halt did not extend to hernia mesh, which has been the subject of separate patient concern and reporting Source.

Australia: the TGA Removal, a National Apology, and a Landmark Class-Action Settlement

The TGA’s 2017 action. Australia’s Therapeutic Goods Administration (TGA) reviewed the clinical evidence for transvaginal mesh and, on 28 November 2017, “decided to remove transvaginal mesh products whose sole use is the treatment of pelvic organ prolapse via transvaginal implantation from the Australian Register of Therapeutic Goods (ARTG),” concluding that “the benefits of using transvaginal mesh products in the treatment of pelvic organ prolapse do not outweigh the risks these products pose to patients” Source. Effective 4 January 2018, transvaginal POP mesh and single-incision mini-slings for SUI “were removed from the ARTG and are now unavailable for legal supply in Australia.” The TGA drew a specific distinction: “mini-slings are different devices to mid-urethral slings, which have not been removed from the ARTG” Source. The TGA cited reported complications including punctures or lacerations of vessels, nerves, or organs; mesh extrusion, exposure, or erosion; infection; and severe chronic pain, with pain and erosion the most common adverse events Source.

The Senate inquiry and national apology. The Senate Community Affairs References Committee inquired into transvaginal mesh and reported on 28 March 2018, finding that the devices “have caused unnecessary physical and emotional pain and suffering to thousands of women who were not told by their doctors of the objective material risks associated with their use,” and making 13 recommendations Source. On 10 October 2018, federal Health Minister Greg Hunt delivered a national apology to affected women: “On behalf of the Australian government, I say sorry to all of those women with the historic agony and pain that has come from mesh implantation which have led to horrific outcomes” Source. The government’s response, tabled the same day, “supports, or supports in principle, 12 of the 13 recommendations” Source.

The Gill v. Ethicon class action and AU$300 million settlement. A class action against Johnson & Johnson and Ethicon proceeded in the Federal Court of Australia. In Gill v Ethicon Sàrl (No 5) [2019] FCA 1905, decided 21 November 2019, Justice Katzmann found in favour of the applicants on both defective-goods and negligence claims across nine polypropylene mesh devices, holding that each device “had a defect,” that the warnings “did not warn of certain risks” and contained “false statements and half-truths,” and that “pre-market evaluations conducted by Ethicon evinced a want of reasonable care” Source. The court awarded the three lead applicants — Kathryn Gill, Diane Dawson, and Ann Sanders — a combined total of more than AU$2 million Source. The Full Court of the Federal Court dismissed Ethicon’s appeal in Ethicon Sàrl v Gill [2021] FCAFC 29 (5 March 2021) Source, and the High Court of Australia refused special leave to appeal on 5 November 2021 Source.

After liability was upheld, the parties reached an in-principle settlement in September 2022, and the Federal Court approved an AU$300 million settlement on 16 March 2023 in Gill v Ethicon Sàrl (No 10) [2023] FCA 228, in proceedings the court records as involving thousands of group members Source. (The AU$300 million figure and the widely reported ≈US$205 million describe the same award expressed in different currencies, not two separate amounts.) This Australian litigation parallels the documented U.S. record against the same manufacturer, set out under Johnson & Johnson / Ethicon.

New Zealand: Medsafe Removes Pelvic Mesh from Supply

Following Australia’s TGA action, New Zealand’s medicines regulator, Medsafe, used the Medicines Act 1981 to require safety information from suppliers and characterized the measure as “the strongest action possible under current legislation” Source. Effective 31 January 2018, the affected mesh products were no longer supplied; the NZ Herald reported that “nine surgical mesh products were removed from supply in New Zealand after Medsafe took regulatory action” Source. The scope covered all transvaginal POP mesh plus one single-incision mini-sling for SUI and did “not affect the ongoing supply of surgical mesh products for other uses such as hernia repair” Source. Medsafe identified that “return of symptoms and erosion (into the vagina or rectum) were the most common problems associated with these devices” Source.

Canada: Health Canada Removes and Restricts Transvaginal POP Mesh

On 26 July 2019, following a safety review, Health Canada removed the highest-risk transvaginal mesh use from the market and restricted the remainder. It concluded that non-absorbable synthetic transvaginal mesh “should no longer be used to treat a type of POP known as ‘posterior compartment’ POP,” because that use “is associated with an increased risk of complications compared to alternative treatment options.” For anterior or apical prolapse, mesh “should only be used for patients who have significant risk factors for recurrence of POP or recurrent POP, or for whom alternative surgical treatments are not appropriate” Source. The three manufacturers then licensed for this use — Coloplast A/S, Boston Scientific Corp., and Cousin Biotech — all indicated they were no longer selling such mesh in Canada Source.

Health Canada cited risks including “abdominal pain, pain during sexual intercourse, repeated infections, urinary problems, organ perforation, nerve damage, and mesh erosion (or exposure) through surrounding tissues,” and noted that complications could be irreversible because the mesh “is not designed to be removed” Source — a difficulty discussed on this page under mesh ingrowth and fibrotic encapsulation. CBC News reported that, for posterior prolapse specifically, the mesh “poses a greater risk of complications including pain, repeated infections, and mesh erosion through surrounding tissues” Source.

The European Union: the SCENIHR Scientific Opinion

At the EU level, action took the form of an authoritative scientific opinion rather than a bloc-wide ban (which is a matter for individual member states). On 3 December 2015, the EU’s Scientific Committee on Emerging and Newly Identified Health Risks (SCENIHR) adopted its final opinion on the safety of surgical meshes used in urogynaecological surgery. The committee “does not advocate” transvaginal synthetic mesh for POP, stating that “the implantation of any mesh for the treatment of POP via the vaginal route should be only considered in complex cases in particular after failed primary repair surgery” Source. It explained that transvaginal POP surgery “involves a much greater surface area of mesh and is associated with a higher risk of mesh-related morbidity than seen with trans-abdominal insertion of this mesh” Source. The committee identified complications including “infection, tissue extrusion, separation of vaginal epithelium leading to mesh exposure, mesh shrinkage and adverse side effects including pain and sexual dysfunction” Source — see mesh contraction and dyspareunia. For SUI, by contrast, SCENIHR supported continuing synthetic sling surgery, calling it “an accepted procedure with proven efficacy and safety in the majority of patients with moderate to severe SUI, when used by an experienced and appropriately qualified surgeon” Source.

Jurisdiction	Issuing body	Date	Action
Scotland	Health Secretary / CMO	12 Sept 2018	Instruction to “halt the use of transvaginal mesh altogether” Source
Australia	TGA	4 Jan 2018	POP mesh + single-incision mini-slings removed from ARTG Source
New Zealand	Medsafe	31 Jan 2018	Nine pelvic mesh products removed from supply Source
Canada	Health Canada	26 July 2019	Posterior-compartment POP mesh removed; anterior/apical restricted Source
European Union	SCENIHR	3 Dec 2015	Scientific opinion: do not advocate transvaginal POP mesh except complex/failed cases Source

The 2018 ICIJ “Implant Files” Investigation

In November 2018, the International Consortium of Investigative Journalists (ICIJ) published the Implant Files, which it described as the “first-ever global examination of the medical device industry” and which found that “health authorities across the globe have failed to protect millions of patients from poorly tested implants” Source. The collaboration involved more than 250 reporters and data specialists at 58 news organizations across 36 countries, analyzing some 8 million device-related records, including 5.4 million FDA adverse-event reports Source.

The investigation’s central, widely cited finding was that “manufacturers, doctors, and others potentially linked more than 1.7 million injuries and nearly 83,000 deaths to medical devices in reports to U.S. regulators over the last decade” Source. It is important to read those figures precisely: they are adverse-event reports, not adjudicated findings of causation. ICIJ itself noted that “doctors and manufacturers often fail to report adverse events, and when they do the information can be unverified and incomplete” Source. The nature and limits of adverse-event reporting are explained on this page under How These Devices Reached the Market.

Surgical (pelvic/transvaginal) mesh was among the devices featured most prominently. ICIJ reported that “more than 100,000 women worldwide have filed lawsuits” alleging harm from mesh products — a figure consistent with the scale of the U.S. mesh litigation Source. The investigation also amplified peer-reviewed work by Carl Heneghan and colleagues at Oxford’s Centre for Evidence-Based Medicine, published in BMJ Open in 2017, which traced transvaginal POP mesh devices cleared through the FDA’s 510(k) substantial-equivalence premarket pathway back through a chain of predicate devices to original devices first marketed in 1985 and 1996 Source. (The full citation: Heneghan CJ, Goldacre B, Onakpoya I, et al., BMJ Open 2017;7:e017125, doi:10.1136/bmjopen-2017-017125 Source.)

Taken together, the international record shows that the same devices examined in the United States were reviewed by independent regulators and reviews on four continents, that those bodies documented a consistent pattern of serious complications, and that several governments restricted, removed, or effectively halted transvaginal mesh for prolapse — while generally preserving hernia mesh and, in most jurisdictions, SUI slings.

If you or a loved one has been affected by a surgical or breast-mesh device, our team offers a free, confidential consultation. This page is intended as legal and medical information, not advice; reading it does not create an attorney-client relationship, and prior results do not guarantee a similar outcome. It is not a substitute for the care of your own physician, and you should consult your doctor about any device you have received.

◀ How These Devices Reached the Market: 510(k), MAUDE Reporting & Expert Review · ↑ Top · Frequently Asked Questions ▶

Frequently Asked Questions

This section answers the questions patients and families most often ask about surgical mesh, breast scaffolds, and the injuries associated with them. The answers below are general legal and medical information, not advice — reading them does not create an attorney-client relationship, and nothing here is a substitute for the care of your own physician. Where a question touches on your specific health or a possible legal claim, the right next step is to speak with a qualified professional. We have tried to keep every answer plain-English, accurate, and tied to primary sources you can check yourself.

What is surgical mesh, and what is a breast “scaffold”?

Surgical mesh is a screen- or net-like material implanted to reinforce weakened tissue — most commonly to repair a hernia or, historically, to support the pelvic organs in women. A breast “scaffold” or acellular dermal matrix (ADM) is a related material used in breast reconstruction or augmentation to create an internal sling or pocket that supports an implant. These products are made from different materials (knitted polypropylene, processed human or animal tissue, or bioabsorbable polymers such as poly-4-hydroxybutyrate). For a full plain-English explanation of each type and how it is meant to work, see What Surgical Mesh and Breast Scaffolds Actually Are.

What injuries have been associated with surgical mesh?

The U.S. Food and Drug Administration’s July 2011 Safety Communication on transvaginal pelvic mesh listed the most frequent complications as “vaginal mesh erosion (also called exposure, extrusion or protrusion), pain (including painful sexual intercourse known as dyspareunia), infection, urinary problems, bleeding, and organ perforation.” Source These map to the injury categories described in detail elsewhere on this page, including structural-failure injuries, mesh erosion, exposure and extrusion, perforation of the bladder, bowel or ureter, chronic pelvic and nerve pain, and infection and inflammatory complications.

How do I know whether my mesh or scaffold is causing a problem?

Only a physician can answer that. Symptoms that patients have reported — and that appear in the FDA’s safety communications — include persistent or worsening pain, painful intercourse, recurrent infections or urinary tract infections, unusual discharge or bleeding, swelling, or a sense that the original repair has failed. Source None of these is unique to mesh, which is exactly why evaluation by your own doctor is essential. This page is educational and cannot diagnose anything; if you are concerned, seek prompt medical attention. The broader pattern of recurring injuries is discussed under structural-failure injuries and pain, nerve and quality-of-life injuries.

Does the mesh have to be removed?

That is a medical decision for you and your surgeon — never one to make based on a web page. It is worth knowing that the FDA has not recommended removing already-implanted mesh from patients who are not having problems. In its November 9, 2023 Letter to Health Care Providers about certain Becton Dickinson mesh products, the FDA stated it “is not recommending reoperation or removal of implanted surgical mesh in asymptomatic patients.” Source Similarly, in its 2021 Safety Communication on ADM products used in breast reconstruction, the FDA did not recommend reoperation or removal as a preventive measure. Source Court records also reflect that, when removal is attempted, mesh can be difficult or impossible to remove safely — in the first pelvic-mesh trial, the record described conclusions that, after multiple surgeries, the devices could not be removed safely. (California Court of Appeal opinion in the C.R. Bard pelvic-mesh appeal; see The Scale of Mesh Litigation for the public-record citation.) These are exactly the kinds of facts to discuss with your physician; see also mesh ingrowth and fibrotic encapsulation.

Were these breast scaffolds approved by the FDA for use in the breast?

No. The FDA has stated plainly that “There are no surgical mesh products cleared or approved by the FDA for use in breast surgery, including in augmentation or reconstruction,” and that “the agency has not determined the safety and effectiveness of surgical mesh products, including the BD products, when used in breast surgery.” Source In a separate 2021 communication, the FDA said it “has not cleared or approved any ADM product for use in breast reconstruction.” Source Products such as GalaFLEX and Phasix are FDA-cleared bioabsorbable poly-4-hydroxybutyrate (P4HB) surgical scaffolds; their use in the breast is off-label — that is, outside the indication for which they were cleared. The breast-scaffold story is covered in depth under Breast Reconstruction & Scaffold Injuries and breast scaffold manufacturers.

Is “off-label” use legal? Did my surgeon do something wrong?

Off-label use by a physician is legal. The FDA does not regulate the practice of medicine, and once a device is legally on the market a physician may, in the exercise of medical judgment, use it for a purpose other than the one for which it was cleared. As one peer-reviewed orthopedic-legal review explains, “FDA approval of a drug or device pertains to regulatory compliance only, with no relation to the practice of medicine,” and “Physicians have the discretion to use a drug or medical device in an off-label manner, if such use is of benefit to the patient.” Source What the law treats differently is promotion: a manufacturer “may not, in any way, promote off-label use of its product to the user surgeons.” Source That use-versus-promotion distinction is central to how breast-scaffold cases are framed; see the breast-scaffold record.

Has surgical mesh been the subject of lawsuits?

Yes — and extensively, in the case of transvaginal (pelvic) mesh. That litigation is one of the largest mass-tort proceedings in U.S. history: the Southern District of West Virginia consolidated the devices into seven coordinated multidistrict litigations (MDL Nos. 2187, 2325, 2326, 2327, 2387, 2440, and 2511) before U.S. District Judge Joseph R. Goodwin. Source Across all manufacturers, reporting of record has described the combined settlements and verdicts as reaching into the billions of dollars; because many settlements are confidential, the full total is not publicly itemized. Source For the full picture — including the major verdicts and the government judgments — see The Scale of Mesh Litigation.

Have juries actually awarded money in these cases?

Yes, in a number of individual cases, and courts have upheld several on appeal. To give just a few examples from the public record: a Kern County, California jury returned an early pelvic-mesh verdict of $5.5 million against C.R. Bard in 2012, later upheld on appeal by the California Court of Appeal. (California Court of Appeal opinion affirming the Kern County pelvic-mesh judgment against C.R. Bard.) A federal jury in the first MDL bellwether (Cisson v. C.R. Bard) awarded $2 million, affirmed by the U.S. Court of Appeals for the Fourth Circuit in 2016. (U.S. Court of Appeals for the Fourth Circuit, Cisson v. C.R. Bard, Inc., 2016.) Separately, in 2020 a California court entered a judgment of nearly $344 million against Johnson & Johnson and its Ethicon unit in an action the California Attorney General brought alleging deceptive marketing of pelvic mesh. Source It is important to understand that these are individual public-record outcomes; they are not promises, and prior results do not guarantee a similar outcome in any other case. More verdicts and judgments are catalogued in The Scale of Mesh Litigation.

What is the status of breast-scaffold (GalaFLEX) lawsuits?

This is a newer and much smaller body of litigation, and accuracy here matters. As of mid-2026, the breast-mesh litigation involving GalaFLEX has been reported to be at an early, individual-filing stage; there is no consolidated MDL, no class action, no reported settlement, and no reported jury verdict. Source Plaintiffs in those early cases have alleged that the scaffolds were defectively designed and were sold for breast surgery despite the lack of FDA clearance or approval for that specific use. Source Those are allegations, not findings. The underlying regulatory facts are detailed under breast scaffold injuries and the breast-scaffold manufacturer record.

Is there a deadline to take legal action?

There can be. Every state has a statute of limitations — a legal deadline for filing a claim — and the time period varies depending on the state, the type of claim, and the specific facts (including when an injury was, or reasonably should have been, discovered). Because these rules differ so much and can be unforgiving, the general guidance is simple: do not wait to find out. If you think you may have a claim, the prudent course is to consult an attorney promptly so your specific deadline can be evaluated. We cannot state a single deadline here because there isn’t one that applies to everyone. For background on why timing and the litigation timeline matter, see The Scale of Mesh Litigation.

What might a claim be worth?

There is no responsible way to put a number on that in advance. Every case is different, and the outcome depends on facts unique to each person — the device involved, the injuries, the medical care required, and many other factors. The public-record verdicts and judgments described on this page ranged widely and were specific to those cases; they are not a forecast for any other case, and no outcome can be guaranteed. No one can responsibly quote a specific figure before reviewing the particulars of your situation. A qualified attorney can explain how value is assessed, but only after learning the specific facts of your case. See The Scale of Mesh Litigation for the documented range of past outcomes.

What does it cost to talk to a lawyer, and how do legal fees work?

A consultation with our firm is free and confidential. Cases of this kind are typically handled on a contingency-fee basis, which means the law firm’s fee is a percentage of any recovery and is paid only if there is a recovery — if there is no recovery, you do not owe an attorney’s fee. The specific percentage and how case costs are handled are set out in a written agreement and explained to you before you sign anything. The general principle is straightforward: you should be able to understand your options without an upfront bill. You can learn more about our team and approach in About Attorney 911.

Who is publishing this page, and can I rely on it as medical or legal advice?

This page is published by The Manginello Law Firm, PLLC (Attorney 911) as a patient-education and attorney-advertising resource. Our team has decades of experience representing seriously injured Texans, and the firm is the author and guide behind this page. But the page is information, not advice: it does not create an attorney-client relationship, it is not a substitute for professional medical care, and prior results do not guarantee a similar outcome. For your health questions, consult your own physician; for the specifics of a possible claim, speak with a lawyer about your individual facts. Please review the Important Disclaimers and learn more about the team behind this guide.

What should I do if I think I or a loved one has been harmed by mesh?

First, see your physician about your symptoms and your medical options — that is the most important step, and it comes before anything legal. Keep your medical records and any information you have about the device that was implanted (the manufacturer, product name, and the dates of your surgeries are especially useful). If you would then like to understand your legal options, our team offers a free, confidential consultation. There is no obligation, and any deadline that may apply to your situation can be reviewed at that time. For more on the injuries and the litigation that frame these questions, see structural-failure injuries, breast scaffold injuries, and The Scale of Mesh Litigation.

◀ What the Rest of the World Did: UK, Australia, Scotland, Canada & the EU · ↑ Top · About Attorney 911 — The Manginello Law Firm, PLLC ▶

About Attorney 911 — The Manginello Law Firm, PLLC

This guide is published by The Manginello Law Firm, PLLC, a Houston, Texas law firm that practices under the brand Attorney 911. We prepared it as a plain-English reference for patients and families trying to understand surgical and breast-mesh injuries — what these devices are, how they can fail in the body, and what the public record actually shows about the companies that made them. Our aim throughout has been education first: to be the calm, knowledgeable guide a worried reader needs, not a sales pitch. For more on why we wrote this page and how to read it, see About This Guide — and the Team Behind It.

Who we are

The Manginello Law Firm, PLLC is a Texas firm that represents seriously injured people, with its principal office in Houston.

Principal office: 1177 West Loop South, Suite 1600, Houston, TX 77027
General phone: 1-888-ATTY-911
Web: attorney911.com

Our practice centers on personal-injury and catastrophic-injury matters for Texans. We are a small, hands-on firm by design — clients work directly with the attorneys handling their case rather than being passed down a chain. The complications described throughout this guide, from structural failure and erosion to chronic pain and breast-reconstruction injuries, are exactly the kind of serious, life-altering harm our team focuses on.

The attorneys behind this guide

Ralph P. Manginello — Managing Partner. Ralph founded the firm in 2001 and serves as its managing partner. He has been licensed to practice in Texas since 1998 — more than two and a half decades — and is admitted to the U.S. District Court for the Southern District of Texas. He earned his B.A. in Journalism from the University of Texas and his J.D. from South Texas College of Law. His Texas licensure and standing are matters of public record with the State Bar of Texas (State Bar of Texas, Find a Lawyer).

Lupe Peña — Associate Attorney. Lupe has been licensed to practice in Texas since 2012 and is admitted to the U.S. District Court for the Southern District of Texas. He earned his B.B.A. in International Business from St. Mary’s University and his J.D. from South Texas College of Law Houston. Before joining the firm, he practiced at a national insurance-defense firm, handling cases from the other side of the table — experience that informs how our team anticipates the strategies an injured client may face. Lupe is fluent in Spanish and provides full Spanish-language consultations, so Spanish-speaking families can get answers in their own language.

Both attorneys are licensed in Texas and the federal courts noted above only. This guide is offered as attorney advertising and as legal and medical information, not legal advice; reading it does not create an attorney-client relationship. Please see the Important Disclaimers for the full statement.

What clients say

Because trust matters when you are choosing who to call, we encourage readers to look to third-party sources they can check for themselves rather than to claims we make about ourselves. The firm maintains a public Google Business Profile under “Attorney 911 | Manginello Law Firm,” and we invite you to read those reviews directly and form your own judgment. Prior results do not guarantee a similar outcome, and every case is unique.

The Attorney 911 app

Consistent with how we work, we built the free Attorney 911 mobile app to put clear information and an easy way to reach a real person in your pocket — a quick, confidential way to ask a question, start a conversation, or organize the facts of what happened to you. It reflects the same idea behind this guide: people facing a medical-device injury deserve straightforward answers and direct access to counsel.

Our approach to mesh and device-injury cases

Surgical-mesh and breast-scaffold injuries are complex. They sit at the intersection of medicine, federal device regulation, and a sprawling litigation history — much of it summarized in The Big Picture: The Scale of Mesh Litigation in the U.S. and Worldwide and detailed in the manufacturer record sections that follow. We approach these matters the way we approach all of our work: methodically, with attention to the medical facts and the documented public record, and with respect for what an injured person is going through.

This page is educational information, not medical or legal advice, and it does not create an attorney-client relationship; it is not a substitute for professional medical care, and you should consult your own physician about your device and your health. No outcome is guaranteed, and prior results do not guarantee a similar outcome.

If you or a loved one has been affected by a surgical-mesh or breast-scaffold injury, our team offers a free, confidential consultation. You can reach The Manginello Law Firm, PLLC, Attorney 911, by phone at 1-888-ATTY-911 or through attorney911.com or the Attorney 911 app. There is no obligation, and the conversation is private.

◀ Frequently Asked Questions · ↑ Top · Important Disclaimers ▶

Important Disclaimers

Please read the following carefully. This page is a patient-education and legal-information resource published by The Manginello Law Firm, PLLC (“Attorney 911”). The disclaimers below govern how the information on this page may be used and explain the limits of what it offers. They appear at the end because the goal of everything above is to inform you clearly and accurately — but these terms are an essential part of that goal.

1. Attorney advertising. This page is attorney advertising. It is intended to provide general legal and medical information of interest to the public and to describe the kinds of matters our firm handles. It is not, and should not be read as, a promise or guarantee about the outcome of any specific matter.

2. Information, not advice. The content on this page — including descriptions of medical devices, injuries, clinical complications, regulatory history, and litigation — is provided for general educational and informational purposes only. It is not legal advice and not medical advice, and it cannot account for the specific facts of your situation. Laws, deadlines, and medical circumstances vary by individual and change over time. Do not act, or refrain from acting, on the basis of anything on this page without seeking professional advice tailored to your circumstances. For background on who prepared this material and the editorial standards behind it, see About This Guide — and the Team Behind It and About Attorney 911 — The Manginello Law Firm, PLLC.

3. No attorney-client relationship. Reading this page, contacting our firm, or sending us information through any form, email, telephone call, or message does not create an attorney-client relationship. No such relationship is formed until we have checked for conflicts of interest, agreed to represent you, and you have signed a written representation agreement with the firm. Until that happens, please do not send us confidential or time-sensitive information, and understand that information you send may not be treated as privileged.

4. Prior results do not guarantee a similar outcome. Every case is unique and is decided on its own facts and law. Any reference on this page or elsewhere on this site to past matters, experience, or results does not guarantee or predict a similar outcome in any future matter. Descriptions of litigation, jury verdicts, settlements, recalls, or regulatory actions involving the devices and manufacturers discussed here describe matters of public record and do not imply that any particular reader has a viable claim or that any particular result is achievable.

5. Not a substitute for medical care. Nothing on this page is a substitute for professional medical evaluation, diagnosis, or treatment. The descriptions of mesh and scaffold complications — for example erosion and exposure, infection, chronic pelvic pain, or bioabsorbable scaffold failure — are general summaries, not statements about any individual’s condition. Always consult your own physician or a qualified healthcare provider about your symptoms, your implanted device, and any decision regarding monitoring, treatment, or surgery. This page does not tell any reader to remove, retain, or alter any medical device; those are medical decisions for you and your treating physicians. If you are experiencing a medical emergency, call 911 or seek immediate care.

6. Intended for adults. This material concerns serious medical and legal subjects and is intended for an adult audience. It is not directed to children.

7. Responsible attorney and licensure. This advertisement is published by The Manginello Law Firm, PLLC, whose principal office is in Houston, Texas. The attorney responsible for this content is Ralph P. Manginello. Our attorneys are licensed to practice in the State of Texas and before the federal courts in which they are admitted; nothing on this page is intended as a solicitation in any jurisdiction where the firm is not authorized to practice or where such advertising would not comply with that jurisdiction’s rules. We do not claim to be certified specialists in any field unless that certification is separately and expressly stated and verifiable. Additional information about the firm and its attorneys appears in About Attorney 911 — The Manginello Law Firm, PLLC.

8. Third-party names and references. Product, company, brand, and device names referenced on this page — including the names of manufacturers and their products discussed in sections such as the documented record on Becton Dickinson / C.R. Bard / Davol and Johnson & Johnson / Ethicon — are the property of their respective owners and are used here only for identification, education, and commentary. Their use does not imply any affiliation with, sponsorship by, or endorsement by those owners. References to lawsuits, verdicts, settlements, recalls, regulatory communications, and other proceedings describe matters of public record, are attributed to their sources, and do not constitute or imply any current claim or assertion by this firm about any specific product, company, or person.

If you or a loved one has been affected by a surgical mesh or breast scaffold complication, our team offers a free, confidential consultation. Contacting us costs nothing and creates no obligation.

◀ About Attorney 911 — The Manginello Law Firm, PLLC · ↑ Top

Surgical&Breast Mesh Injuries: The Complete Patient Guide

Free Case Evaluation

Surgical & Breast Mesh Injuries: The Complete Patient Guide

About This Guide — and the Team Behind It

Who wrote this

How to use this guide

What Surgical Mesh and Breast Scaffolds Actually Are

Breast scaffolds and the “internal bra”

Broadening the lens: pelvic mesh and hernia mesh

How these devices reached the market: the 510(k) pathway, in neutral terms

Why this foundation matters

How Mesh Is Supposed to Work — and How It Fails in the Body

The breast: scaffolds and the “internal bra”

Broadening out: pelvic mesh and hernia mesh

What “supposed to work” means — and why it fails

The regulatory backdrop, in neutral terms

Structural-Failure Injuries (Pelvic & Hernia Mesh)

Mesh Erosion, Exposure & Extrusion

Perforation of Bladder, Bowel or Ureter

Fistula Formation (Vesicovaginal, Rectovaginal, Enterocutaneous)

Mesh Migration & Displacement

Mesh Contraction / Shrinkage (“Roping” or Banding)

Pain, Nerve & Quality-of-Life Injuries

Chronic Pelvic Pain (Fibrotic Foreign-Body Injury)

Neuropathic Pain & Nerve Entrapment

Dyspareunia, Loss of Sensation & Sexual Dysfunction

Fat Necrosis & Chronic Breast Pain (Mastalgia)

Psychological & Quality-of-Life Sequelae

Infection & Life-Threatening Complications

Mesh Infection, Bacterial Biofilm & Chronic Inflammation

Foreign-Body Granuloma & Chronic Granulomatous Reaction

Fatal Complications (Sepsis, Necrotizing Infection, Hemorrhage)

Functional & Organ-System Injuries

Urinary Dysfunction (Urgency, Retention, Obstruction, Recurrent UTI)

Bowel Dysfunction (Constipation, Obstructed Defecation, Obstruction)

Failure of the Repair & Recurrence of Prolapse or Hernia

Visceral Adhesions from Intraperitoneal Hernia Mesh

Mesh Ingrowth & Fibrotic Encapsulation (Hard-to-Remove Mesh)

Material Degradation & Systemic / Immune Reactions

In-Vivo Oxidative Degradation & Cracking of Polypropylene Mesh

Particle & Debris Shedding from Degrading Mesh

Calcification of Implanted Mesh

Autoimmune & Systemic Illness (ASIA / Shoenfeld Syndrome)

Allergy, Hypersensitivity & Foreign-Body Reaction

The Foreign-Body Response (Why the Body Reacts to Mesh)

Breast Reconstruction & Scaffold Injuries

Bioabsorbable Scaffold Failure: P4HB (GalaFLEX) “Internal Bra” Collapse

Seroma Formation with Breast ADM & Scaffolds

Red Breast Syndrome (Sterile Inflammatory Erythema of ADM)

Capsular Contracture (Periprosthetic Fibrous Capsule)

Mastectomy Skin-Flap & Nipple-Areola Necrosis

Failure of Breast Reconstruction Requiring Explantation

Breast Contour Deformities from Scaffold Failure

The Big Picture: The Scale of Mesh Litigation in the U.S. and Worldwide

Two distinct litigation families

Pelvic mesh: 100,000+ lawsuits, seven federal MDLs, ~$8 billion in combined settlements

Reported per-manufacturer settlement components

What courts actually decided: landmark pelvic-mesh outcomes

Hernia mesh: four active or wound-down federal MDLs

Bard / Davol — MDL 2846 (Southern District of Ohio)

Ethicon (Johnson & Johnson) — Physiomesh — MDL 2782 (Northern District of Georgia)

Atrium Medical (Getinge) — C-QUR — MDL 2753 (District of New Hampshire)

Covidien (Medtronic) — MDL 3029 (District of Massachusetts)

Hernia-mesh settlement landscape at a glance

Regulatory context

Why the scale matters to you

Becton Dickinson / C.R. Bard / Davol — The Documented Record

Who owns whom

The products

FDA actions and recalls

The litigation record — pelvic (Avaulta) mesh

The litigation record — hernia mesh

What the securities filings disclose

Johnson & Johnson / Ethicon — The Documented Record

Corporate identity and chain of ownership

The products

Injuries associated with these products

FDA regulatory history

The litigation record — pelvic mesh (MDL 2327 and state courts)

The litigation record — Physiomesh hernia mesh (MDL 2782)